question,question_raw,contexts,contexts_raw,ground_truth,evolution_type,metadata,episode_done
How does the Emergency Treatment Guidelines for Sepsis and Septic Shock (2022) address the management of organ dysfunction in sepsis and septic shock?,How does the Emergency Treatment Guidelines for Sepsis and Septic Shock (2022) address the management of organ dysfunction in sepsis and septic shock?,[''],['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],"The Emergency Treatment Guidelines for Sepsis and Septic Shock (2022) recommend early initiation of fluid resuscitation for patients with septic shock. It suggests administering at least 30ml/kg of crystalloid solution for initial resuscitation within 3 hours of diagnosing septic shock. After completing initial resuscitation, the guidelines advise evaluating hemodynamic status to guide further fluid use.",no_reference,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"What protocols are recommended for glucose control during relaxation, including criteria for initiating insulin therapy?","What protocols are recommended for glucose control during relaxation, including criteria for initiating insulin therapy?",[''],"['                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 17 | N      | RelaxierungGlucosekontrolle | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 18 | N      | RelaxierungGlucosekontrolle | Analgosedierung, Minimal mögliche Analgosedierund                                                                                                                                                                                                                                            | BPS                                                 |\n| 19 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                          ']","Protocols recommended for glucose control during relaxation include the use of analgosedation with minimal possible sedation, and a glucose control protocol involving insulin therapy initiation if two measurements yield a glucose level >10 mmol/l (>180 mg/dl).",no_reference,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
How should dose optimization be approached in patients with sepsis or septic shock?,How should dose optimization be approached in patients with sepsis or septic shock?,[''],['�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�'],"Dose optimization in patients with sepsis or septic shock should consider several factors, including the risk of hepatic and renal dysfunction, undetected immune dysfunction, and susceptibility to drug-resistant bacteria. The increase in extracellular volume due to fluid resuscitation enlarges the distribution volume of most antimicrobial drugs, leading to suboptimal drug levels in most patients. Therefore, initial antimicrobial therapy in these patients should use the highest loading dose. Additionally, various physiological disturbances emerging in sepsis and septic shock patients can greatly alter the pharmacokinetic stability of antimicrobial drugs, such as changes in hemodynamics and renal clearance rates. Thus, when applying combination antimicrobial therapy to patients with sepsis and septic shock, therapeutic drug monitoring should be conducted.",no_reference,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"What challenges do regional centers face in establishing ECMO centers, and why is centralized management of ECMO patients considered crucial for improving patient outcomes?","What challenges do regional centers face in establishing ECMO centers, and why is centralized management of ECMO patients considered crucial for improving patient outcomes?",[''],"['的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�']","Regional centers face challenges in establishing ECMO centers due to the vast territory of China, long-distance transportation challenges for both medical personnel and patients, and limitations in widespread adoption of long-distance fixed-wing aircraft and ground transportation for ECMO transfer. Centralized management of ECMO patients is considered crucial for improving patient outcomes because it ensures proper utilization of ECMO technology, avoids wastage of medical resources, and establishes a comprehensive regional system for rescuing critically ill patients.",no_reference,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
"What are the recommended strategies for tidal volume reduction in patients with ALI/ARDS, and what are the associated rationales and outcomes discussed in the provided context?","What are the recommended strategies for tidal volume reduction in patients with ALI/ARDS, and what are the associated rationales and outcomes discussed in the provided context?",[''],"[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","The recommended strategy for tidal volume reduction in patients with ALI/ARDS involves initially reducing tidal volumes by 1-2 mL/kg predicted body weight. This reduction aims to achieve tidal volumes around 6 mL/kg predicted body weight, as opposed to 12 mL/kg, while aiming for a plateau pressure of less than 30 cm H₂O. This strategy has shown a decrease in mortality rates in patients ventilated with lower tidal volumes. Additionally, allowing permissive hypercapnia can help minimize plateau pressures and tidal volumes, contributing to improved outcomes. It's noted that while larger trials aiming to limit tidal volumes and airway pressures have demonstrated improved outcomes, permissive hypercapnia was not the primary treatment goal in these studies. However, it's acknowledged that the use of hypercarbia is limited in patients with certain conditions such as preexisting metabolic acidosis and increased intracranial pressure. Despite this, in select patients, sodium bicarbonate infusion may be considered to facilitate the use of permissive hypercarbia.",no_reference,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
What are the benefits of using a minimally invasive sedation approach for mechanically ventilated septic patients?,What are the benefits of using a minimally invasive sedation approach for mechanically ventilated septic patients?,[''],"['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动', '剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ']","The benefits of using a minimally invasive sedation approach for mechanically ventilated septic patients include shortening the duration of mechanical ventilation, reducing ICU and total hospital stay, and promoting early mobilization. This approach can also benefit septic patients by minimizing sedation, which may involve strategies such as including sedation assessment in care plans, using intermittent rather than continuous sedation, avoiding sedatives and opting for short-acting agents like propofol and dexmedetomidine.",no_reference,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"What is the significance of implementing step-down antimicrobial therapy in the management of severe infections, as suggested in the given clinical context?","What is the significance of implementing step-down antimicrobial therapy in the management of severe infections, as suggested in the given clinical context?",[''],['�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�'],"The significance of implementing step-down antimicrobial therapy in the management of severe infections, as suggested in the given clinical context, lies in its ability to narrow the spectrum of antimicrobial coverage once the pathogen causing the infection has been identified. This approach helps in minimizing unnecessary exposure to broad-spectrum antibiotics, thereby potentially reducing adverse effects on both society and individuals. Several observational studies have indicated that step-down antimicrobial therapy can lower mortality rates. Additionally, Guo et al.'s meta-analysis, which included 99 studies, found no statistically significant difference in mortality rates between step-down antimicrobial therapy and continued broad-spectrum antibiotic use. Therefore, recommending step-down antimicrobial therapy is important for optimizing treatment outcomes and avoiding the development of antimicrobial resistance and adverse reactions.",no_reference,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are the recommended fluid resuscitation strategies for patients with septic shock?,What are the recommended fluid resuscitation strategies for patients with septic shock?,[''],"['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反']",The answer to the given question is present in the context,no_reference,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
What factors should be considered when deciding to administer hydrocortisone therapy to children with catecholamine resistance and suspected or proven adrenal insufficiency?,What factors should be considered when deciding to administer hydrocortisone therapy to children with catecholamine resistance and suspected or proven adrenal insufficiency?,[''],"['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","Factors to consider when deciding to administer hydrocortisone therapy to children with catecholamine resistance and suspected or proven adrenal insufficiency include: the presence of severe septic shock and purpura, previous steroid therapies for chronic illness, pituitary or adrenal abnormalities, and specific biochemical markers such as a random total cortisol concentration less than 10 ug/dL (496 nmol/L) or a positive response to a 30- or 60-min ACTH stimulation test with an increase in cortisol of ≤9 ug/dL (248 nmol/L). Dose recommendations vary depending on the situation, ranging from stress coverage doses of 1-2 mg/kg based on clinical diagnosis of adrenal insufficiency to higher doses for empirical therapy of shock followed by a 24-hour infusion.",no_reference,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
What is the recommendation regarding the use of bicarbonate in patients with hemodynamic instability when evidence is low?,What is the recommendation regarding the use of bicarbonate in patients with hemodynamic instability when evidence is low?,[''],"['                              | nan                                                 |\n| 26 | nan    | nan                         | Hämofiltration beim hämodynamisch instabilen Patienter                                                                                                                                                                                                                                       | Schwache EmptehlungEvidenz niedrig                  |\n| 27 | R      | Bikarbonat                  | Kein Bikarbonat bei pH >7,15                                                                                                                                                                                                                                                                 | Schwache EmpfehlungEvidenz moderatStarke Empfehlunc |\n| 28 | R      | Bikarbonat                  | Kein Bikarbonat bei pH >7,15                                                                                                                                                                                                                                             ']",nan,no_reference,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
How can dynamic indicators be utilized to predict fluid responsiveness during hemodynamic assessment?,How can dynamic indicators be utilized to predict fluid responsiveness during hemodynamic assessment?,['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反'],['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反'],"Dynamic indicators such as passive leg raising, volume loading, changes in stroke volume after fluid administration, changes in systolic pressure, changes in pulse pressure, and changes in intrathoracic pressure after mechanical ventilation can be used to predict fluid responsiveness during hemodynamic assessment, improving diagnostic accuracy. Retrospective analysis of relevant studies indicates that using pulse pressure variation to predict fluid responsiveness in septic or septic shock patients has high sensitivity and specificity.",simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What is the preferred method for blood sampling in the context of arteriellem Kathetel use?,What is the preferred method for blood sampling in the context of arteriellem Kathetel use?,"['                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |']","['                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |']",Blutentnahme bevorzugt aus arteriellem Kathetel,simple,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
"What are some recommendations regarding the use of antibiotics in the treatment of septic shock, according to the provided context?","What are some recommendations regarding the use of antibiotics in the treatment of septic shock, according to the provided context?",['�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�'],['�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�'],"The provided context offers several recommendations regarding the use of antibiotics in the treatment of septic shock. It suggests that early de-escalation of antibiotic therapy is associated with better clinical outcomes and reduced occurrence of bacterial resistance. Additionally, daily assessment of antibiotic therapy de-escalation feasibility may lower patient mortality rates. The context also recommends long-term (>10 days) antibiotic therapy for certain situations, including slow clinical improvement, difficulty in controlling the infection source, infections related to Staphylococcus aureus (especially MRSA), certain fungi, viral infections, and immunocompromised patients. Furthermore, it suggests using procalcitonin (PCT) levels as an adjunctive measure to guide antibiotic therapy for septic shock patients, citing evidence that PCT-guided antibiotic use can significantly shorten treatment duration, reduce daily drug doses, and decrease patient mortality rates without increasing mortality. Therefore, the context implies that the detection of PCT or other biomarkers can serve as auxiliary tools in clinical assessment, with the initiation and discontinuation of antibiotic therapy determined based on specific clinical circumstances.",simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are some unresolved technical challenges associated with VA-ECMO technology?,What are some unresolved technical challenges associated with VA-ECMO technology?,"['��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�']","['��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�']","Some unresolved technical challenges associated with VA-ECMO technology include: 1) Uncertainty regarding whether patients benefit from ECMO support due to a lack of well-designed randomized controlled studies, especially for VV-ECMO; 2) Challenges in determining anticoagulation strategies and targets due to the high coagulation state of ECMO patients, leading to a significant risk of bleeding events; 3) Lack of consensus on how to set respiratory machine parameters during VV-ECMO support to ensure adequate rest for the patient's lungs and prevent further lung injury; 4) The majority of VA-ECMO cases involve arterial cannulation, which can increase left ventricular afterload and may not be conducive to heart recovery.",simple,[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}],True
What are the recommended strategies for reducing tidal volume in patients with ALI/ARDS and what evidence supports their effectiveness?,What are the recommended strategies for reducing tidal volume in patients with ALI/ARDS and what evidence supports their effectiveness?,"[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","The recommended strategies for reducing tidal volume in patients with ALI/ARDS include aiming for tidal volumes of around 6 mL/kg predicted body weight and maintaining a plateau pressure of <30 cm H2O. Evidence supporting these strategies comes from multiple-center randomized trials that have shown a decrease in mortality when using a volume- and pressure-limited strategy. Additionally, allowing permissive hypercapnia can help minimize plateau pressures and tidal volumes, which has been demonstrated to be safe in larger trials. Prone positioning should also be considered in patients at high risk for adverse consequences of positional changes. These recommendations are supported by evidence from smaller studies and a larger multiple-center trial.",simple,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
"What are the recommended approaches for managing sedation and pain, as well as blood sugar levels, in patients with sepsis in the ICU?","What are the recommended approaches for managing sedation and pain, as well as blood sugar levels, in patients with sepsis in the ICU?",['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU '],['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU '],"The recommended approaches for managing sedation and pain in ICU sepsis patients include using the minimum effective dose of either continuous or intermittent sedation to achieve specific sedation goals (BPS). It is suggested that sedative use be limited by implementing nursing protocols that include sedation assessment, using intermittent rather than continuous sedation, opting for opioid drugs to avoid sedatives, and using short-acting drugs such as propofol and dexmedetomidine. These measures have been shown to benefit patients requiring mechanical ventilation. As for blood sugar management, it is recommended to implement a protocolized blood sugar management plan for ICU sepsis patients. Blood sugar should be monitored every 1-2 hours, and insulin therapy should be initiated when blood sugar levels are >10mmol/L for two consecutive measurements, with a target blood sugar level of ≤10mmol/L (strong recommendation, high-quality evidence). Once blood sugar levels and insulin dosage are stabilized, monitoring should be reduced to every 4 hours (BPS). It is also suggested to collect arterial blood for blood sugar measurement in patients with arterial catheters (weak recommendation, low-quality evidence).",simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"Question: What are the recommended fluid resuscitation guidelines for patients with septic shock, particularly regarding the timing and volume of initial resuscitation fluids?","Question: What are the recommended fluid resuscitation guidelines for patients with septic shock, particularly regarding the timing and volume of initial resuscitation fluids?",['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],"The recommended fluid resuscitation guidelines for patients with septic shock include initiating early fluid resuscitation, with a recommendation to administer at least 30ml/kg of crystalloid solution within the first 3 hours of diagnosing septic shock. After completing the initial resuscitation, the hemodynamic status should be evaluated to guide further fluid use.",simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
How does the initial Mean Arterial Pressure (MAPP) target of 60mmHg impact clinical outcomes in patients with septic shock?,How does the initial Mean Arterial Pressure (MAPP) target of 60mmHg impact clinical outcomes in patients with septic shock?,['映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�'],['映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�'],"The initial Mean Arterial Pressure (MAPP) target of 60mmHg is strongly recommended as it has been found to have no significant improvement in clinical outcomes such as 28-day and 90-day mortality rates, urine output, renal function, and arterial lactate levels compared to higher MAPP targets. Moreover, higher MAPP targets may increase the risk of arrhythmias in patients, and studies have shown an association between higher MAPP targets and increased mortality rates in patients over 75 years old. However, individualized MAPP targets may be necessary for special cases, such as patients with septic shock and pre-existing hypertension who may require higher MAPP targets.",simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are the recommended interventions and considerations for managing pediatric septic shock according to the cited source?,What are the recommended interventions and considerations for managing pediatric septic shock according to the cited source?,"['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","The recommended interventions and considerations for managing pediatric septic shock according to the cited source include: 1. Optimizing preload to optimize cardiac index. 2. Reserving hydrocortisone therapy for children with catecholamine resistance and suspected or proven adrenal insufficiency. 3. Using protein C concentrate or rhAPC, with greater efficacy observed in young children. 4. Considering granulocyte macrophage colony-stimulating factor for patients with secondary or primary immune deficiency. 5. Addressing deep vein thrombosis (DVT) prophylaxis, particularly in children with femoral central venous catheters. 6. Stress ulcer prophylaxis, although its effect is uncertain in mechanically ventilated children. 7. Considering continuous venovenous hemofiltration for children with anuria/severe oliguria and fluid overload. 8. Monitoring glycemic control in infants dependent on intravenous nutrition to prevent hypoglycemia.",simple,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
What factors should be considered when discussing the limitation of support in end-of-life care for patients in the ICU?,What factors should be considered when discussing the limitation of support in end-of-life care for patients in the ICU?,"["" Large fluid deficits typically ex- ist. and initial volume resuscitation, usuall requires 40-60 mL/kg but can be much higher (112-114) 3. Vasopressors/Inotropes (Should Onluy Be Used After Anpropriate Volume Resuscita tion). Children with severe sepsis can present with low cardiac output and high svstemid vascular resistance, high cardiac output and low svstemic vascular resistance., or low car diac output and low svstemic vascular resis tance shock. Denending s on which situatior exists, inotropic support should be started in the case of fluid refractory shock or a combi nation of an inotrope together with a vaso- pressor or a vasodilator, Dopamine is the firs choice of support for the pediatric patient with hypotension refractory to fluid resuscitation The choice of vasoactive agent is determined by the clinica examination Dopamine refractory shock may reverse with epinephrine infusion (l14). Pediatri norepinephrine patients with low cardiac output states may benefit from use of dobutamine. The e use o vasodilators can reverse shock in pediatric pa tients who remain hemodynamically unstable with a high systemic vascular resistance state despite fluid Iresuscitation and implementa tion of inotropic support (114, 115). Nitroso- vasodilators with a very short half-lifte (nitro prusside or nitroglvcerin) are used as first-lin therapy for children with epinephrine-resis tant low cardiac output and elevated systemid vascular-resistance shock. Inhaled nitric oxid reduced extracorporeal membrane oxvgen ation (ECMO) use when given to term neo nates with persistent pulmonary artery hyper\n\n### Q. Stress Ulcer Prophylaxis\n\nRecommendation: Grade A\n\nRationale. Although no study has been performed specifically in patients with severe of trials confirming the benefit sepsis, large stress ulcer prophylaxis in general ICU popu- lations have included significant numbers septic patients (105-108). This benefit should be applicable to patients with severe sepsis and shock. In addition, the conditions septic shown to benefit from stress ulcer prophvlaxis (coagulopathy, mechanical ventilation, hypo: o patients frequently are tension) present with severe sepsis and septic shock.\n\n### R. Consideration for Limitation of Support\n\n+ 1. Advance care planning, including 5 the communication of likely s and outcomes of treatment. should be realistic goals discussed with patients and families. De- for less or cisions support aggressive withdrawal of support may h be in the pa- tient's best interest.\n\nIt is too frequent that inade- Rationale, physician/family communication char- quate acterizes end-of-life care in the ICU. The leve) of life ICU patients 1 support g given may not and fre- be consistent with their wishes, Early quent caregiver discussions with patients whd face death in the ICU and their loved ones may facilitate with and application appropriate drawal of life-sustaining therapies.\n\n### S. Pediatric Considerations\n\n1. Mechanical Ventilation. Due low to functional capacity, young infants residual and neonates with severe sepsis may require early intubation (109). The principles of lung- protective strategies are applied to children as to adults. In premature infants, addi- they are tional attention is paid to avoiding hyperox- emia to prevent retinopathy. 2. Fluid Resuscitation. Intravenous access for f fluid resuscitation and inotrope/vasopres- difficult to attain in chil- sor infusion is more dren than in adults. The Heart As- American sociation has developed pediatric advanced life establish guidelines for support emergency\n\nof the and tensior newborr sepsis in randomized controlled trial (116), When pedi atric patients remain in a normotensive lovy cardiac output and high vascular resistance state. despite epinephrine and nitrosovasodi lator therapy, then the use of a phosphodies terase inhibitor should be strongly considered (117-119). Pentoxifylline (not available in the United States) improved outcome in prema-  with given for f ture neonates when sensis brs/day for 5 davs in a randomized controlled trial (120) 4 Theraneutic End Points. Therapeutic end points are canillary refill of <2 secs nor mal pulses with no differential between ne ripheral and central pulses, warm extremities urine output >1 mL.ko-1.hr""]","["" Large fluid deficits typically ex- ist. and initial volume resuscitation, usuall requires 40-60 mL/kg but can be much higher (112-114) 3. Vasopressors/Inotropes (Should Onluy Be Used After Anpropriate Volume Resuscita tion). Children with severe sepsis can present with low cardiac output and high svstemid vascular resistance, high cardiac output and low svstemic vascular resistance., or low car diac output and low svstemic vascular resis tance shock. Denending s on which situatior exists, inotropic support should be started in the case of fluid refractory shock or a combi nation of an inotrope together with a vaso- pressor or a vasodilator, Dopamine is the firs choice of support for the pediatric patient with hypotension refractory to fluid resuscitation The choice of vasoactive agent is determined by the clinica examination Dopamine refractory shock may reverse with epinephrine infusion (l14). Pediatri norepinephrine patients with low cardiac output states may benefit from use of dobutamine. The e use o vasodilators can reverse shock in pediatric pa tients who remain hemodynamically unstable with a high systemic vascular resistance state despite fluid Iresuscitation and implementa tion of inotropic support (114, 115). Nitroso- vasodilators with a very short half-lifte (nitro prusside or nitroglvcerin) are used as first-lin therapy for children with epinephrine-resis tant low cardiac output and elevated systemid vascular-resistance shock. Inhaled nitric oxid reduced extracorporeal membrane oxvgen ation (ECMO) use when given to term neo nates with persistent pulmonary artery hyper\n\n### Q. Stress Ulcer Prophylaxis\n\nRecommendation: Grade A\n\nRationale. Although no study has been performed specifically in patients with severe of trials confirming the benefit sepsis, large stress ulcer prophylaxis in general ICU popu- lations have included significant numbers septic patients (105-108). This benefit should be applicable to patients with severe sepsis and shock. In addition, the conditions septic shown to benefit from stress ulcer prophvlaxis (coagulopathy, mechanical ventilation, hypo: o patients frequently are tension) present with severe sepsis and septic shock.\n\n### R. Consideration for Limitation of Support\n\n+ 1. Advance care planning, including 5 the communication of likely s and outcomes of treatment. should be realistic goals discussed with patients and families. De- for less or cisions support aggressive withdrawal of support may h be in the pa- tient's best interest.\n\nIt is too frequent that inade- Rationale, physician/family communication char- quate acterizes end-of-life care in the ICU. The leve) of life ICU patients 1 support g given may not and fre- be consistent with their wishes, Early quent caregiver discussions with patients whd face death in the ICU and their loved ones may facilitate with and application appropriate drawal of life-sustaining therapies.\n\n### S. Pediatric Considerations\n\n1. Mechanical Ventilation. Due low to functional capacity, young infants residual and neonates with severe sepsis may require early intubation (109). The principles of lung- protective strategies are applied to children as to adults. In premature infants, addi- they are tional attention is paid to avoiding hyperox- emia to prevent retinopathy. 2. Fluid Resuscitation. Intravenous access for f fluid resuscitation and inotrope/vasopres- difficult to attain in chil- sor infusion is more dren than in adults. The Heart As- American sociation has developed pediatric advanced life establish guidelines for support emergency\n\nof the and tensior newborr sepsis in randomized controlled trial (116), When pedi atric patients remain in a normotensive lovy cardiac output and high vascular resistance state. despite epinephrine and nitrosovasodi lator therapy, then the use of a phosphodies terase inhibitor should be strongly considered (117-119). Pentoxifylline (not available in the United States) improved outcome in prema-  with given for f ture neonates when sensis brs/day for 5 davs in a randomized controlled trial (120) 4 Theraneutic End Points. Therapeutic end points are canillary refill of <2 secs nor mal pulses with no differential between ne ripheral and central pulses, warm extremities urine output >1 mL.ko-1.hr""]","Factors to consider when discussing the limitation of support in end-of-life care for patients in the ICU include advance care planning with realistic goals communicated to patients and families, ensuring that decisions for less aggressive withdrawal of support may be in the patient's best interest. Inadequate physician/family communication often characterizes end-of-life care in the ICU, with the level of life support given potentially inconsistent with the patient's wishes. Early caregiver discussions with patients facing death in the ICU and their loved ones may facilitate appropriate withdrawal of life-sustaining therapies.",simple,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
What are the recommended guidelines for initiating fluid resuscitation in patients with septic shock?,What are the recommended guidelines for initiating fluid resuscitation in patients with septic shock?,"['17):1583-1593 10. Holst LB. Haase N. Wettersley J. Wernerman J Aneman A. Guttormsen AB et al (2013)Transfusiot requirements in septic shock (TRISS) trial- comparing the effects and safety of liberal versu: restrictivered blood celltransfusion insepticshoc patients in the ICU: protocol for a randomised controlledtrial Trials 14:150 Damiani E. Donati A. Serafini G. Rinaldi. Adraris E. Pelaia P et al (2015) Effect of performance improvementprograms on compliance withsepsi bundles and mortality: a svstematic review and meta-analvsis of observational studies. PLOS ON 10(5)e0125821 Scheer CS. Fuchs C. Kubn SO. Vollmer M. Rehber S. Friesecke S et al (2017) Quality improvement initiative for severe sepsis andsepticshockreduce 90-day mortality: A 7.5-year observational study Crit Care Med 45(2):241-25 Bloos E. Thomas-Ruddel D, Ruddel H, Enge C, Schwarzkopf D, Marshall JC et al (2014 Impact of compliance with infection managemen quidelines on outcome in patients with severe sepsis: A prospective observational multi-cente study. Crit Care 18(2):R42 Azuhata T. Kinoshita K. Kawano D. Komatsu1 SakuraiA. Chiba Yetal (2014) Timefrom admissior to initiation of surgery for source controli a critical determinant of survival in patients wit gastrointestinal perforation with associated septi shock. Crit Care 18(3):R8: 5. ARDSNetwork (2000) Ventilation with lowe tidal volumes as compared with traditiona tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Svndrome Network. N Engl Med 342(18):1301-1308 Amato MB, Meade MO, Slutsky AS, Brochard L Costa EL, Schoenfeld DA et al (2015) Driving pressure and survival in the acute respirator distress syndrome.N EnglJ Med 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandlL Austin P et al (2013) High-frequency oscillation ir early acute respiratory distress syndrome. N Engl Med 368(9):795-805 . Frat JP, Thille AW, Mercat A, Girault C, Ragot S Perbet S et al (2015) High-flow oxygen througl nasal cannula in acute hypoxemic respiratory failure. N Engl JMed 372(23):2185-2196 .Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK Jaschinski U et al (2016) Effect of sodium selenite administration and Procalcitonin-guided therapy on mortalityin patients with severesepsis or septi shock: Arandomized clinical trial. JAMA Intern Med 176(9):1266-1276\n\n### Buchbesprechung\n\nKiefer, T. (Hrsg. Thoraxdrainager Berlin Heidelberg: Springer-Verlae Berlin Heidelberg 2016. 1., 126 S (ISBN: 978-3-662-49739-5), Softcove 39,99 EUR Es ist sehr schwer. innerhalb der Welt de thoraxchirurgischen Bücher ein neues Werk zu schaffen, das einzigartig ist. Das Buch Thoraxdrainggen iedoch herausgegeber von Thomas Kiefer erfüillt ganz klar diese Definition, Und dies aleich aus mehrerer Gründen Zu allererst ist die: ein enorm praxisori entiertes Buch Die Drainage des Pleu Thorax raspaltes und das drainagen Management vor Thoraxdrainagen sind fundamentale Bestandteil der tho raxchirurgischen Arbeit. Die Tatsache, dass diese Themen in dem Buch mit aroBer Ernst haftigkeit besprochen werden, zeugen vor seiner Intention: es will praxisorientiert seir Das Buch will in einer einfachen, praktischer Weise hilfreich sein, Einzelne einfache De tails, die bei der täg', 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome"", ""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", ' wissenschaftlich zu schaffen, das einzigartig ist. Das Buch Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel L-E. Grelon E. Megarbane Thoraxdrainggen iedoch, herausgegeber men sind sicherlich noch nicht um B Anquel N et al (2014) Hiab versus low blood- von Thomas Kiefer erfiillt ganz klar diese aufgearbeitet, aber Thomas Kiefer pressuretargetin patientswith senticshock NEng Definition, Und dies gleich aus mehrerer existierenden wissenschaftlichen E JMed 370(17):1583-1593 10 Holst IB Haase N Wettersley I Wernerman Gründen. nisse gründlich aufgearbeitet. Er ha Aneman A. Guttormsen AB etal (2013) Transfusior Zu allererst ist dies Erkenntnisse an ieder Stelle in eine reauirements in septic shock (TRIsS) trial. ein enorm praxisori- baren, einfachen Art und Weise ein comparing the effects and safety of liberal versus restrictivered blood cell transfusion in senticshoc entiertes Buch Die immer offen und ehrlich betonend patients in the ICU: protocol for a randomises Drainage des Pleu- wissen und was wir nicht wissen. D controlledtrial. Trials 14:150 Thorax raspaltes und das dazu. dass er einige der häufig zitie Damiani E. Donati A. Serafini G. Rinaldi L, Adraric drainagen E Pelaia P et al (2015) Effect of performance Management vor men entlarvt -er tut dies in einere improvement programson compliance with sepsi Thoraxdrainager an Fakten orientieren und sachlich bundles and mortality: a svstematic review and sind fundamentaler und Weise. Dieser aufrichtige und s meta-analysis of observational studies. PLOS ONP 10(5):e012582) Bestandteil der tho- Stil der Diskussion und das sich dar Scheer CS, Fuchs C, Kuhn SO, Vollmer M, Rehberc raxchirurgischen Arbeit. Die Tatsache., dass gebende Management, basierend a S. Friesecke S et al (2017) Ouality improvemen vorliegenden wissenschaftlichen Eir diese Themen in dem Buch mit grofBer Ernst initiative for severe sepsis and septicshockreduce: 90-dav mortality: A 7.5-year observational study haftigkeit besprochen werden, zeugen vor sen, zeichnen dieses Buch im Besc Crit Care Med 45(2):241-25: seiner Intention: es will praxisorientiert sein aus Bloos E. Thomas-Ruddel D, Ruddel H, Enge Das Buch will in einer einfachen, praktischer Schlussendlich ist dieses Buch gese C. Schwarzkopf D. Marshall JC et al (2014 Impact of compliance with infection management Weise hilfreich sein, Einzelne einfache De um im klinischen Alltag zu untersti quidelines on outcome in patients with severe tails, die bei der täglichen Arbeit helfen, die zu helfen, Es enthält Aspekte der ä sepsis: A prospective observational multi-centel für sich genommen jedoch nicht die grole wie der pflegerischen und der phy study, Crit Care 18(2):R42 Azuhata I. Kinoshita K. Kawano D. Komatsu Aufmerksamkeit genieBen, können in ihre rapeutischen Arbeit, was sich auch SakuraiA. Chiba Yetal (2014) Time from admissior Addition einen signifikanten Einfluss auf das Auswahl der Co-Autoren widerspie to initiation of surgery for source control i Gelingen haben. Dieses Buch ist einzigartic Gesamteinfluss des']","['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�']",nan,negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
Why is there a recommendation against the administration of immunoglobulins?,Why is there a recommendation against the administration of immunoglobulins?,"[""Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732-747 Warren"", '��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�', 'ressor agents); c) no new po- d) low tentially serious conditions; ventilatory and end-expiratory pressure e) requiring levels of requirements: and F102 that could be safely delivered with a face mask or nasal cannula. If the spon- breathing trial is successful taneous consideration should be given for extu- Appendix bation (see D). Spontaneous breathing trial options n include level of pressure continu- support with ous positive airway pressure 5 cm H.O or a T-piece\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Recent studies demonstrate that daily spontaneous breathing trials the c duration of mechanical ventilation ducet (78-80). Although these studies had limited of patients with documented ALI/ numbers ARDS. believe that there is to no reason different out- ALI/ARDS patients would have comes from other critically ill patients. Suc- breath- cessful completion of spontaneous of a high likelihood trials leads to ing discontinuation of successful mechanical ventilation.\n\n### L. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis\n\n1. Protocols should be used when sedation of critically ill mechanically ventilated patients is required. The protocol should include the usec of a sedation goal, ,mea- a standardized subjective sured by seda- tion scale.\n\nR\n\nRationale (Ll and L2). Mechanically ven- tilated patients receiving continuous sedation duration of a significantly have longer may mechanical ventilation as well as ICU and hos- pital length of stay (81). A daily interruption or ""continuous"" sedative infusion lightening of a patient is awake the until the may decrease 1 ICU duration of and ventilation mechanical (82). The sedation stay use  protocols in mechanically ventilated patients has shown a duration of reduced Iventilation, mechanica. length of stay, and tracheostomy rates (83).\n\nblockers should be 3. Neuromuscular avoided if all possible in the septic patient due to the risk of prolonged neu- blockade following discon- romuscular tinuation. If blockers neuromuscular than the first must be e used for longer hours mechanical ventilation, either intermittent bolus as required or contin uous infusion with monitoring of depth of block: with train of four rmonitoring should be used\n\nRationale. Prolonged skeletal muscle n critically ill weakness has been reported in patients following the use of intermediate- and long-acting neuromuscular blockers (84-91). The risk of prolonged be re- paralysis may\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nof the duced if an intermittent assessment depth blockade is of neuromuscular per- formed (92, 93),\n\n### M. Glucose Control\n\n1. Following initial stabilization of patients with severe sepsis, maintain blood glu- <150 mg/dL (8.3 mmol/L). Studies cose the role e of glycemic control supportingt have used continuous infusion of insulin and glucose. With this protocol, glucose should be monitored frequently after ini 30-60 tiation of the protocol (every mins) and on a regular basis (every 4 hrs. the blood glucose concentration once has stabilized\n\noiuue Rationale. A large single-center trial of showed signit postoperative e surgical patients icant improvement in I survival when continu- ous infusion insulin  was used to maintair 80 and 110 mg/dL (4.4-6.1 glucose between (94). Exogenous glucose was begun mmol/L) simultaneously with insulin with frequent monitoring of glucose (every 1 hr) and inten- sity of monitoring greatest at the time of ini- tiation of insulin. Hvpoglvcemia 1may occur There is 1 no reason to think that these data are not generalizable to all severely septic pa- tients. Post hoc data analysis of the trial data revealed that although best results were ob- glucose was maintained between tained when: 80 and 110 mg/dL (4.4 and 6.1 mmol/L) <150 mg/dL (8.3 mmol/L achieving a goal of < also improved outcome when compared with This goal will likely higher concentrations.T reduce the risk of hypoglycemia. The contro. of the blood glucose concentration appears to be more important than the amount of insulin infused (95, 96). The frequency of blood glu cose determinations may require the use of central or arterial catheters for blood sam pling\n\n2. In patients with severe sepsis, a strategy of glycemic control should include a nu- trition protocol with the preferential use of the enteral route.', "" Caspani ML, et al Constant mean airway pressure with differ ent patterns of positive pressure breathing during the adult respiratory distress syn- drome. Bull Eur Physiopathol Respir 1985 21:275-279 Pesenti A, Marcolin R. Prato P. et al: Mear airway pressure vs. positive end-expiratory pressure during mechanical ventilation Crit Care Med 1985: 13:34-3 Stocker R. Neff T, Stein  S, et al: Prone positioning and low-volume pressure limited ventilation improve survival in pa- tients with severe ARDS. Chest 1997; 111 1008-1017 Lamm WJ, Graham MM, Albert RK: Mech- anism by which  prone position improve: oxygenation in acute lung injury. Am J Re spir Crit Care Med 1994; 150:184-193 Jolliet P, Bulpa P, Chevrolet JC: Effects of the  position on gas exchange and e prone hemodynamics in severe acute respiratory distress syndrome. Crit Care Med 1998: 26 1977-1985 Gattinoni L, Tognoni G, Pesenti A, et al Effect of prone positioning on the surviva of patients with acute respiratory failure N Engl J Med 2001; 345:568-573\n\nprofiles of vecuronium and recovery cisatracurium 51W89 in intensive care uni patients, Anesth Analg 1995: 81:3-12 Brandom BW, Yellon FF. Lloyd ME, et al Recovery from doxacurium infusion admin istered I to produce immobility for more than four days in pediatric patients in the intensive care unit. Anesth Anala 1997: 84 307-314 Rudis MI. Sikora CA. Angus E. et al: / prospective, randomized., controlled evalua tion of peripheral nerve stimulation versu standard clinical dosing of neuromusculal blocking agents in critically ill patients Cr Core Med 1997: 25-25575-2558'3 Frankel H. Jeng J. Tilly E. et al: The impac of implementation of neuromuscular block ade monitoring standards in a surgical in tensive care unit Am Suro 1996: 62 503-506 van den Berohe G Wouters P Weekers F e al: Intensive insulin therapy in the critically ill patients. N Enal J Med 2001: 345 1359-1367 Finney SJ, Zekveld C. Elia A., et al: Glucose control and mortality in critically ill pa tients, JAMA 2003: 2041-2047 Van den Berohe G Wouters PI Bouillon F et al: Outcome benefit of intensive insulir therapy in the critically ill: Insulin dose Crit Care Med glvcemic control. versus 2003:31:359-366 Klein S. Kinney J. Jeeieebhoy K. et al: Nu trition support in clinical practice: Reviev of published data and recommendations fo future research directions. A summary of a conference sponsored by the National Insti tutes of Health. American Society for Par enteral and Enteral Nutrition, and Ameri can Society for Clinical Nutrition. Am J Cli Nutr 1997: 66:683-706 Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical trial of continuous ver sus intermittent dialysis for acute renal fail ure. Kidney Int 2001; 60:1154-1163 al Kellum J. Angus DC. Johnson JP et Continuous  versus intermittent renal re placement therapy: A meta-analysis. Inten sive Care Med 2002: 28:29-37 Cooper DJ, Walley KR. Wiggs BR, et al Bicarbonate does not improve hemody namics in critically ill patients who have lactic acidosis: A prospective, controlled clinical study. Ann Intern Med 1990; 112 492-498 Mathieu D. Neviere R. Billard V. et al: Ef fects of bicarbonate therapy on hemody namics and tissue oxygenation in patient with lactic : acidosis: A prospective, con trolled clinical study. Crit Care Med 1991 19:1352-1356 102. Cade JF: High risk of the critically ill fo: Crit Care Mes venous thromboembolism. 1982:10:448-450 103. Belch JJ, Lowe GD, Ward AG, et al: Preven tion of deep vein thrombosis in medica patients by low-dose heparin. Scott Med. 1981:26:115-117\n\nCrit Care Med 2004 Vol. 32, No. 3\n\n104. Samama MM, Cohen AT, Darmon JY, et al A comparison of enoxaparin with placebo"", "" and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD; Alain""]","['                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |', '        |\n| 21 | nan   | nan                                                           | Keine Gabe von FFP ohne klinisch manifeste Blutung, ohne bevorstehende Operatiorklinischer Blutung, >50.000/ul bei Blutung oder Eingriffer                                   | Schwache EmpfehlungEvidenz sehr niedrid Schwache EmpfehlungEvidenz sehr niedrig |\n| 22 | nan   | ImmunglobulineHämofiltration/g                                | Keine Gabe von lmmunglobuliner                                                                                                                                               | nan                                                                             |\n| 23 | K     | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Evidenz sehr niedric                                                            |\n| 24 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | nan                   ']","There is a recommendation against the administration of immunoglobulins because it is stated that they should not be given. However, further details or reasons for this recommendation are not provided in the context.",negative_rejection,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
What factors should be considered for optimizing the dosage of antimicrobial therapy in patients with sepsis and septic shock?,What factors should be considered for optimizing the dosage of antimicrobial therapy in patients with sepsis and septic shock?,"[""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-', ' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(', '-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence""]","['�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�', '体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�']","Factors to consider for optimizing the dosage of antimicrobial therapy in patients with sepsis and septic shock include risks associated with liver and kidney dysfunction, undetected immune dysfunction, susceptibility to drug-resistant bacteria, and changes in pharmacokinetics due to fluid resuscitation-induced increase in extracellular volume. Additionally, various physiological disruptions emerging in patients with sepsis and septic shock, such as alterations in hemodynamics and renal clearance rates, can greatly affect the pharmacokinetic stability of antimicrobial drugs. Therefore, when applying combination antimicrobial therapy to patients with sepsis and septic shock, therapeutic drug monitoring should be conducted.",negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"How has the COVID-19 pandemic influenced the development and implementation of ECMO (Extracorporeal Membrane Oxygenation) in China, and what challenges have emerged in its deployment during this period?","How has the COVID-19 pandemic influenced the development and implementation of ECMO (Extracorporeal Membrane Oxygenation) in China, and what challenges have emerged in its deployment during this period?","['uch die e Empfehlung gegen rou- des tinemäfsiges Monitoring gastralen Residualvolumens. Bei Ernährungsin- und hohem toleranz Aspirationsrisiko\n\nwird das Monitoring des gastralen Resi- dualvolumens jedoch empfohlen.\n\n### Antikoaqulation, Thrombose- und Stressulkusprophylaxe\n\nDie Empfehlungen zur :Thrombosepro- der aktuellen Leitli- phylaxe sind in c nienversion strukturierter : und prag- dies Im Kern 1 betrifft dargelegt. nanter die Anwendung einer medikamentöser Thromboseprophylaxe beim Fehlen von Kontraindikationen (hohe Empfehlungs: der stärke, moderate Qualität r Evidenz mit Bevorzugungvon niedermolekularen unfrak- gegeniiber Heparinpraparaten tioniertem Heparin (hohe Empfehlungs-\n\n2 Vereinfachte Darstellung von Empfehlungsstärke und Qualität der Evidenz nach GRADE-System (Grading of Recommendations Assessment\n\n\n|    | 0                                      | 1                                                                                                                                              |\n|---:|:---------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Development,and Evaluation,[1,3]       | Development,and Evaluation,[1,3]                                                                                                               |\n|  1 | Empfehlungsstärke                      | Empfehlungsstärke                                                                                                                              |\n|  2 | Starke Empfehlungstrong recommendation | Mainahmen, welche in den meisten Fällen angewandt werden sollten                                                                               |\n|  3 | Schwache Empfehluncweak recommendation | MaBnahmen, welche nach individueller Abwäqung für den jeweiligen Patienten sinnvoll sein können          ', ""Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732-747 Warren"", '17):1583-1593 10. Holst LB. Haase N. Wettersley J. Wernerman J Aneman A. Guttormsen AB et al (2013)Transfusiot requirements in septic shock (TRISS) trial- comparing the effects and safety of liberal versu: restrictivered blood celltransfusion insepticshoc patients in the ICU: protocol for a randomised controlledtrial Trials 14:150 Damiani E. Donati A. Serafini G. Rinaldi. Adraris E. Pelaia P et al (2015) Effect of performance improvementprograms on compliance withsepsi bundles and mortality: a svstematic review and meta-analvsis of observational studies. PLOS ON 10(5)e0125821 Scheer CS. Fuchs C. Kubn SO. Vollmer M. Rehber S. Friesecke S et al (2017) Quality improvement initiative for severe sepsis andsepticshockreduce 90-day mortality: A 7.5-year observational study Crit Care Med 45(2):241-25 Bloos E. Thomas-Ruddel D, Ruddel H, Enge C, Schwarzkopf D, Marshall JC et al (2014 Impact of compliance with infection managemen quidelines on outcome in patients with severe sepsis: A prospective observational multi-cente study. Crit Care 18(2):R42 Azuhata T. Kinoshita K. Kawano D. Komatsu1 SakuraiA. Chiba Yetal (2014) Timefrom admissior to initiation of surgery for source controli a critical determinant of survival in patients wit gastrointestinal perforation with associated septi shock. Crit Care 18(3):R8: 5. ARDSNetwork (2000) Ventilation with lowe tidal volumes as compared with traditiona tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Svndrome Network. N Engl Med 342(18):1301-1308 Amato MB, Meade MO, Slutsky AS, Brochard L Costa EL, Schoenfeld DA et al (2015) Driving pressure and survival in the acute respirator distress syndrome.N EnglJ Med 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandlL Austin P et al (2013) High-frequency oscillation ir early acute respiratory distress syndrome. N Engl Med 368(9):795-805 . Frat JP, Thille AW, Mercat A, Girault C, Ragot S Perbet S et al (2015) High-flow oxygen througl nasal cannula in acute hypoxemic respiratory failure. N Engl JMed 372(23):2185-2196 .Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK Jaschinski U et al (2016) Effect of sodium selenite administration and Procalcitonin-guided therapy on mortalityin patients with severesepsis or septi shock: Arandomized clinical trial. JAMA Intern Med 176(9):1266-1276\n\n### Buchbesprechung\n\nKiefer, T. (Hrsg. Thoraxdrainager Berlin Heidelberg: Springer-Verlae Berlin Heidelberg 2016. 1., 126 S (ISBN: 978-3-662-49739-5), Softcove 39,99 EUR Es ist sehr schwer. innerhalb der Welt de thoraxchirurgischen Bücher ein neues Werk zu schaffen, das einzigartig ist. Das Buch Thoraxdrainggen iedoch herausgegeber von Thomas Kiefer erfüillt ganz klar diese Definition, Und dies aleich aus mehrerer Gründen Zu allererst ist die: ein enorm praxisori entiertes Buch Die Drainage des Pleu Thorax raspaltes und das drainagen Management vor Thoraxdrainagen sind fundamentale Bestandteil der tho raxchirurgischen Arbeit. Die Tatsache, dass diese Themen in dem Buch mit aroBer Ernst haftigkeit besprochen werden, zeugen vor seiner Intention: es will praxisorientiert seir Das Buch will in einer einfachen, praktischer Weise hilfreich sein, Einzelne einfache De tails, die bei der täg', ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", ""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation.""]","['新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�', '��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�', '��疗的心源性休克\n\n患者的左心室减压与较低的死亡率相关。 而 VA-ECMO期间左心室减压的时机、最佳减压方式 如何选择[23]?(5)最近的研究表明,对于脓毒症合并 脓毒症心肌病,存在严重心功能障碍、心源性休克 惠者,使用VA-ECMO可降低病死率,然而该研究为 回顾性、观察性研究,且多聚焦于脓毒症引起的左 心收缩功能障碍。 对于脓毒症相关的右心 小全心功 能障碍,是否可应用ECMO支持?对于心输出量正 常或相对偏高,但存在严重血管张力不足的患者可 [24-25] )。(6)神经 否应用VA-ECMO支持目前尚无定论 统并发症严重影响ECMO患者的短期和长期预 后,尤其是ECPR患者,ECMO运行过程中如何进行 脑功能监测?如何及早识别神经系统预后不佳的 患者以免不必要的长期ECMO支持,避免增加不义 要的医疗花费和患者痛苦(26-27]?关于ECMO技术还 有更多未知值得进一步探索 索研究 综上,ECMO技术目前在中国蓬勃发展,但与 发达国家相比仍存在巨大差距,自面临着区域发展 不均、区域化ECMO中心不完善以及ECMO学科建 设等方面的诸多问题,但随着对该技术认识的不断 进步和国家行政部门对未来发展方向的把控,相信 ECMO在中国一定能够得到长足发展,切实改善患 者预后 利益冲突作者声明不存在', '的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�']","The COVID-19 pandemic has further propelled the development and implementation of ECMO in China. However, this process has encountered several challenges. Some grassroots medical centers have hastily initiated ECMO projects without strict control over indications, leading to improper management and significant medical expenses. Despite the capability of these centers to perform ECMO procedures, patients ultimately need to be transferred to higher-level medical institutions for unified management. The complexity and high risks associated with ECMO necessitate a high demand for medical resource allocation. The implementation of ECMO should involve a multidisciplinary team rather than a single department. However, the diverse backgrounds of the multidisciplinary team have caused ambiguity in departmental attribution, with various departments such as cardiovascular surgery, critical care medicine, and respiratory medicine all involved in ECMO implementation. Differences in the departments responsible for ECMO implementation across different hospitals have resulted in decentralized departmental management, limiting intra-hospital and inter-hospital coordination for multidisciplinary collaboration and hindering the advancement of guidelines and research related to ECMO. In addition to personnel and equipment requirements, the establishment of ECMO centers should also consider the number of cases the center may handle annually. Although there is controversy regarding the minimum acceptable number of cases per year, evidence suggests a correlation between patient prognosis and the number of cases conducted by the center. ELSO recommends that ECMO centers should conduct a minimum of six cases annually. Analysis of data from 2017 to 2019 indicates that the quality control level in the intensive care unit (ICU) is also an important factor affecting patient prognosis. Therefore, the establishment of ECMO regional centers should also fully consider the quality control level. Despite the rapid development of ECMO technology in China, there still exists a significant gap compared to developed countries. Challenges such as regional uneven development, imperfect regional ECMO centers, and ECMO discipline construction need to be addressed. However, with the continuous improvement in understanding this technology and the control of future development directions by national administrative departments, ECMO in China is believed to undergo significant development, effectively improving patient prognosis.",negative_rejection,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
How does maintaining mechanically ventilated patients in a semirecumbent position help prevent the development of ventilator-associated pneumonia?,How does maintaining mechanically ventilated patients in a semirecumbent position help prevent the development of ventilator-associated pneumonia?,"[""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', "":1851-1858 Esteban A. Alia I. Tobin MJ, et al: Effect of spontaneous breathing trial duration attemnts to discontinue me chanical ventilation Snanish Lung Failur Collaborative Group, Am J Respir Crit Care Med 1999: 159:512-518 Ely EW. Baker AM. Dunagan DP., et al: Ef fect on the duration of mechanical ventila tion of identifving patients capable o breathing spontaneously, N Enal J Med 1996:335:1864-1869 Esteban A. Alia I. Gordo E. et al: Extubatior outcome after spontaneous breathing trial: with T-tube or pressure support ventilation The Snanish Lung Failure Collaborativ Group. Am J Respir Crit Care Med 1997 156:459-465 Kollef MH, Levy NT. Ahrens TS, et al: The use of continuous IV sedation is associated with prolongation of mechanical ventila tion Chest 1998: 114:541-548 Kress JP. Pohlman AS. O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechani cal ventilation. N Enal J Med 2000: 342 1471-1477 Brook AD. Ahrens TS, Schaiff R, et al: Effec of a nursing-implemented sedation protoco on the duration of mechanical ventilation Crit Care Med 1999: 27:2609-2615 Giostra E. Magistris MR. Pizzolato G. et al Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group o: seven patients and two sporadic cases, with electrophysiologic and histologic examina tion. Chest 1994: 106:210-220 Rossiter A, Souney PF, McGowan S, et al Pancuronium-induced prolonged neuro muscular blockade. Crit Care Med 1991 19:1583-1587 Partridge BL, Abrams JH, Bazemore C, et al Prolonged neuromuscular blockade afte long-term intusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-1179 Vanderheyden BA, Reynolds HN, Gerole KB, et al: Prolonged paralysis after long term vecuronium infusion. Crit Care Med 1992; 20:304-30 Meyer KC, Prielipp RC, Grossman JE, et al Prolonged weakness after infusion of atra curium in two intensive care unit patients Anesth Analg 1994: 78:772-774 Manthous CA. Chatila W: Prolonged weak ness after withdrawal of atracurium. Am. Respir Crit Care Med 1994; 150:1441-1443 Prielipp RC, Coursin DB, Scuderi PE, et al Comparison o of the e intusior requirement\n\ncenter Trial Group on Tidal Volume reduc tion in ARDS. Am J Respir Crit Care Med 1998:158:1831-1838 Brower RG. Shanholtz CB. Fessler HE, et al Prospective, randomized, controlled clinica trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients, Crit Care Med 1999: 27:1492-1498 Brower RG Fessler HE: Mechanical venti lation in acute lung iniury and acute respi ratory distress Clin Chest Med svndrome 2000:21:491-510 Eichacker PO. Gerstenberger EP. Bank: SM. et al: Meta-analysis of acute lung iniury and acute respiratory distress svndrome tri als testing low tidal volumes. Am J Respit Crit Care Med 2002: 166:1510-1514 with lower tidal volumes Ventilation as compared with traditional tidal volumes fo: acute lung injury and the acute respirator: distress svndrome The Acute Respiratory Distress Syndrome Network. N Enal J Mer 2000: 342:1301-1308 Hickling KG. Walsh J. Henderson S, et al Low mortality rate in adult respiratory dis tress svndrome : using low-volume, pres sure-limited ventilation with nermissive by percapnia: A prospective study. Crit Car Med 1994:22:1568-1578 Bidani A. Tzouanakis AE, Cardenas VJ, et al Permissive hypercapnia in acute respiratory failure. JAMA 272:957-962 J. Ravenscraft - SA: Mean Marini 1 airway pressure: Physiologic determinants clinical importance-Part I: Physiologic de measurements. Crit terminants and Med 1992: 20:1461-1472 Gattinoni L, Marcolin R."", 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,""]","[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","Maintaining mechanically ventilated patients in a semirecumbent position helps prevent the development of ventilator-associated pneumonia by decreasing the incidence of pneumonia. This position has been demonstrated to be effective in reducing the occurrence of ventilator-associated pneumonia. Patients are not laid flat, which can contribute to the incidence of pneumonia. Consistently returning patients to a semirecumbent position should be viewed as a quality indicator in patients receiving mechanical ventilation.",negative_rejection,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
How effective is the routine use of pulmonary artery catheters in managing patients with sepsis-induced acute respiratory distress syndrome (ARDS)?,How effective is the routine use of pulmonary artery catheters in managing patients with sepsis-induced acute respiratory distress syndrome (ARDS)?,"['��与脓毒性休克治疗国际指南_p15_f2.png)\n\nPEEP, positive end-expiratory pressure: F/TV, frequency/tidal volume; SBP, ,systolic blood pressure: MV, mechanical ventilation ""Options include T-piece. continuous positive airway pressure 5 cm H-O. or low-level (5-10 cm H₂O typically based on endotracheal tube size) pressure support ventilation (78-80, 135)\n\n', ' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(', '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-', '. internationa multicenter prospective cohortill. Am Respir Crit Care Med, 2019, 200(8) 1002-1012.DO1:10.1164/rccm.201806-109400 [23] Schrage B. Becher PM. Bernhardt A. et al. Left ventricula unloading is associated with lower mortality in patients with shocl treated with cardiogenid venoarteria extracorporeal membrane oxvgenation: : results from an international Circulation multicenter cohor studyll DO1: 142(22) 2095-2106 10.1161/ CIRCULATIONAHA.120.048792 24 WH, et al. Venoarterial Ling RR. Ramanathan K. Poor extracorporea oxygenation as mechanical membrane circulatory support in adult septic shock: a systematic review and meta-analysis with individual participant data analysis[]. Crit Care, 2021, 25(1): 246 meta-regressionr D01:10.1186/s13054-021-03668-5 [25] D, Kimmoun A. et al. Venoarteria Brechot t N, Hajage extracorporea to membrane oxygenation rescue sepsis-induced shock: cardiogenic retrospective multicentre, international cohort study ] . Lancet, 2020 396(10250):545-552. DO1 10.1016/S0140-6736(20 30733-9 [26] Ong CS, Etchill E, Dong J, et al. Neuromonitoring detects brain injury 1n patients receiving extracorporea membrane oxygenation support]]. Thorac Cardiovasd Surg, 2021 2022-02-04].  published online ahead of print October 29.2021l. DO1: 10.1016/iitcvs.2021.09.063 ([27] Hunt MF. Clark KT. Whitman G. et al. The use of cerebra NIRS monitoring to identify acute brain injury in patients with VA-ECMOIIl.I Intensive Care Med. 2021. 36(12) 1403-1409.D01:10.1177/0885066620966962\n\nELSO Member Centers EB/OL (2021-11-23 [2022-01-29] https://www elso org/Membership/ CenterMap.aspx El Sibai R. Bachir R., El Saved M. ECMO use and mortalit in adult patients with cardiogenic shock: a retrospective observational study in U.S. hospitals[ll. BMC Emerg Med 2018,18(1):20.D01:10.1186/s12873-018-0171-8 [9] Park M, Mendes PV, Zampieri FG. G et al The economic effect extracornorea membrane oxvgenation support adults with severe respiratory failure in Brazil: a  2014 hypothetica analysis[Il. Rey Bras ; Ter Intensiva 26(3):253-262.D01:10.5935/0103-507x.20140036 I J 10] Ouweneel DM Limpens Schotborgh et al. life cardiac and Extracorporeal support during arrest cardiogenic shock: a systematic review and meta-analysis [11. Intensive Care > Med 2016 42(12): 1922-1934 DO1 10.1007/s00134-016-4536-8 11] Natt BS. Desai H. Singh N, et al. Extracorporeal membrane oxygenation for ards: national trends in the United States 2008-2012Ⅲ. Respir Care. 2016. 61(10):1293-1298. DO1 10.4187/respcare.04760 [12] Cheng W. Ma XD. Su LX, et al. Cross-sectional study for the of clinical application extracorporeal membrane oxvgenation in Mainland China. 2018[ll. Crit Care. 2020 24(1):554.D01:10.1186/s13054-020-03270-1 [13] Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume extracorporea membrane and of the cases mortality Analysis oxygenation extracorporeal life support organization registry[. Am 2015. 191(8): 894-901. DOL Respir Crit Care Med 10.1164/rccm.201409-16340C [14] C, Hou X, Tong Z et al. Extracorporeal membrane oxygenation programs for COVID-19 in China[]. Crit Care 2020.24(1):317.D01:10.11', "" J 2002: 21 330-336 123. Riordan FA, Thomson AP, Ratcliffe JM., et al Admission cortisol ang adrenocorticotro phic hormone levels in children with me ningococcal disease: Evidence of adrenal in suffciency: Care Med 1999: 27 2257-2261 124. Min M. U T. Ave M. et al: Hydrocortisone in the of dengue shock managemen syn drome. Southeast Asian J Trop Med Public Health 1975: 6:573-579 125. Sumarmo. Talogo W. Asrin A. et al: Failure of hydrocortisone to affect outcome in den\n\n;1982: 69 gue shock syndrome, Pediatrics 45-49 Hazelzet JA. de Kleiin ED. de Groot R: En dothelial protein C activation in meningo- coccal sepsis. N Enal J Med 2001: 345 1776-1777 127, de Kleiin ED. de Groot R. Hack CE, et al Activation of protein C following infusion o protein C concentrate in children with se vere meningococcal sensis and purpura ful. minans: A randomized., double-blinded, pla cebo-controlled. dose-finding study. Cri. Core Med 2003: 31:1839-184' Bilgin K. Yaramis A. Haspolat K. et al: A randomized trial of granulocvte-macroph colonv-stimulating factor in neonates age with neutropenia. Pediatric: sensis and 2001: 107:36-41 La Gamma EF. De Castro MH: What the rationale for -the granulocvte and granulocvte-macronhage colony stimulating factors in the neonatal intensiv  Suppl 2002: 91 care unit? Acta Paediatr 109-116 130. Chaibou M. Tucci M. Dugas MA, et al: Clin ically 2 significant upper gastrointestina bleeding acquired in a pediatric intensive care unit: A prospective study. Pediatrics 1998:102-933-938 131. Gauvin F. Dugas M. Chaibou M. et al: The impact of clinically significant upper gas- trointestinal bleeding in a pediatric inten sive care unit. Pediatr Crit Care Med 2001 2:294-298 132. Aleiandria MM. Lansang MA. Dans LF, et al immunoglobulin for treating Intravenous sepsis and septic shock. Cochrane Database Syst Reu 2002; (1):CD001090 133. Mever DM. Jessen ME: Results of extracor poreal membrane e oxygenation in childrer with sepsis. The Extracorporeal LifeSuppor Organization. Ann Thorac Surg 1997: 63 756-761 134. Goldman AP. Kerr SJ. Butt W. et al: Extra corporeal support for intractable cardiore spiratory failure due to meningococcal dis ease. Lancet 1997: 349:466-469 135. Brochard L, Rauss A., Benito S, et al: Com parison of three methods of gradual with drawal from 2 support during ventilatory weaning from mechanical ventilation Am J Respir Crit 2 Med 1994: 150 Care 896-903\n\n\n|    | 0                        | 1                                                                                                                                                           |\n|---:|:-------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Source Control Technique | Examples                                                                                  ""]","['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ', ' 患者病死率， 并可显著增加严重低血糖风险。一项针对 脓毒症患者的 Meta 分析结果显示， 胰岛素强化治疗对患者 28d 及 90d 病死率无显著改善， 但增加患者低血糖风险。多个医疗机构(如美国临床内分泌学家协会、美国糖尿病协会、美 国心脏协会、美国医师学会和重症监护医学学会) 所发布的住院患者血糖控制的共识将葡萄\n如有侵权请联系网站删除\n糖水平定在 7.8-10.0mmol/L，因为没有证据表明 7.8-10.0mmol/L 的指标与 6.1-7.8mmol/L 的 指标不同。在没有显著低血糖的情况下可实施更严格的范围，如 6. 1-7.8mmol/L。应避免与 高病死率相关的高血糖(＞10mmol/L)、低血糖和血糖水平波动较大。研究表明，多数患者 1-2h  的监测间隔能满足血糖的及时调整，又能避免低血糖的发生，血糖较稳定后可延长监 测时间。 由于脓毒症患者糖代谢状态并非相同， 具体监测间隔也应根据具体病情判定， 对于 血流动力学不稳定和应用儿茶酚胺的患者需注意低血糖的发生。床旁末梢血糖测定的准确性 易受多种因素的影响，如设备类型、患者红细胞压积、氧分压及药物影响等。一项系统综述 结果表明使用动脉血测定血糖的准确度显著高于末梢', '剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�', '�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�']","The routine use of pulmonary artery catheters is not recommended for managing patients with sepsis-induced acute respiratory distress syndrome (ARDS), as it is strongly recommended against with high-quality evidence. There is currently a lack of evidence demonstrating that the use of pulmonary artery catheters improves patient outcomes, including mortality or ICU length of stay, according to the combined analysis of two multicenter randomized trials.",negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"How should respiratory secretions be sampled and processed for patients suspected of respiratory infections, according to the provided clinical guidelines?","How should respiratory secretions be sampled and processed for patients suspected of respiratory infections, according to the provided clinical guidelines?","['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', "" with categori zation previouslye described (Table as adapted from Ref. 3). The this e methods for document build on a 2001 publication spon- sored by the International Sepsis Forum and use the same method of grading recommen. dations (4). The supplement submission wil include background material, questions posed that led to the recommendation, and expanded rationale. This executive summary is targeted to be concise and user friendly for the bedside clinician, The 2001 publication that was s used as a starting point for current : process included a MEDLINE search for clinical trials in the preceding 10 vrs. supplemented by manual search of other relevant journals, Sub topics for each recommendation were cross referenced to sepsis, septic sepsis, severe shock. sepsis syndrome, and infection. The Surviving Sepsis Campaign guidelines consid ered the in the 2001 evidence 1 publication (through 1999) and repeated the process for 2000 through 2003. The committee process began in June 2003 with a meeting featuring the first presentations of data and recommen dations. Recommendations discussed were and critiqued. Each clinical trial used to sup port recommendations was graded based lor the methodology in Table 1 and included pres- ence or absence of important elements such as concealed randomization, blinded outcome adjudication, intention to treat analysis, and explicit definition of primary outcome. All ar- v reviewed ticles were initially based on sub- group assignments and d typically by  two on three participants. Survival (28-30 days) was the standard outcome measure used to assess outcome benefit, and when an alternative was used this is the rationale. Where $ stated in strong trial evidence existed for outcome ben- efit in critically ill populations known to con tain a larger number of sepsis patients, these trials were considered in determination of rec ommendation grading. A strict evidence-based methodology with a scoring system was\n\nused. The goal was total consensus, which wa: reached in all recommendations except two. In those circumstances (recommendations C3 ang H1), the solution was achieved with the inclu subrecommendations that expressed some difference in expert opinion, When there difference of opinion was 1about grading clinical trial, an outside epidemiologist was con sulted This occurred in one circumstance with resolution of differences. Each participant com pleted a conflict of interest form, and individual: were not assigned to a subgroup topic if they had a potential conflict of interest. A full listing of al potential conflicts of interest is included with this article. Following that meeting. the process continued with o further refinement t of recom mendations through electronic communicatior among committee members. A second meeting of core members of the committee occurred inr early October 2003. The document was finalized and approved by the consensus committee and by sponsoring organizations in December 2003 Evidence-based anproaches more readily applied to data from therapeutic trials 1 of diagnostic techniques is less Evaluation well suited to this approach. Readers will note that the maiority of the recommendations ar nof supported by high-level evidence. Most are supported by expert opinion only. In order fo a general recommendation to carry a higher level of evidence (grades A. B. C. or D). a supporting study or studies must have shown a clinical outcome difference. Studies showing physiologic changes that could be potential sur of clinical outcome benefit were rogates e not used by themselves as pivotal studies but were used to support the validity of studies showing an outcome in a clinically important variable such as survival or length of ICU stay. A grade o A, B, or C required randomized trials. Recom mendations are graded and followed with ratio nale. References are provided to support grades A-D. In the committee's deliberations, the grad i did not establish the ing of a recommendation level of priority or importance of a specific in tervention, only the degree of literature support Pediatric considerations are provided at the end of the document for aspects of management that differ from 1adults. Recommendations are grouped by category and not by hierarchy\n\n### A. Initial Resuscitation\n\n1. The resuscitation of a patient in severe sepsis or sepsis-induced tissuel hypoperfu lactic acidosis sion (hypotension or should begin as soon as the syndrome is should be not and delayed recognized pending ICU admission. An elevated se- concentration identifies tis- lactate rum sue hypoperfusion in patients at risk who are not hypotensive. During the first 6 hrs the goals of initial resus- of resuscitation, t citation of sepsis-induced hypoperfusion should include all of the following as one part of a treatment protocol:\n\nCentral venous pressure: 8-12 mm I Hg Mean arterial pressure ≥65 mm Hg Urine output ≥0.5 mL-kg .hr-1 Central venous ("", '                              | nan                                                 |\n| 26 | nan    | nan                         | Hämofiltration beim hämodynamisch instabilen Patienter                                                                                                                                                                                                                                       | Schwache EmptehlungEvidenz niedrig                  |\n| 27 | R      | Bikarbonat                  | Kein Bikarbonat bei pH >7,15                                                                                                                                                                                                                                                                 | Schwache EmpfehlungEvidenz moderatStarke Empfehlunc |\n| 28 | R      | Bikarbonat                  | Kein Bikarbonat bei pH >7,15                                                                                                                                                                                                                                             ', ' for the prevention of venous thromboembo lism in acutely ill medical patients. Prophy laxis in Medical Patients  with Enoxaparil Study Group. N Enal J Med d 1999: 341 793-800 105. Borrero E. Bank S. Margolis I. et al: Com parison of antacid and sucralfate in the pre gastrointestinal bleeding in na. tients who are critically ill Am I Med 1985 79:62-64 106. Bresalier RS. Grendell JH. Cello JP., et al antacid for Sucralfate versus ; titrated  the prevention of acute stress-related gastroin testinal hemorrhage in critically ill pa tients. Am J Med 1987: 83:110-116 107. Cook D. Guvatt G. Marshall J. et al: A com parison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleed ing in patients requiring mechanical venti lation, Canadian Critical Care Trials Group N Enal J Med 1998: 338:791-797 108, Stothert JC. Simonowitz DA. Dellinger EF et al: Randomized prospective evaluation of cimetidine and antacid control of gastric ph in the critically ill. Ann Sura 1980: 192 169-174 109. Pollard AJ, Britto J. Nadel S, et al: Emer- 1 dis gency management of meningococcal ease. Arch Dis Child 1999: 80:290-296 110. Kanter RK. Zimmerman JJ. Strauss RH, et al: Pediatric emergency intravenous access Evaluation of a protocol. Am J Dis : Child 1986:140:132-134 111. Ngo NT. Cao XT. Kneen 1 R, et al: Acute management of dengue shock svndrome:/ 1 of 4 randomized double-blind comparisor intravenous fluid in the first regimens hour. Clin Infect Dis 2001; 32:204-213 112. Carcillo JA. Davis AL. Zaritsky A: Role of early fluid resuscitation in pediatric septid shock. JAMA 1991: 266:1242-1245 113. Powell KR. Sugarman LI, Eskenazi AE, et al: Normalization of plasma arginine vaso- pressin concentrations when children with meningitis are given maintenance plus re placement fluid therapy.J Pediatr 1991 117:515-522 G. Paschall JA, Maffei F, et al: I14. Ceneviva : support in fluid-refractory Hemodvnamid pediatric septic shock. Pediatrics 1998: 102 115. Keeley SR. Bohn DJ: The use of inotropic\n\nand afterload-reducing agents in neonates Clin Perinatol 1988: 15:467-489 116. Roberts JD Jr. Fineman JR. Morin FC ⅢI. e al: Inhaled nitric oxide and persistent pul monary hypertension of the new born. In haled Nitric ( Oxide Study  Group. N Eng JMed 1997:336:605-610 117 Barton P Garcia I Kouatli A et al: Hemo dynamic effects of i v milrinone lactate ir nediatric patients with sentic shock A pro spective. double-blinded I randomized nla cebo-controlled interventional study Ches 1996:109-1302-1312 118. Lindsay CA. Barton P. Lawless S, et al Pharmacokinetics and pharmacodvnam s of milrinone lactate in pediatric pa- tients with septic shock.J Pediatr 1998 132:329-334 119. Irazuzta JE. Pretzlaff RK. Rowin ME: Amri none in pediatric refractory 2 septic shock An open-label pharmacodvnamic study. Pe diatr Crit Care Med 2001: 2:24-28 120. Lauterbach R. Pawlik D. Kowalczvk D. et al Effect of the immunomodulating agent pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo controlled. double-bling trial. Crit Care Med 1999: 27:807-814 121. Carcillo JA. Fields AI, American College of Critical Care Medicine Task Force Commit tee Members: Clinical practice parameters for hemodvnamic support of pediatric ang neonatal patients in septic shock, Crit Care Med 2002: 30:1365-1378 De Kleiin ED. Joosten KF. Van Riin B. et al Low with serum cortisol in combination high adrenocorticotrophic hormone con- centrations are associated with poor out come in children with severe menigococ cal disease. Pediatr Infect Dis', 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion']","['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '��推荐对可能有特定感染源的脓毒症患者，应尽快明确其感染源，并尽快 采取适当的控制措施 (BPS)。\n脓毒症和脓毒性休克的感染源控制原则是感染部位的快速诊断和及时处理。对易于清除 的感染灶，包括腹腔内脓肿、胃肠道穿孔、胆管炎、胆囊炎、肾盂肾炎伴梗阻或者脓肿、肠缺 血、坏死性软组织感染和其他深部间隙感染(如脓胸或者严重的关节内感染)，应在初始复苏 后尽快控制感染灶，普通诊断后不超过 6-12 h 。当血管内植入装置为疑似感染源时，拔除 导管可能是有益的。\n7.3 血管活性药物\n如有侵权请联系网站删除\n推荐意见 18：推荐去甲肾上腺素作为首选血管加压药(强推荐，中等证据质量)；对于 快速性心律失常风险低或者心动过缓的患者，可将多巴胺作为替代药物(弱推荐，低证据质量)。\n去甲肾上腺素通过其缩血管作用而升高 MAP，对心率和每搏输出量的影响小，可有效 改善脓毒性休克患者的低血压状态。多巴胺主要通过增加心率和每搏输出量升高 MAP，可 能对心脏收缩功能受损的患者疗效更好，但可能引起心动过速，增加患者心律失常的风险。\n一项纳入11项随机试验的比较去甲肾上�', 'RT 需求、 尿量、生存期、住院时间、 心律失常发生率等疗效指标均无显著改善。 我国相关研究表明， LDD 不能降低脓毒症急性肾衰竭患者 RRT 需求及病死率。\n推荐意见 21 ：经过充分的液体复苏以及使用血管活性药物后，如果仍持续低灌注，建 议使用多巴酚丁胺(弱推荐，低证据质量)。\n多巴酚丁胺作为一线正性肌力药，为 EGDT 临床试验标准治疗的一部份，在其使用中 未发现对病死率的不良影响。 两项 ICU 脓毒症患者的大型前瞻性临床试验显示，使用多巴 酚丁胺将患者心输出量提高至高于正常水平不会改善临床结局。然而， 一些患者可能通过正 性肌力药物改善组织灌注，增加氧气输送。我国一项评价多巴酚丁胺联用去甲肾上腺素治疗 脓毒性休克伴顽强性低血压的研究表明，多巴酚丁胺可有效升高血压， 改善循环与灌注，提 高救治成功率。\n推荐意见 22：建议所有需要血管活性药物的患者置入动脉导管进行连续性血压测定(弱 推荐， 极低证据质量)。\n在休克状态， 使用动脉导管监测血压比袖带血压计测量更准确，可进行连续监测且允许\n如有侵权请联系网站删除\n每搏分析，有助于医务人员更准确', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ']","Respiratory secretions should be sampled and processed for patients suspected of respiratory infections according to the provided clinical guidelines by collecting specimens from the respiratory tract. These specimens include blood, cerebrospinal fluid, urine, wounds, respiratory secretions, and other body fluids, excluding specimens from invasive procedures. If the clinical examination clearly indicates the site of infection, sampling from other sites (except for blood samples) is not necessary. For patients with indwelling venous catheters for more than 48 hours and no clear site of infection, it is recommended to collect at least two sets of blood cultures, one aerobic and one anaerobic. For patients suspected of catheter-related infection, it is recommended to obtain one blood sample by percutaneous puncture and one blood sample from each vascular access device.",negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
What are the recommended approaches for fluid resuscitation and management in patients with sepsis?,What are the recommended approaches for fluid resuscitation and management in patients with sepsis?,"[""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", "" with categori zation previouslye described (Table as adapted from Ref. 3). The this e methods for document build on a 2001 publication spon- sored by the International Sepsis Forum and use the same method of grading recommen. dations (4). The supplement submission wil include background material, questions posed that led to the recommendation, and expanded rationale. This executive summary is targeted to be concise and user friendly for the bedside clinician, The 2001 publication that was s used as a starting point for current : process included a MEDLINE search for clinical trials in the preceding 10 vrs. supplemented by manual search of other relevant journals, Sub topics for each recommendation were cross referenced to sepsis, septic sepsis, severe shock. sepsis syndrome, and infection. The Surviving Sepsis Campaign guidelines consid ered the in the 2001 evidence 1 publication (through 1999) and repeated the process for 2000 through 2003. The committee process began in June 2003 with a meeting featuring the first presentations of data and recommen dations. Recommendations discussed were and critiqued. Each clinical trial used to sup port recommendations was graded based lor the methodology in Table 1 and included pres- ence or absence of important elements such as concealed randomization, blinded outcome adjudication, intention to treat analysis, and explicit definition of primary outcome. All ar- v reviewed ticles were initially based on sub- group assignments and d typically by  two on three participants. Survival (28-30 days) was the standard outcome measure used to assess outcome benefit, and when an alternative was used this is the rationale. Where $ stated in strong trial evidence existed for outcome ben- efit in critically ill populations known to con tain a larger number of sepsis patients, these trials were considered in determination of rec ommendation grading. A strict evidence-based methodology with a scoring system was\n\nused. The goal was total consensus, which wa: reached in all recommendations except two. In those circumstances (recommendations C3 ang H1), the solution was achieved with the inclu subrecommendations that expressed some difference in expert opinion, When there difference of opinion was 1about grading clinical trial, an outside epidemiologist was con sulted This occurred in one circumstance with resolution of differences. Each participant com pleted a conflict of interest form, and individual: were not assigned to a subgroup topic if they had a potential conflict of interest. A full listing of al potential conflicts of interest is included with this article. Following that meeting. the process continued with o further refinement t of recom mendations through electronic communicatior among committee members. A second meeting of core members of the committee occurred inr early October 2003. The document was finalized and approved by the consensus committee and by sponsoring organizations in December 2003 Evidence-based anproaches more readily applied to data from therapeutic trials 1 of diagnostic techniques is less Evaluation well suited to this approach. Readers will note that the maiority of the recommendations ar nof supported by high-level evidence. Most are supported by expert opinion only. In order fo a general recommendation to carry a higher level of evidence (grades A. B. C. or D). a supporting study or studies must have shown a clinical outcome difference. Studies showing physiologic changes that could be potential sur of clinical outcome benefit were rogates e not used by themselves as pivotal studies but were used to support the validity of studies showing an outcome in a clinically important variable such as survival or length of ICU stay. A grade o A, B, or C required randomized trials. Recom mendations are graded and followed with ratio nale. References are provided to support grades A-D. In the committee's deliberations, the grad i did not establish the ing of a recommendation level of priority or importance of a specific in tervention, only the degree of literature support Pediatric considerations are provided at the end of the document for aspects of management that differ from 1adults. Recommendations are grouped by category and not by hierarchy\n\n### A. Initial Resuscitation\n\n1. The resuscitation of a patient in severe sepsis or sepsis-induced tissuel hypoperfu lactic acidosis sion (hypotension or should begin as soon as the syndrome is should be not and delayed recognized pending ICU admission. An elevated se- concentration identifies tis- lactate rum sue hypoperfusion in patients at risk who are not hypotensive. During the first 6 hrs the goals of initial resus- of resuscitation, t citation of sepsis-induced hypoperfusion should include all of the following as one part of a treatment protocol:\n\nCentral venous pressure: 8-12 mm I Hg Mean arterial pressure ≥65 mm Hg Urine output ≥0.5 mL-kg .hr-1 Central venous ("", '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-', 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion']","['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反']","The recommended approaches for fluid resuscitation and management in patients with sepsis include using dynamic indicators to predict fluid responsiveness, such as passive leg raising test, volume challenge test, changes in stroke volume after fluid administration, changes in blood pressure, changes in pulse pressure, and changes in intra-thoracic pressure after mechanical ventilation. These dynamic indicators can improve diagnostic accuracy in predicting fluid responsiveness. Additionally, for septic shock patients requiring vasopressor therapy, it is recommended to target a mean arterial pressure (MAPP) of 65mmHg for initial resuscitation. For patients with elevated blood lactate levels, resuscitation guided by lactate levels to restore lactate to normal levels is suggested. However, individualized targets should be considered based on patient conditions, such as the presence of hypertension in septic shock patients, who may require maintaining higher MAPP levels.",negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
What is the recommended timing for initiating intravenous antibiotic therapy in patients with severe sepsis?,What is the recommended timing for initiating intravenous antibiotic therapy in patients with severe sepsis?,"['ochte und der sich nicht nur auf die glamourösen"" Themen konzentrieren wil te,\n\nDer Anaesthesist 7 2017\n\n', ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", ""Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732-747 Warren"", '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-', 'uch die e Empfehlung gegen rou- des tinemäfsiges Monitoring gastralen Residualvolumens. Bei Ernährungsin- und hohem toleranz Aspirationsrisiko\n\nwird das Monitoring des gastralen Resi- dualvolumens jedoch empfohlen.\n\n### Antikoaqulation, Thrombose- und Stressulkusprophylaxe\n\nDie Empfehlungen zur :Thrombosepro- der aktuellen Leitli- phylaxe sind in c nienversion strukturierter : und prag- dies Im Kern 1 betrifft dargelegt. nanter die Anwendung einer medikamentöser Thromboseprophylaxe beim Fehlen von Kontraindikationen (hohe Empfehlungs: der stärke, moderate Qualität r Evidenz mit Bevorzugungvon niedermolekularen unfrak- gegeniiber Heparinpraparaten tioniertem Heparin (hohe Empfehlungs-\n\n2 Vereinfachte Darstellung von Empfehlungsstärke und Qualität der Evidenz nach GRADE-System (Grading of Recommendations Assessment\n\n\n|    | 0                                      | 1                                                                                                                                              |\n|---:|:---------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Development,and Evaluation,[1,3]       | Development,and Evaluation,[1,3]                                                                                                               |\n|  1 | Empfehlungsstärke                      | Empfehlungsstärke                                                                                                                              |\n|  2 | Starke Empfehlungstrong recommendation | Mainahmen, welche in den meisten Fällen angewandt werden sollten                                                                               |\n|  3 | Schwache Empfehluncweak recommendation | MaBnahmen, welche nach individueller Abwäqung für den jeweiligen Patienten sinnvoll sein können          ']","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', "" Large fluid deficits typically ex- ist. and initial volume resuscitation, usuall requires 40-60 mL/kg but can be much higher (112-114) 3. Vasopressors/Inotropes (Should Onluy Be Used After Anpropriate Volume Resuscita tion). Children with severe sepsis can present with low cardiac output and high svstemid vascular resistance, high cardiac output and low svstemic vascular resistance., or low car diac output and low svstemic vascular resis tance shock. Denending s on which situatior exists, inotropic support should be started in the case of fluid refractory shock or a combi nation of an inotrope together with a vaso- pressor or a vasodilator, Dopamine is the firs choice of support for the pediatric patient with hypotension refractory to fluid resuscitation The choice of vasoactive agent is determined by the clinica examination Dopamine refractory shock may reverse with epinephrine infusion (l14). Pediatri norepinephrine patients with low cardiac output states may benefit from use of dobutamine. The e use o vasodilators can reverse shock in pediatric pa tients who remain hemodynamically unstable with a high systemic vascular resistance state despite fluid Iresuscitation and implementa tion of inotropic support (114, 115). Nitroso- vasodilators with a very short half-lifte (nitro prusside or nitroglvcerin) are used as first-lin therapy for children with epinephrine-resis tant low cardiac output and elevated systemid vascular-resistance shock. Inhaled nitric oxid reduced extracorporeal membrane oxvgen ation (ECMO) use when given to term neo nates with persistent pulmonary artery hyper\n\n### Q. Stress Ulcer Prophylaxis\n\nRecommendation: Grade A\n\nRationale. Although no study has been performed specifically in patients with severe of trials confirming the benefit sepsis, large stress ulcer prophylaxis in general ICU popu- lations have included significant numbers septic patients (105-108). This benefit should be applicable to patients with severe sepsis and shock. In addition, the conditions septic shown to benefit from stress ulcer prophvlaxis (coagulopathy, mechanical ventilation, hypo: o patients frequently are tension) present with severe sepsis and septic shock.\n\n### R. Consideration for Limitation of Support\n\n+ 1. Advance care planning, including 5 the communication of likely s and outcomes of treatment. should be realistic goals discussed with patients and families. De- for less or cisions support aggressive withdrawal of support may h be in the pa- tient's best interest.\n\nIt is too frequent that inade- Rationale, physician/family communication char- quate acterizes end-of-life care in the ICU. The leve) of life ICU patients 1 support g given may not and fre- be consistent with their wishes, Early quent caregiver discussions with patients whd face death in the ICU and their loved ones may facilitate with and application appropriate drawal of life-sustaining therapies.\n\n### S. Pediatric Considerations\n\n1. Mechanical Ventilation. Due low to functional capacity, young infants residual and neonates with severe sepsis may require early intubation (109). The principles of lung- protective strategies are applied to children as to adults. In premature infants, addi- they are tional attention is paid to avoiding hyperox- emia to prevent retinopathy. 2. Fluid Resuscitation. Intravenous access for f fluid resuscitation and inotrope/vasopres- difficult to attain in chil- sor infusion is more dren than in adults. The Heart As- American sociation has developed pediatric advanced life establish guidelines for support emergency\n\nof the and tensior newborr sepsis in randomized controlled trial (116), When pedi atric patients remain in a normotensive lovy cardiac output and high vascular resistance state. despite epinephrine and nitrosovasodi lator therapy, then the use of a phosphodies terase inhibitor should be strongly considered (117-119). Pentoxifylline (not available in the United States) improved outcome in prema-  with given for f ture neonates when sensis brs/day for 5 davs in a randomized controlled trial (120) 4 Theraneutic End Points. Therapeutic end points are canillary refill of <2 secs nor mal pulses with no differential between ne ripheral and central pulses, warm extremities urine output >1 mL.ko-1.hr"", 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion', "" cardiac output\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Two large e prospective clinical trials that included critically ill ICU patients who had severe sepsis failed to demonstrate benefit from increasing oxygen delivery to su- (37. pranormal levels by use of dobutamine 38). The: goal of resuscitation should instead be to achieve adequate levels of oxygen deliv. ery or avoid flow-dependent tissue e hypoxia.\n\n### Steroids H.\n\n### Grade\n\nRationale. One multiple-center, random- ized, controlled trial (RCT) with patients in se- shock showed a a significant shock septic vere reversal and reduction of mortality rate in 1 pa- tients with relative adrenal insufficiency (defined IACTH as post-adrenocorticotropic hormone cortisol increase =9 μg/dL) (39). Two additional RCTs showed significant smaller effects shock reversal (40, 41). In the first study, pa- had tients shock (systolic septic severe blood pressure <90 )mm despite vasopres- the latter sors) than in two studies (systolic blood >90 mm Hg with vasopressors).\n\na. Some experts would use a 250-μg ACTH stimulation test to identify responders (>9 μg/dL increase in cortisol 30-60 mins post ACTH administration) and discontinue therapy in these patients. Clinicians should for ACTH not wait stimulation results administer corticosteroids.\n\nRationale. One study demonstrated that an incremental increase of >9 μg/dL after 250-μg ACTH stimulation test (responders) identifies survivors of septic shock (42). A subsequent trial demonstrated that stress dose steroids improved e patients who failed to produce survival in those this increase in cortisol with ACTH (nonre sponders). Treatment with corticosteroids was ineffective in responders (39). Recommenda- tions for t the identification of relative adrenal insufficiency vary based on different cutoff levels of random cortisol, peak cortisol after stimula- tion, incremental cortisol increase atter stimu lation, a and combinations of these criteria (43 45). In patients with septic shock, clinicians should e of dexa- consider administering a dose methasone until such time e that an ACTH stim ulation test can be administered because dexa- does not methasone, unlike e hvdrocortisone, interfere with the cortisol assay.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nGrade\n\nRationale. There has been no comparative between a fixed duration and clinically study guided regimen. Two RCTs used a fixed dura tion protocol for treatment (39, 41), and inone RCT, therapy was decreased I after shock reso- lution and discontinued after 6 days (40).\n\nc. Some experts would consider tapering the dose of corticosteroids at the end of therapy.\n\nRationale. One study showed hemody- namic and immunologic rebound effects after abrupt cessation of corticosteroids (46).\n\nd. Some experts would add fludrocortisone (50 μg orally four times per day) to this regimen.\n\nE Grade\n\nof 50 Rationale. One study added ug fludrocortisone orally (39). Since hydrocorti- has intrinsic mineralocorticoid activity, sone to whether fludrocor- there is controversy as tisone should be added\n\nRationale. Two randomized prospective clinical trials and two meta-analyses s concluded that for therapy of severe sepsis or septic shock high-dose corticosteroid therapy is ineffective or harmful (47-50). There may be reasons to main- doses of corticosteroid for medical tain higher conditions other than septic shock\n\n3. In the absence of shock, corticosteroids should not be administered for the treat- ment sepsis. There is, however, no contraindication to continuing g mainte nance steroid therapy or t to using stress dose steroids if the patient's history corticosteroid administration or the pa tient's endocrinel history warrants.\n\nRationale. There are no studies document the s of steroids improve ing that stress doses of shock sepsis in the absence outcome unless the patient requires stress dose replace- ment due to a prior history of steroid therapy or adrenal dysfunction.\n\n### I. Recombinant Human Activated Protein C (rhAPC)\n\n1. rhAPC is recommended in patients at high risk of death (Acute Physiology and Chronic Health Evaluation II ≥25, sepsis-induced organ failure, septic shock, multiple""]","Intravenous antibiotic therapy should be started within the first hour of recognition of severe sepsis, after appropriate cultures have been obtained",negative_rejection,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
What are the considerations for fluid resuscitation in pediatric patients with severe sepsis and shock?,What are the considerations for fluid resuscitation in pediatric patients with severe sepsis and shock?,"[""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', '17):1583-1593 10. Holst LB. Haase N. Wettersley J. Wernerman J Aneman A. Guttormsen AB et al (2013)Transfusiot requirements in septic shock (TRISS) trial- comparing the effects and safety of liberal versu: restrictivered blood celltransfusion insepticshoc patients in the ICU: protocol for a randomised controlledtrial Trials 14:150 Damiani E. Donati A. Serafini G. Rinaldi. Adraris E. Pelaia P et al (2015) Effect of performance improvementprograms on compliance withsepsi bundles and mortality: a svstematic review and meta-analvsis of observational studies. PLOS ON 10(5)e0125821 Scheer CS. Fuchs C. Kubn SO. Vollmer M. Rehber S. Friesecke S et al (2017) Quality improvement initiative for severe sepsis andsepticshockreduce 90-day mortality: A 7.5-year observational study Crit Care Med 45(2):241-25 Bloos E. Thomas-Ruddel D, Ruddel H, Enge C, Schwarzkopf D, Marshall JC et al (2014 Impact of compliance with infection managemen quidelines on outcome in patients with severe sepsis: A prospective observational multi-cente study. Crit Care 18(2):R42 Azuhata T. Kinoshita K. Kawano D. Komatsu1 SakuraiA. Chiba Yetal (2014) Timefrom admissior to initiation of surgery for source controli a critical determinant of survival in patients wit gastrointestinal perforation with associated septi shock. Crit Care 18(3):R8: 5. ARDSNetwork (2000) Ventilation with lowe tidal volumes as compared with traditiona tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Svndrome Network. N Engl Med 342(18):1301-1308 Amato MB, Meade MO, Slutsky AS, Brochard L Costa EL, Schoenfeld DA et al (2015) Driving pressure and survival in the acute respirator distress syndrome.N EnglJ Med 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandlL Austin P et al (2013) High-frequency oscillation ir early acute respiratory distress syndrome. N Engl Med 368(9):795-805 . Frat JP, Thille AW, Mercat A, Girault C, Ragot S Perbet S et al (2015) High-flow oxygen througl nasal cannula in acute hypoxemic respiratory failure. N Engl JMed 372(23):2185-2196 .Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK Jaschinski U et al (2016) Effect of sodium selenite administration and Procalcitonin-guided therapy on mortalityin patients with severesepsis or septi shock: Arandomized clinical trial. JAMA Intern Med 176(9):1266-1276\n\n### Buchbesprechung\n\nKiefer, T. (Hrsg. Thoraxdrainager Berlin Heidelberg: Springer-Verlae Berlin Heidelberg 2016. 1., 126 S (ISBN: 978-3-662-49739-5), Softcove 39,99 EUR Es ist sehr schwer. innerhalb der Welt de thoraxchirurgischen Bücher ein neues Werk zu schaffen, das einzigartig ist. Das Buch Thoraxdrainggen iedoch herausgegeber von Thomas Kiefer erfüillt ganz klar diese Definition, Und dies aleich aus mehrerer Gründen Zu allererst ist die: ein enorm praxisori entiertes Buch Die Drainage des Pleu Thorax raspaltes und das drainagen Management vor Thoraxdrainagen sind fundamentale Bestandteil der tho raxchirurgischen Arbeit. Die Tatsache, dass diese Themen in dem Buch mit aroBer Ernst haftigkeit besprochen werden, zeugen vor seiner Intention: es will praxisorientiert seir Das Buch will in einer einfachen, praktischer Weise hilfreich sein, Einzelne einfache De tails, die bei der täg', ' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(', 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion']","["" Large fluid deficits typically ex- ist. and initial volume resuscitation, usuall requires 40-60 mL/kg but can be much higher (112-114) 3. Vasopressors/Inotropes (Should Onluy Be Used After Anpropriate Volume Resuscita tion). Children with severe sepsis can present with low cardiac output and high svstemid vascular resistance, high cardiac output and low svstemic vascular resistance., or low car diac output and low svstemic vascular resis tance shock. Denending s on which situatior exists, inotropic support should be started in the case of fluid refractory shock or a combi nation of an inotrope together with a vaso- pressor or a vasodilator, Dopamine is the firs choice of support for the pediatric patient with hypotension refractory to fluid resuscitation The choice of vasoactive agent is determined by the clinica examination Dopamine refractory shock may reverse with epinephrine infusion (l14). Pediatri norepinephrine patients with low cardiac output states may benefit from use of dobutamine. The e use o vasodilators can reverse shock in pediatric pa tients who remain hemodynamically unstable with a high systemic vascular resistance state despite fluid Iresuscitation and implementa tion of inotropic support (114, 115). Nitroso- vasodilators with a very short half-lifte (nitro prusside or nitroglvcerin) are used as first-lin therapy for children with epinephrine-resis tant low cardiac output and elevated systemid vascular-resistance shock. Inhaled nitric oxid reduced extracorporeal membrane oxvgen ation (ECMO) use when given to term neo nates with persistent pulmonary artery hyper\n\n### Q. Stress Ulcer Prophylaxis\n\nRecommendation: Grade A\n\nRationale. Although no study has been performed specifically in patients with severe of trials confirming the benefit sepsis, large stress ulcer prophylaxis in general ICU popu- lations have included significant numbers septic patients (105-108). This benefit should be applicable to patients with severe sepsis and shock. In addition, the conditions septic shown to benefit from stress ulcer prophvlaxis (coagulopathy, mechanical ventilation, hypo: o patients frequently are tension) present with severe sepsis and septic shock.\n\n### R. Consideration for Limitation of Support\n\n+ 1. Advance care planning, including 5 the communication of likely s and outcomes of treatment. should be realistic goals discussed with patients and families. De- for less or cisions support aggressive withdrawal of support may h be in the pa- tient's best interest.\n\nIt is too frequent that inade- Rationale, physician/family communication char- quate acterizes end-of-life care in the ICU. The leve) of life ICU patients 1 support g given may not and fre- be consistent with their wishes, Early quent caregiver discussions with patients whd face death in the ICU and their loved ones may facilitate with and application appropriate drawal of life-sustaining therapies.\n\n### S. Pediatric Considerations\n\n1. Mechanical Ventilation. Due low to functional capacity, young infants residual and neonates with severe sepsis may require early intubation (109). The principles of lung- protective strategies are applied to children as to adults. In premature infants, addi- they are tional attention is paid to avoiding hyperox- emia to prevent retinopathy. 2. Fluid Resuscitation. Intravenous access for f fluid resuscitation and inotrope/vasopres- difficult to attain in chil- sor infusion is more dren than in adults. The Heart As- American sociation has developed pediatric advanced life establish guidelines for support emergency\n\nof the and tensior newborr sepsis in randomized controlled trial (116), When pedi atric patients remain in a normotensive lovy cardiac output and high vascular resistance state. despite epinephrine and nitrosovasodi lator therapy, then the use of a phosphodies terase inhibitor should be strongly considered (117-119). Pentoxifylline (not available in the United States) improved outcome in prema-  with given for f ture neonates when sensis brs/day for 5 davs in a randomized controlled trial (120) 4 Theraneutic End Points. Therapeutic end points are canillary refill of <2 secs nor mal pulses with no differential between ne ripheral and central pulses, warm extremities urine output >1 mL.ko-1.hr""]","In pediatric patients with severe sepsis and shock, intravenous access for fluid resuscitation and inotrope/vasopressor infusion may be difficult to attain. The Heart Association has established guidelines for the emergency support of neonatal sepsis. If pediatric patients remain in a normotensive, low cardiac output, and high vascular resistance state despite epinephrine and nitrosovasodilator therapy, the use of a phosphodiesterase inhibitor should be strongly considered. Pentoxifylline, although not available in the United States, has shown improved outcomes in premature neonates with sepsis when given for five days. Therapeutic endpoints for fluid resuscitation include capillary refill of less than two seconds, normal pulses with no differential between peripheral and central pulses, warm extremities, and urine output greater than 1 mL/kg/hr.",negative_rejection,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
How has ECMO technology spread worldwide?,How has the exchange and application of ECMO technology evolved globally over time?,"['功率并不高。为了推动全球范围 内的ECMO技术交流与应用,在Bartlet教授推动 下国际体外生命支持组织(Extracorporeal Life Support Organization,ELSO)于1989年在密歇根大 学成立但直至2004年,全世界仅有100多家医院 开展此项工作,并且主要集中在西方发达国家。从 2008年ECMO用于成功救治甲型流感患者之后,全 球ECMO数量开始呈现快速增长趋势13 中国内地最早1例真正意义上的ECMO支持 病例始于2002年,但限于当时的经济水平、医疗条 件和医疗报销制度的限制,这一设备没有得到大范 围推广,到2015年全国ECMO中心的数量才突码 随着医疗水平的逐渐发展和医保政策的 100家。 整,中国的ECM0开始有了飞速发展。2019年底 新型冠状病毒肺炎(新冠肺炎)爆发ECMO被用干 重症新冠肺炎惠者的救治,开始进入大众视野;手) 目由于其在新冠疫情救治中起到的重要作用,国家 卫生健康委员会在《新型冠状病毒感染的肺炎诊疗 方案》中将ECMO列为危重症新冠肺炎患者的重要 救治技术,极大地促进了国内各医疗机构进一步开 展ECMO相关培训学习,成立ECMO中心(45 二、ECMO开展现状 近年ECMO临床应用突飞猛进。世界范围内 据ES0的统计数据显示,2019年全球共有488个 ECMO中心,实施ECMO的病例达到17078例,截¥ 2021年10月的统计数据显示2020年注册的ECMQ 中心数增至521个,全年开']","['功率并不高。为了推动全球范围 内的ECMO技术交流与应用,在Bartlet教授推动 下国际体外生命支持组织(Extracorporeal Life Support Organization,ELSO)于1989年在密歇根大 学成立但直至2004年,全世界仅有100多家医院 开展此项工作,并且主要集中在西方发达国家。从 2008年ECMO用于成功救治甲型流感患者之后,全 球ECMO数量开始呈现快速增长趋势13 中国内地最早1例真正意义上的ECMO支持 病例始于2002年,但限于当时的经济水平、医疗条 件和医疗报销制度的限制,这一设备没有得到大范 围推广,到2015年全国ECMO中心的数量才突码 随着医疗水平的逐渐发展和医保政策的 100家。 整,中国的ECM0开始有了飞速发展。2019年底 新型冠状病毒肺炎(新冠肺炎)爆发ECMO被用干 重症新冠肺炎惠者的救治,开始进入大众视野;手) 目由于其在新冠疫情救治中起到的重要作用,国家 卫生健康委员会在《新型冠状病毒感染的肺炎诊疗 方案》中将ECMO列为危重症新冠肺炎患者的重要 救治技术,极大地促进了国内各医疗机构进一步开 展ECMO相关培训学习,成立ECMO中心(45 二、ECMO开展现状 近年ECMO临床应用突飞猛进。世界范围内 据ES0的统计数据显示,2019年全球共有488个 ECMO中心,实施ECMO的病例达到17078例,截¥ 2021年10月的统计数据显示2020年注册的ECMQ 中心数增至521个,全年开']","The exchange and application of ECMO technology globally have evolved significantly over time. Professor Bartlet pushed for the establishment of the Extracorporeal Life Support Organization (ELSO) in 1989 at the University of Michigan. However, until 2004, only a little over 100 hospitals worldwide were engaged in this work, mainly concentrated in developed Western countries. After the successful use of ECMO in treating patients with type A influenza in 2008, the number of ECMO cases globally began to grow rapidly. The first genuine ECMO support case in mainland China occurred in 2002, but due to economic conditions, medical limitations, and healthcare reimbursement systems at the time, this equipment was not widely promoted until around 2015 when the number of ECMO centers nationwide suddenly increased to 100. With the gradual development of medical standards and healthcare policies, ECMO in China began to develop rapidly. At the end of 2019, with the outbreak of COVID-19, ECMO was used to treat critically ill patients, gaining public attention. Due to its significant role in treating COVID-19, the National Health Commission of China included ECMO as an important treatment technology for critically ill COVID-19 patients in the Diagnosis and Treatment Plan for Novel Coronavirus Infection, greatly promoting further ECMO-related training and the establishment of ECMO centers in various medical institutions across the country.",k_context,[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}],True
"What are the treatment options and considerations for pediatric patients with septic shock, especially concerning preload optimization and hydrocortisone therapy?",What treatment options and considerations should be taken into account for pediatric patients experiencing septic shock?,"['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","Treatment options and considerations for pediatric patients experiencing septic shock include optimizing preload to optimize cardiac index, reserving hydrocortisone therapy for children with catecholamine resistance and suspected or proven adrenal insufficiency, considering the role of protein C and Activated Protein C, administering Granulocyte Macrophage Colony Stimulating Factor for patients with neutropenia, monitoring for and preventing deep vein thrombosis (DVT) associated with central venous catheters, considering stress ulcer prophylaxis especially in mechanically ventilated children, and using renal replacement therapy such as continuous venovenous hemofiltration in cases of anuria/severe oliguria and fluid overload. Glycemic control is also important, especially for infants dependent on intravenous glucose.",k_context,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
"How do factors influence pulmonary edema in ARDS patients, and what's the effect of restrictive fluid therapy on outcomes?",What are the mechanisms underlying pulmonary edema in ARDS patients?,['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动'],['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动'],"The mechanisms underlying pulmonary edema in ARDS patients include increased capillary permeability, increased hydrostatic pressure, and decreased colloid osmotic pressure. Studies suggest that restrictive fluid therapy for ARDS can reduce patients' mechanical ventilation time and ICU stay without significantly affecting the incidence of renal failure or mortality. Restrictive fluid strategy is beneficial in reducing the incidence of ARDS in septic patients, and within 12 hours of septic shock onset, a decrease in extravascular lung water index indicates improved survival rates. Small-sample studies indicate that restrictive fluid therapy for critically ill patients results in lower mortality rates, shorter mechanical ventilation time, and shorter hospital stays compared to fluid balance strategies. A study of 1000 patients with acute lung injury found no significant improvement in 60-day mortality in the restrictive fluid therapy group compared to the open fluid therapy group, but there was improved oxygenation, decreased lung injury score, and shortened mechanical ventilation time.",k_context,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What oversight does CSECLS have over ECMO centers and procedures in mainland China?,What role does the Chinese Medical Association play in the development and regulation of ECMO (Extracorporeal Membrane Oxygenation) centers and procedures in mainland China?,"['展18260例,累计总共) 展ECM0154106例,54%的患者可存活至出院或转 从ECMO中心分布上看,ECMO中心尤其是 高水平的ECMO中心,主要集中于北美\n\n近年来,ECMO在中国大陆地区同样发展迅 猛,ECMO中心及开展ECMO的例数均有明显增 加,中国医师协会体外生命支持专业委员 (CSECLS)第四届中国体外生命支持年会上布的 数据显示,2020年共有500家ECM0中心上报数 据共开展ECMO患者6937例较2019年增加 6.3%。在患者人群与适应证方面,成人患者占绝大 数,成人接受呼吸、心脏辅助患者的生存率分别 达到54.5%和51.6%,与ELS0数据相当但体外心 肺复苏(ECPB)患者生存率仅为27.6%. 随着ECMO开展例数的逐渐增加,接受ECMO 支持患者的流行病学和临床特征,影响患者死广的 危险因素及社会经济影响等逐渐被揭示为后 :结 ECMO患者适应证的选择,判断患者预后等起到重 要作用(8-11] 然而虽然从2017年开始国内ECMO 开展例数明显增加,但国内尚无准确客观的统计 资料详细描述ECMO患者的流行病学及预后情况 CSECLS虽然收集每年国内ECMO中心和开展例 数、死亡率等相关信息,但缺乏更加客观、详尽的统 计,不能为后续ECMO的发展提供进一步的指导。 笔者团队在国家卫生健康委员会领 面导下对 2018年全国1700家三级医院接受ECMO治疗患者 的临床及预后信息进�']","['展18260例,累计总共) 展ECM0154106例,54%的患者可存活至出院或转 从ECMO中心分布上看,ECMO中心尤其是 高水平的ECMO中心,主要集中于北美\n\n近年来,ECMO在中国大陆地区同样发展迅 猛,ECMO中心及开展ECMO的例数均有明显增 加,中国医师协会体外生命支持专业委员 (CSECLS)第四届中国体外生命支持年会上布的 数据显示,2020年共有500家ECM0中心上报数 据共开展ECMO患者6937例较2019年增加 6.3%。在患者人群与适应证方面,成人患者占绝大 数,成人接受呼吸、心脏辅助患者的生存率分别 达到54.5%和51.6%,与ELS0数据相当但体外心 肺复苏(ECPB)患者生存率仅为27.6%. 随着ECMO开展例数的逐渐增加,接受ECMO 支持患者的流行病学和临床特征,影响患者死广的 危险因素及社会经济影响等逐渐被揭示为后 :结 ECMO患者适应证的选择,判断患者预后等起到重 要作用(8-11] 然而虽然从2017年开始国内ECMO 开展例数明显增加,但国内尚无准确客观的统计 资料详细描述ECMO患者的流行病学及预后情况 CSECLS虽然收集每年国内ECMO中心和开展例 数、死亡率等相关信息,但缺乏更加客观、详尽的统 计,不能为后续ECMO的发展提供进一步的指导。 笔者团队在国家卫生健康委员会领 面导下对 2018年全国1700家三级医院接受ECMO治疗患者 的临床及预后信息进�']",nan,k_context,[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}],True
What are the recommendations for using dynamic indicators to predict fluid responsiveness in patients with sepsis or septic shock?,What are the recommendations for using dynamic indicators to predict fluid responsiveness in patients with sepsis or septic shock?,"['RT 需求、 尿量、生存期、住院时间、 心律失常发生率等疗效指标均无显著改善。 我国相关研究表明， LDD 不能降低脓毒症急性肾衰竭患者 RRT 需求及病死率。\n推荐意见 21 ：经过充分的液体复苏以及使用血管活性药物后，如果仍持续低灌注，建 议使用多巴酚丁胺(弱推荐，低证据质量)。\n多巴酚丁胺作为一线正性肌力药，为 EGDT 临床试验标准治疗的一部份，在其使用中 未发现对病死率的不良影响。 两项 ICU 脓毒症患者的大型前瞻性临床试验显示，使用多巴 酚丁胺将患者心输出量提高至高于正常水平不会改善临床结局。然而， 一些患者可能通过正 性肌力药物改善组织灌注，增加氧气输送。我国一项评价多巴酚丁胺联用去甲肾上腺素治疗 脓毒性休克伴顽强性低血压的研究表明，多巴酚丁胺可有效升高血压， 改善循环与灌注，提 高救治成功率。\n推荐意见 22：建议所有需要血管活性药物的患者置入动脉导管进行连续性血压测定(弱 推荐， 极低证据质量)。\n在休克状态， 使用动脉导管监测血压比袖带血压计测量更准确，可进行连续监测且允许\n如有侵权请联系网站删除\n每搏分析，有助于医务人员更准确', 'ressor agents); c) no new po- d) low tentially serious conditions; ventilatory and end-expiratory pressure e) requiring levels of requirements: and F102 that could be safely delivered with a face mask or nasal cannula. If the spon- breathing trial is successful taneous consideration should be given for extu- Appendix bation (see D). Spontaneous breathing trial options n include level of pressure continu- support with ous positive airway pressure 5 cm H.O or a T-piece\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Recent studies demonstrate that daily spontaneous breathing trials the c duration of mechanical ventilation ducet (78-80). Although these studies had limited of patients with documented ALI/ numbers ARDS. believe that there is to no reason different out- ALI/ARDS patients would have comes from other critically ill patients. Suc- breath- cessful completion of spontaneous of a high likelihood trials leads to ing discontinuation of successful mechanical ventilation.\n\n### L. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis\n\n1. Protocols should be used when sedation of critically ill mechanically ventilated patients is required. The protocol should include the usec of a sedation goal, ,mea- a standardized subjective sured by seda- tion scale.\n\nR\n\nRationale (Ll and L2). Mechanically ven- tilated patients receiving continuous sedation duration of a significantly have longer may mechanical ventilation as well as ICU and hos- pital length of stay (81). A daily interruption or ""continuous"" sedative infusion lightening of a patient is awake the until the may decrease 1 ICU duration of and ventilation mechanical (82). The sedation stay use  protocols in mechanically ventilated patients has shown a duration of reduced Iventilation, mechanica. length of stay, and tracheostomy rates (83).\n\nblockers should be 3. Neuromuscular avoided if all possible in the septic patient due to the risk of prolonged neu- blockade following discon- romuscular tinuation. If blockers neuromuscular than the first must be e used for longer hours mechanical ventilation, either intermittent bolus as required or contin uous infusion with monitoring of depth of block: with train of four rmonitoring should be used\n\nRationale. Prolonged skeletal muscle n critically ill weakness has been reported in patients following the use of intermediate- and long-acting neuromuscular blockers (84-91). The risk of prolonged be re- paralysis may\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nof the duced if an intermittent assessment depth blockade is of neuromuscular per- formed (92, 93),\n\n### M. Glucose Control\n\n1. Following initial stabilization of patients with severe sepsis, maintain blood glu- <150 mg/dL (8.3 mmol/L). Studies cose the role e of glycemic control supportingt have used continuous infusion of insulin and glucose. With this protocol, glucose should be monitored frequently after ini 30-60 tiation of the protocol (every mins) and on a regular basis (every 4 hrs. the blood glucose concentration once has stabilized\n\noiuue Rationale. A large single-center trial of showed signit postoperative e surgical patients icant improvement in I survival when continu- ous infusion insulin  was used to maintair 80 and 110 mg/dL (4.4-6.1 glucose between (94). Exogenous glucose was begun mmol/L) simultaneously with insulin with frequent monitoring of glucose (every 1 hr) and inten- sity of monitoring greatest at the time of ini- tiation of insulin. Hvpoglvcemia 1may occur There is 1 no reason to think that these data are not generalizable to all severely septic pa- tients. Post hoc data analysis of the trial data revealed that although best results were ob- glucose was maintained between tained when: 80 and 110 mg/dL (4.4 and 6.1 mmol/L) <150 mg/dL (8.3 mmol/L achieving a goal of < also improved outcome when compared with This goal will likely higher concentrations.T reduce the risk of hypoglycemia. The contro. of the blood glucose concentration appears to be more important than the amount of insulin infused (95, 96). The frequency of blood glu cose determinations may require the use of central or arterial catheters for blood sam pling\n\n2. In patients with severe sepsis, a strategy of glycemic control should include a nu- trition protocol with the preferential use of the enteral route.', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', "" Caspani ML, et al Constant mean airway pressure with differ ent patterns of positive pressure breathing during the adult respiratory distress syn- drome. Bull Eur Physiopathol Respir 1985 21:275-279 Pesenti A, Marcolin R. Prato P. et al: Mear airway pressure vs. positive end-expiratory pressure during mechanical ventilation Crit Care Med 1985: 13:34-3 Stocker R. Neff T, Stein  S, et al: Prone positioning and low-volume pressure limited ventilation improve survival in pa- tients with severe ARDS. Chest 1997; 111 1008-1017 Lamm WJ, Graham MM, Albert RK: Mech- anism by which  prone position improve: oxygenation in acute lung injury. Am J Re spir Crit Care Med 1994; 150:184-193 Jolliet P, Bulpa P, Chevrolet JC: Effects of the  position on gas exchange and e prone hemodynamics in severe acute respiratory distress syndrome. Crit Care Med 1998: 26 1977-1985 Gattinoni L, Tognoni G, Pesenti A, et al Effect of prone positioning on the surviva of patients with acute respiratory failure N Engl J Med 2001; 345:568-573\n\nprofiles of vecuronium and recovery cisatracurium 51W89 in intensive care uni patients, Anesth Analg 1995: 81:3-12 Brandom BW, Yellon FF. Lloyd ME, et al Recovery from doxacurium infusion admin istered I to produce immobility for more than four days in pediatric patients in the intensive care unit. Anesth Anala 1997: 84 307-314 Rudis MI. Sikora CA. Angus E. et al: / prospective, randomized., controlled evalua tion of peripheral nerve stimulation versu standard clinical dosing of neuromusculal blocking agents in critically ill patients Cr Core Med 1997: 25-25575-2558'3 Frankel H. Jeng J. Tilly E. et al: The impac of implementation of neuromuscular block ade monitoring standards in a surgical in tensive care unit Am Suro 1996: 62 503-506 van den Berohe G Wouters P Weekers F e al: Intensive insulin therapy in the critically ill patients. N Enal J Med 2001: 345 1359-1367 Finney SJ, Zekveld C. Elia A., et al: Glucose control and mortality in critically ill pa tients, JAMA 2003: 2041-2047 Van den Berohe G Wouters PI Bouillon F et al: Outcome benefit of intensive insulir therapy in the critically ill: Insulin dose Crit Care Med glvcemic control. versus 2003:31:359-366 Klein S. Kinney J. Jeeieebhoy K. et al: Nu trition support in clinical practice: Reviev of published data and recommendations fo future research directions. A summary of a conference sponsored by the National Insti tutes of Health. American Society for Par enteral and Enteral Nutrition, and Ameri can Society for Clinical Nutrition. Am J Cli Nutr 1997: 66:683-706 Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical trial of continuous ver sus intermittent dialysis for acute renal fail ure. Kidney Int 2001; 60:1154-1163 al Kellum J. Angus DC. Johnson JP et Continuous  versus intermittent renal re placement therapy: A meta-analysis. Inten sive Care Med 2002: 28:29-37 Cooper DJ, Walley KR. Wiggs BR, et al Bicarbonate does not improve hemody namics in critically ill patients who have lactic acidosis: A prospective, controlled clinical study. Ann Intern Med 1990; 112 492-498 Mathieu D. Neviere R. Billard V. et al: Ef fects of bicarbonate therapy on hemody namics and tissue oxygenation in patient with lactic : acidosis: A prospective, con trolled clinical study. Crit Care Med 1991 19:1352-1356 102. Cade JF: High risk of the critically ill fo: Crit Care Mes venous thromboembolism. 1982:10:448-450 103. Belch JJ, Lowe GD, Ward AG, et al: Preven tion of deep vein thrombosis in medica patients by low-dose heparin. Scott Med. 1981:26:115-117\n\nCrit Care Med 2004 Vol. 32, No. 3\n\n104. Samama MM, Cohen AT, Darmon JY, et al A comparison of enoxaparin with placebo"", '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome"", 'uch die e Empfehlung gegen rou- des tinemäfsiges Monitoring gastralen Residualvolumens. Bei Ernährungsin- und hohem toleranz Aspirationsrisiko\n\nwird das Monitoring des gastralen Resi- dualvolumens jedoch empfohlen.\n\n### Antikoaqulation, Thrombose- und Stressulkusprophylaxe\n\nDie Empfehlungen zur :Thrombosepro- der aktuellen Leitli- phylaxe sind in c nienversion strukturierter : und prag- dies Im Kern 1 betrifft dargelegt. nanter die Anwendung einer medikamentöser Thromboseprophylaxe beim Fehlen von Kontraindikationen (hohe Empfehlungs: der stärke, moderate Qualität r Evidenz mit Bevorzugungvon niedermolekularen unfrak- gegeniiber Heparinpraparaten tioniertem Heparin (hohe Empfehlungs-\n\n2 Vereinfachte Darstellung von Empfehlungsstärke und Qualität der Evidenz nach GRADE-System (Grading of Recommendations Assessment\n\n\n|    | 0                                      | 1                                                                                                                                              |\n|---:|:---------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Development,and Evaluation,[1,3]       | Development,and Evaluation,[1,3]                                                                                                               |\n|  1 | Empfehlungsstärke                      | Empfehlungsstärke                                                                                                                              |\n|  2 | Starke Empfehlungstrong recommendation | Mainahmen, welche in den meisten Fällen angewandt werden sollten                                                                               |\n|  3 | Schwache Empfehluncweak recommendation | MaBnahmen, welche nach individueller Abwäqung für den jeweiligen Patienten sinnvoll sein können          ', '                                                                                             | 2                                                                                                                                                                                              | 3                                      |\n|---:|:-----|:-------------------------------------------------------------------------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------|\n|  0 | Tab. | nan                                                                                                    | nan                                                                                                                                                                                            | nan                                    |\n|  1 | nan  | MaBnahme/Empfehlunc                                                                                    | nan                                                                                                                                                                                            | Empfehlungsstärke,Oualität der Evidenz |\n|  2 | S ', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�']",['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反'],"The recommendations for using dynamic indicators to predict fluid responsiveness in patients with sepsis or septic shock include passive leg raising test, volume challenge test, changes in stroke volume after fluid administration, changes in systolic blood pressure, changes in pulse pressure, and changes in intrathoracic pressure after mechanical ventilation. These dynamic indicators can improve diagnostic accuracy. Retrospective analysis of relevant studies shows that using pulse pressure variation to predict fluid responsiveness in patients with sepsis or septic shock has high sensitivity and specificity.",noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What is the preferred method for blood sampling when utilizing an arterial catheter?,What is the preferred method for blood sampling when utilizing an arterial catheter?,"['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", 'uch die e Empfehlung gegen rou- des tinemäfsiges Monitoring gastralen Residualvolumens. Bei Ernährungsin- und hohem toleranz Aspirationsrisiko\n\nwird das Monitoring des gastralen Resi- dualvolumens jedoch empfohlen.\n\n### Antikoaqulation, Thrombose- und Stressulkusprophylaxe\n\nDie Empfehlungen zur :Thrombosepro- der aktuellen Leitli- phylaxe sind in c nienversion strukturierter : und prag- dies Im Kern 1 betrifft dargelegt. nanter die Anwendung einer medikamentöser Thromboseprophylaxe beim Fehlen von Kontraindikationen (hohe Empfehlungs: der stärke, moderate Qualität r Evidenz mit Bevorzugungvon niedermolekularen unfrak- gegeniiber Heparinpraparaten tioniertem Heparin (hohe Empfehlungs-\n\n2 Vereinfachte Darstellung von Empfehlungsstärke und Qualität der Evidenz nach GRADE-System (Grading of Recommendations Assessment\n\n\n|    | 0                                      | 1                                                                                                                                              |\n|---:|:---------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Development,and Evaluation,[1,3]       | Development,and Evaluation,[1,3]                                                                                                               |\n|  1 | Empfehlungsstärke                      | Empfehlungsstärke                                                                                                                              |\n|  2 | Starke Empfehlungstrong recommendation | Mainahmen, welche in den meisten Fällen angewandt werden sollten                                                                               |\n|  3 | Schwache Empfehluncweak recommendation | MaBnahmen, welche nach individueller Abwäqung für den jeweiligen Patienten sinnvoll sein können          ', '                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |', '                                                                                                                                                                       | nan                                    |\n|  6 | nan  | Keine frühe parenterale Ernährung, auch kombiniert mit enteraler Ernährung, wenn enterale              | Ernährung möalich                                                                                                                                                                              | Evidenz moderat                        |\n|  7 | nan  | falls keine enterale Ernährung möglich ist, stattdessen: i. v. Glucose und langsame Steigerung         | der enteralen Ernährung                                                                                                                                                                        | Starke EmpfehlungEvidenz moderat       |\n|  8 | nan  | nan                                                                                                    | Früher Start der enteralen Ernährung, wenn möglich                                                                                                                                             | Schwache EmpfehlungEvidenz niedrio ', ' | nan                                    |\n| 26 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n| 27 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n\nBPS Best Practice Statement, Ha Hämoglobin, FFP Fresh Frozen Plasma, PEEP positive endexpiratory pressure"", paO2 arterieller Sauerstoffpartialdruck FIO  inspiratorische Sauerstofffraktion, HFOV.high frequency oscillatory yentilation"" Gl gastrointestina\n\nWeiterhin wird unverändert von der Anwendung von Hydrokortison bei sep- tischem Schock abgeraten, wenn man durch Volumen- und Vasopressorthera- pie eine hämodynamische Stabilität zielen kann; falls dies nicht gelingt, , wird die Gabe von Hydrokortison in einer Ta- gesdosis von 200 mg empfohlen. Die Gabe von Selen wird gemäf den deutschen SISPCT-Studie als Daten dere ,strong recommendation"" nicht empfoh- len [19].\n\n### Ernährung\n\nIn der aktuellen Version der Leitlinien ist der Stellenwert der enteralen Ernährung\n\nder gegenüiber Ernährung parenteralen l Eine frühe mehrfach betont: enterale hypo- Ernährung, bzw. trophisch auch Neu ist wird klar favorisiert kalorisch, mit niedri- eine schwache Empfehlung ger Evidenz zum Einsatz postpylorischer bei mit Patienten Ernährungssonden Aspi- oder hoher Ernährungsintoleranz rationsgefahr. Neu sind die Stellungnah Zu Omega-3-Fettsäuren, Arginin men Glutamin, empfohlen welche nicht unde der Neu  aktuellen Version werden. ist a']","['                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |']",The preferred method for blood sampling when utilizing an arterial catheter is to draw blood from the arterial catheter.,noise_robustness,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
"What are the benefits of implementing a stepped approach to antibiotic treatment in patients with sepsis and septic shock, according to recent research findings?","What are the benefits of implementing a stepped approach to antibiotic treatment in patients with sepsis and septic shock, according to recent research findings?","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,"", 'uch die e Empfehlung gegen rou- des tinemäfsiges Monitoring gastralen Residualvolumens. Bei Ernährungsin- und hohem toleranz Aspirationsrisiko\n\nwird das Monitoring des gastralen Resi- dualvolumens jedoch empfohlen.\n\n### Antikoaqulation, Thrombose- und Stressulkusprophylaxe\n\nDie Empfehlungen zur :Thrombosepro- der aktuellen Leitli- phylaxe sind in c nienversion strukturierter : und prag- dies Im Kern 1 betrifft dargelegt. nanter die Anwendung einer medikamentöser Thromboseprophylaxe beim Fehlen von Kontraindikationen (hohe Empfehlungs: der stärke, moderate Qualität r Evidenz mit Bevorzugungvon niedermolekularen unfrak- gegeniiber Heparinpraparaten tioniertem Heparin (hohe Empfehlungs-\n\n2 Vereinfachte Darstellung von Empfehlungsstärke und Qualität der Evidenz nach GRADE-System (Grading of Recommendations Assessment\n\n\n|    | 0                                      | 1                                                                                                                                              |\n|---:|:---------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Development,and Evaluation,[1,3]       | Development,and Evaluation,[1,3]                                                                                                               |\n|  1 | Empfehlungsstärke                      | Empfehlungsstärke                                                                                                                              |\n|  2 | Starke Empfehlungstrong recommendation | Mainahmen, welche in den meisten Fällen angewandt werden sollten                                                                               |\n|  3 | Schwache Empfehluncweak recommendation | MaBnahmen, welche nach individueller Abwäqung für den jeweiligen Patienten sinnvoll sein können          ', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', ""Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732-747 Warren"", "" and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD; Alain""]",['�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�'],"Recent research findings suggest that implementing a stepped approach to antibiotic treatment in patients with sepsis and septic shock is associated with better clinical outcomes and reduced occurrence of bacterial resistance. Additionally, daily assessment of antibiotic de-escalation feasibility may decrease patient mortality rates. Therefore, it is recommended to evaluate antibiotic use in patients with sepsis and septic shock on a daily basis.",noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are some unresolved technical challenges associated with VA-ECMO technology?,What are some unresolved technical challenges associated with VA-ECMO technology?,"[' auch\n\nin aktuellen Untersuchungen demons triert werden,wobeinach Daten der deut schen MEDUSA-Studie die Verzögerung der Fokuskontrolle um sechs Stunder einen nachteiligen Effekt auf das Out come darstellt [13, 14]. Die Empfehlung zum raschen Wechsel bzw. Neuanleger von intravasalen Kathetern blieb im Ver gleich zur Vorversion der Leitlinien weit gehend unverändert: während hingeger zwei spezifische Empfehlungen der vor herigen Version, bezüglich peripankrea tischer Nekrose sowie Vorzug yon mini malinvasiven Verfabren zur Fokuskon trolle beim schwer erkrankten Patienten in die neuen Leitlinien keinen o Einzus fanden Die Empfehlungen zur antimikrobiel len Therapie wurden erweitert und spezi fiziert. Die Empfehlung zur möglichst ra schen Gabe einer antimikrobiellen The rapie, in der Vorgängerversion der Leitli nie noch mit dem Schwerpunkt der Gabe innerhalb der ersten Stunde, wurde sinn vollerweise mit der Angabe ,so schnel wie möglich nach Erkennen und inner halb der ersten Stunde von Sepsis und septischen Schock"" spezifiziert, als stark Empfehlung mit moderatem Evidenzni veau. Eine ebenso sinnvolle Neuerung stellt die Best-Practice-Statement-Emp tehlung zur Deeskalation der antimikro biellen Therapie dar, hier wird explizi zur Verschmälerung des antimikrobiel len Spektrums nach Erhalt von Erre gerbestimmung und Resistenzspektrun bzw. bei klinischer Besserung geraten Eine interessante Neuerung ist eben Best-Practice-Statement-Emp fehlung einer für Sepsis/septischer Schock optimierten Dosierung der anti mikrobiellen Therapie auf der Basis vor pharmakokinetischen und 1 pharmako dynamischen Prinzipien. Die in diesen Kontext wesentlichen pathophysiologi schen Besonderheiten beim Patienter mit Sepsis bzw. septischem Schock sind ein erhöhtes Verteilungsvolumen sowie Veranderungen von Nierenfunktion und Leberfunktion. Unterdosierung bei de: antimikrobiellen Therapie, wie wieder holt nach Möglichkei muss t gezeigt vermieden werden, hierbei gilt es auch spezifische Unterschiede bei den einzel nen Substanzgruppen zu beachten\n\n inhalt- Eine zur Vorgängerversion lich weitgehend unveränderte schwache Stellenwert abneh- Empfehlung zum als Ent- Procalcitoninwerte mender scheidungshilfe Beendigung einer zur Therapie empirischen antimikrobiellen bei ohne Hinweis Patienten weiteren den ak- auf eine Infektion wurde Zudem tuellen 1 Leitlinien fortgefüihrt. die wird dass Bestimmung vermerkt, Procalcitoninwerten dazu von beitragen die der Dauer antimikrobiellen kann, Die bei Sepsis verkiirzen. Therapie haben Procalcitonin Empfehlungen jedoch nur schwache Empfehlungsstärke und niedrige Qualität der Evidenz.\n\n### Infektionsprävention\n\nDas Kapitel Infektionsprävention, das den Einsatz', ""Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732-747 Warren"", '��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�', "" and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD; Alain"", "":1851-1858 Esteban A. Alia I. Tobin MJ, et al: Effect of spontaneous breathing trial duration attemnts to discontinue me chanical ventilation Snanish Lung Failur Collaborative Group, Am J Respir Crit Care Med 1999: 159:512-518 Ely EW. Baker AM. Dunagan DP., et al: Ef fect on the duration of mechanical ventila tion of identifving patients capable o breathing spontaneously, N Enal J Med 1996:335:1864-1869 Esteban A. Alia I. Gordo E. et al: Extubatior outcome after spontaneous breathing trial: with T-tube or pressure support ventilation The Snanish Lung Failure Collaborativ Group. Am J Respir Crit Care Med 1997 156:459-465 Kollef MH, Levy NT. Ahrens TS, et al: The use of continuous IV sedation is associated with prolongation of mechanical ventila tion Chest 1998: 114:541-548 Kress JP. Pohlman AS. O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechani cal ventilation. N Enal J Med 2000: 342 1471-1477 Brook AD. Ahrens TS, Schaiff R, et al: Effec of a nursing-implemented sedation protoco on the duration of mechanical ventilation Crit Care Med 1999: 27:2609-2615 Giostra E. Magistris MR. Pizzolato G. et al Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group o: seven patients and two sporadic cases, with electrophysiologic and histologic examina tion. Chest 1994: 106:210-220 Rossiter A, Souney PF, McGowan S, et al Pancuronium-induced prolonged neuro muscular blockade. Crit Care Med 1991 19:1583-1587 Partridge BL, Abrams JH, Bazemore C, et al Prolonged neuromuscular blockade afte long-term intusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-1179 Vanderheyden BA, Reynolds HN, Gerole KB, et al: Prolonged paralysis after long term vecuronium infusion. Crit Care Med 1992; 20:304-30 Meyer KC, Prielipp RC, Grossman JE, et al Prolonged weakness after infusion of atra curium in two intensive care unit patients Anesth Analg 1994: 78:772-774 Manthous CA. Chatila W: Prolonged weak ness after withdrawal of atracurium. Am. Respir Crit Care Med 1994; 150:1441-1443 Prielipp RC, Coursin DB, Scuderi PE, et al Comparison o of the e intusior requirement\n\ncenter Trial Group on Tidal Volume reduc tion in ARDS. Am J Respir Crit Care Med 1998:158:1831-1838 Brower RG. Shanholtz CB. Fessler HE, et al Prospective, randomized, controlled clinica trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients, Crit Care Med 1999: 27:1492-1498 Brower RG Fessler HE: Mechanical venti lation in acute lung iniury and acute respi ratory distress Clin Chest Med svndrome 2000:21:491-510 Eichacker PO. Gerstenberger EP. Bank: SM. et al: Meta-analysis of acute lung iniury and acute respiratory distress svndrome tri als testing low tidal volumes. Am J Respit Crit Care Med 2002: 166:1510-1514 with lower tidal volumes Ventilation as compared with traditional tidal volumes fo: acute lung injury and the acute respirator: distress svndrome The Acute Respiratory Distress Syndrome Network. N Enal J Mer 2000: 342:1301-1308 Hickling KG. Walsh J. Henderson S, et al Low mortality rate in adult respiratory dis tress svndrome : using low-volume, pres sure-limited ventilation with nermissive by percapnia: A prospective study. Crit Car Med 1994:22:1568-1578 Bidani A. Tzouanakis AE, Cardenas VJ, et al Permissive hypercapnia in acute respiratory failure. JAMA 272:957-962 J. Ravenscraft - SA: Mean Marini 1 airway pressure: Physiologic determinants clinical importance-Part I: Physiologic de measurements. Crit terminants and Med 1992: 20:1461-1472 Gattinoni L, Marcolin R."", '                                                                           |\n| 11 | Sehr niedrig ,very low                 | Evidenz basiert auf Studien mit eingeschränkter Oualität und/oder Expertenmeinung bzw., sonstige Evidenz                                       |\n| 12 | Best Practice Statement(BPS)           | Empfehlung, welche als klar, notwendig, eindeutig, jedoch mit schwer zu erfassender oder schwer zuklassifizierender Evidenz bewertet wird      |\n\nder Evidenz). stärke, moderate Qualität Die Kombination medikamentöser und wenn im- Mafnahmen, physikalischer die möglich, wird wie empfohlen mer Anwendung physikalischer Mafsnahmen bei Kontraindikationen zur medikamen- tösen Prophylaxe (Empfehlung schwach, Qualität o der Evidenz niedrig). Bezüiglichdermedikamentösen Stress- ulkusprophylaxe werden 1 Protonenpum- peninhibitoren, welche in der vorherigen Version bevorzugt Hist- und wurden, als amin-2-Rezeptorantagonisten gleichwertig empfohlen. Allerdings wird die auf Qualität der c Evidenz niedrige explizit hingewiesen.\n\n### Definition von Therapiezielen\n\nObwohl in c den neuen Leitlinien eini- ge Formulierungen anders gewählt wur- den, blieben die Kernaussagen unverän- nämlich die Diskussion dert, 1 der Prog und der r Therapieziele Patient nose und Familie (Best Statement). Practice Die Einbeziehung palliativer Therapie- die prinzipien, wenn notwendig, sowie Formulierung von Therapiezielen sollter baldmöglichst t nach Aufnahme und in nerhalb von 72 h erfolgen.\n\n### Fazit für die Praxis\n\nWesentliche Kernpunkte in der The- gemäl den aktuellen rapie der Sepsis c Leitlinien sind: die hämodynamische Stabilisierung mittels ,volume-chal-\n\nDer Anaesthesist 7  2017\n\nlenge"" unter Berücksichtiqung dyna mischer hämodynamischer Paramete sowie unter Einsatz yon Noradrenalir die schnellstmöaliche Fokussuche und Fokuskontrolle, die initial kalkulierte antimikrobielle Therapie mit möalichs breitem Spektrum gefolat von Deeska ation sobald vertretbar, die Bevorzu qung enteraler gegenüber parenterale Ernährung, beim beatmungspflichtiger ARDS die Bevorzuqung von niedriger Tidalvolumina und hohem PEEP, de Einsatz von Nierenersatzverfahren be Nierenversagen sowie Malnahmen zu Thromboseprophvlaxe. Adiuvanter Therapieverfahren wird in den aktr ellen Leitlinien insgesamt kein hohe Stellenwert eingeräumt: institutionelle Programme zur Optimierung von Scree hing und Therapie der Sepsis sowie im individuellen Fall Therapieplanung so wie Definition']","['��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�']","The unresolved technical challenges associated with VA-ECMO technology include: (1) Whether patients benefit from ECMO support, as there is limited rigorous randomized controlled research on VV-ECMO, and no clinical controlled studies on VA-ECMO due to ethical concerns. (2) Selection of anticoagulation strategies and targets, considering the high risk of clot formation in ECMO patients. (3) Setting of ventilator parameters during VV-ECMO support to allow the patient's lungs to rest while avoiding further lung injury, which currently lacks consensus. (4) The majority of VA-ECMO cases involve arterial cannulation, which may increase left ventricular afterload, leading to left ventricular distension and potentially compromising cardiac function.",noise_robustness,[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}],True
What criteria should be met for mechanically ventilated patients to undergo a spontaneous breathing trial as part of a weaning protocol?,What criteria should be met for mechanically ventilated patients to undergo a spontaneous breathing trial as part of a weaning protocol?,"[""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop', '-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '毛细血管血。 美国食品药品管理局     (FDA)及联邦医疗保险和医疗津贴服务中心 (CMS)也呼吁住手重症患者的末梢毛细管 血糖测定。\n7.10   应激性溃疡\n推荐意见 36：对于脓毒症及脓毒性休克患者，如果存在消化道出血危（wei）险因素，推荐进 行应激性溃疡的预防 (强推荐，低证据质量)。\n消化道应激性溃疡与重症患者的病死率相关。 一项 Meta 分析显示，预防应激性溃疡可 降低重症患者的消化道出血风险。针对脓毒症患者的研究表明， 应激性溃疡的预防不会增加 患者艰难梭菌的感染风险。脓毒症患者常浮现消化道出血的危（wei）险因素，如凝血障碍、机械通 气超过 48h 等，因此在有危（wei）险因素的患者中预防应激性溃疡的获益大于其风险。\n来源：临床急诊医学 2022 年第 9 期']","[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']",The criteria for mechanically ventilated patients to undergo a spontaneous breathing trial as part of a weaning protocol include being arousable and hemodynamically stable (without vasopressor support).,noise_robustness,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
What are the recommended procedures for blood sugar management in ICU patients with sepsis?,What are the recommended procedures for blood sugar management in ICU patients with sepsis?,"[' von Therapiezielen und entsprechende Kommunikation mit Patient und Angehörigen werden klal empfohlen. Die aktuellen Leitlinien der Surviving Sepsis Campaign bieten in der Sum me aktuelle, klare und praxisrelevante Empfehlungen zu den wichtigsten The menkomplexen bei der Behandlune der Sepsis. Zudem bieten die Leitlinier ausführliche Hintergrundinformatio- nen sowohl für den klinisch als auch wissenschaftlich interessierten Leser die Leitlinien stellen somit eine wert volle Ressource im klinischen Alltag wie auch bei im Einzelfall tiefergehender\n\nFragestellungen und Entscheidungen dar.\n\nKorrespondenzadresse\n\nProf. Dr. J. Briegel Klinik für Anaesthesiologie, Klinikum Groβhadern MarchioninistraBe 15, 81377 München, Deutschland josef.briegel@med.uni-muenchen.de\n\n### Einhaltung ethischer Richtlinien\n\nInteressenkonflikt. J. Briegel und P. Möhnle geben an, dass kein Interessenkonflikt besteht.\n\n### Literatur\n\n1. Rhodes A. Evans LE., Alhazzani W. Levy MM Antonelli l M. Ferrer R et al (2017) Surviving sepsis campaign: International quidelines for management of sepsis and septicshock: 2016. Crit Care Med 45(3):486-552 2. Singer M, Deutschman CS, Seymour CW, Shankar- Hari M. Annane D. Bauer M et al (2016) The thirc international consensus definitions for sepsis ang septicshock (sepsis-3).JAMA315(8):801-810 3. Kunz R, Burnand B, Schunemann HJ (2008) The GRADE System. A An international approach to standardize the graduation of evidence and recommendations in guidelines. Internist 49(6):673-680 4. Dellinger RP, Schorr CA, Levy MM (2017) A users quide to the 2016 Surviving Sepsis Guidelines Intensive Care Med 43(3):299-303 5. Angus DC, Barnato AE, Bell D, Bellomo R, Chong CR, Coats TJ et al (2015) A systematic review and meta-analysis of early goal-directed therapy for\n\nKiefer, T. (Hrsg.) ditionen, die vorhandene wissensc septic shock: The ARISE. ProCESS and ProMISe Investigators. Intensive Care Med 41(9):1549-1560 Thoraxdrainager Evidenz tritt zumeist in der Hinterd 6. Investigators A. Group ACT. Peake SL. Delanev A Dieser Bereich illustriert sehr aut d Bailey M. Bellomo R et al (2014) Goal-directec Berlin Heidelberg: Springer-Verlae achtung yon Stuart Chase. die er be resuscitation for patients with early septic shock.N Berlin Heidelberg 2016. 1.. 126 S Enal IMed371(16):1496-150 gemacht hat:,Für die, die glauben 7. Mouncey PR. Osborn TM. Power GS, Harrison DA (SBN: 978-3-662-49739-5) Softcover es keinen Beweis, für die., die nicht Sadique MZ, Grieve RD et al (2015) Trial of early 39,99 EUR ist kein Beweis möglich"" Trotz der goal-directed resuscitation for septicshock.N Eng IMed 372(14)-1301-131 tischen Glaubensarundsätze und L Es ist sehr schwer, innerhalb der Welt der 8 Investigators. TP (2014) A randomized trial of thoraxchirurgischen Bücher ein neues Werk existieren, gibt es eine arore Zabhl protocol-based careforearly senticshock N Enal Daten Finige der', 'Anaesthesist 2017-66:530-538 DO110.1007/s00101-017-0299-z Online publiziert: 31. März 2017 © Springer Medizin Verlag GmbH 2017\n\nCrossMark\n\n### Hintergrund\n\nDie ersten Leitlinien der Surviving Sep sis Campaign wurden 2004veröffentlicht seitdem erfolgte alle vier Jahre die Publi kation eines Updates bzw, einer aktuali sierten Revision,jeweils auf der Grundla ge der neu hinzugekommenen Literatu Die Leitlinien basieren o auf einem mit tels Wablverfabren 1 ermittelten Konsen eines Komitees von 55 nominierter internationalen Experten [1) Eine der wesentlichen Neuerungen in den aktuellen Leitlinien im Vergleich zu den Vorversionen betrifft die Definition der Sepsis nach den aktuellen Kriterier gemäf Sepsis-3 [2] Sepsis ist nun definiert als lebensge fährdende Organdysfunktion verursach durch eine fehlregulierte Wirtsantwort auf eine Infektion Der Terminus host ,,dysregulated dass 1 Ausdruck, response"" bringt zum die sowohl 1 durch in-  Immunantwort Hlammatorisch : üiberschiefsende als auch durch immunsuppressive Komponenter charakterisiert ist. Der septische Schock der wiederum stellt eine Untergruppe Sepsis mit Kreislauf- sowie zellulärem bzw. metabolischem Versagen i dar und hat ein deutlich höheres Letalitätsrisikd [2]. Die Beurteilung der Empfehlunger nach klinischer Relevanz und Evidenz grad, welche in den Leitlinien 2012 als Zahlenwerte bzw. Buchstaben beschrie ben wurden, sind nun lesbarer geworder GRADE aTab. 1). Entsprechend dem( System (Grading of Recommendations Assessment, Development, and Evalua tion) wurde die Bedeutung einer Emp fehlung als stark (,,strong"") oder schwacl\n\nDer Anaesthesist7.2017\n\nJ.Briegel-P. Möhnle Klinik für Anaesthesiologie, Klinikum GroBhadern, München, Deutschland\n\n### Internationale Leitlinien der Surviving Sepsis Campaign\n\nUpdate 2016\n\n(,weak"") beurteilt; die Qualität der Evi denz wird nun mit den Begriffen hoch (,,high""), moderat (,,moderate""), niedrig (,low"") oder sehr niedrig (-very low"" a Tab. 2). Eine Empfeh- klassifiziert (s. : als klar, notwendig,o lung, welche ein deutig, jedoch mit schwer zu erfassender Evidenz bewertet wurde, ist in den neuen Leitlinien mit dem Begriff Best Practice Statement (BPS) beschrieben 31. Die Leitlinien der Surviving Sepsis 2016 bieten dabei auf un- Campaign terschiedlichen Ebenen Informationen Zum einen 1 werden kurze, prägnante Empfehlungen gegeben, welche im kli- nischen Alltag als Basis einer sinnvollen Therapie dienen. Darüber hinaus wird im Text eine fundierte wissenschaftliche Diskussion basierend auf den Daten der iktuellen Literatur gefüihrt, ergänzt um Evidenztabellen und Literaturreferenzen [4]. Im Folgenden werden kurz die we sentlichen einzelner Anderungen skiz der Mafsnahmen Sepsistherapie ziert und deren Hintergrund erläutert\n\n### Initial', "" and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD; Alain"", '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ', '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-']",['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU '],"For ICU patients with sepsis, it is recommended to implement a protocolized blood sugar management plan. Blood sugar should be monitored every 1-2 hours, and insulin therapy should be initiated if blood sugar exceeds 10mmol/L for two consecutive measurements. The target blood sugar level is ≤10mmol/L. Once blood sugar levels and insulin doses are stable, monitoring can be reduced to every 4 hours. For patients with arterial catheters, arterial blood should be collected for blood sugar measurement. These recommendations are based on strong evidence.",noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are the key recommendations and strategies outlined in the '1-hour bundle therapy' approach for the management of sepsis?,What are the key recommendations and strategies outlined in the '1-hour bundle therapy' approach for the management of sepsis?,"[' wissenschaftlich zu schaffen, das einzigartig ist. Das Buch Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel L-E. Grelon E. Megarbane Thoraxdrainggen iedoch, herausgegeber men sind sicherlich noch nicht um B Anquel N et al (2014) Hiab versus low blood- von Thomas Kiefer erfiillt ganz klar diese aufgearbeitet, aber Thomas Kiefer pressuretargetin patientswith senticshock NEng Definition, Und dies gleich aus mehrerer existierenden wissenschaftlichen E JMed 370(17):1583-1593 10 Holst IB Haase N Wettersley I Wernerman Gründen. nisse gründlich aufgearbeitet. Er ha Aneman A. Guttormsen AB etal (2013) Transfusior Zu allererst ist dies Erkenntnisse an ieder Stelle in eine reauirements in septic shock (TRIsS) trial. ein enorm praxisori- baren, einfachen Art und Weise ein comparing the effects and safety of liberal versus restrictivered blood cell transfusion in senticshoc entiertes Buch Die immer offen und ehrlich betonend patients in the ICU: protocol for a randomises Drainage des Pleu- wissen und was wir nicht wissen. D controlledtrial. Trials 14:150 Thorax raspaltes und das dazu. dass er einige der häufig zitie Damiani E. Donati A. Serafini G. Rinaldi L, Adraric drainagen E Pelaia P et al (2015) Effect of performance Management vor men entlarvt -er tut dies in einere improvement programson compliance with sepsi Thoraxdrainager an Fakten orientieren und sachlich bundles and mortality: a svstematic review and sind fundamentaler und Weise. Dieser aufrichtige und s meta-analysis of observational studies. PLOS ONP 10(5):e012582) Bestandteil der tho- Stil der Diskussion und das sich dar Scheer CS, Fuchs C, Kuhn SO, Vollmer M, Rehberc raxchirurgischen Arbeit. Die Tatsache., dass gebende Management, basierend a S. Friesecke S et al (2017) Ouality improvemen vorliegenden wissenschaftlichen Eir diese Themen in dem Buch mit grofBer Ernst initiative for severe sepsis and septicshockreduce: 90-dav mortality: A 7.5-year observational study haftigkeit besprochen werden, zeugen vor sen, zeichnen dieses Buch im Besc Crit Care Med 45(2):241-25: seiner Intention: es will praxisorientiert sein aus Bloos E. Thomas-Ruddel D, Ruddel H, Enge Das Buch will in einer einfachen, praktischer Schlussendlich ist dieses Buch gese C. Schwarzkopf D. Marshall JC et al (2014 Impact of compliance with infection management Weise hilfreich sein, Einzelne einfache De um im klinischen Alltag zu untersti quidelines on outcome in patients with severe tails, die bei der täglichen Arbeit helfen, die zu helfen, Es enthält Aspekte der ä sepsis: A prospective observational multi-centel für sich genommen jedoch nicht die grole wie der pflegerischen und der phy study, Crit Care 18(2):R42 Azuhata I. Kinoshita K. Kawano D. Komatsu Aufmerksamkeit genieBen, können in ihre rapeutischen Arbeit, was sich auch SakuraiA. Chiba Yetal (2014) Time from admissior Addition einen signifikanten Einfluss auf das Auswahl der Co-Autoren widerspie to initiation of surgery for source control i Gelingen haben. Dieses Buch ist einzigartic Gesamteinfluss des', ' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome"", ""Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732-747 Warren"", ' | nan                                    |\n| 26 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n| 27 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n\nBPS Best Practice Statement, Ha Hämoglobin, FFP Fresh Frozen Plasma, PEEP positive endexpiratory pressure"", paO2 arterieller Sauerstoffpartialdruck FIO  inspiratorische Sauerstofffraktion, HFOV.high frequency oscillatory yentilation"" Gl gastrointestina\n\nWeiterhin wird unverändert von der Anwendung von Hydrokortison bei sep- tischem Schock abgeraten, wenn man durch Volumen- und Vasopressorthera- pie eine hämodynamische Stabilität zielen kann; falls dies nicht gelingt, , wird die Gabe von Hydrokortison in einer Ta- gesdosis von 200 mg empfohlen. Die Gabe von Selen wird gemäf den deutschen SISPCT-Studie als Daten dere ,strong recommendation"" nicht empfoh- len [19].\n\n### Ernährung\n\nIn der aktuellen Version der Leitlinien ist der Stellenwert der enteralen Ernährung\n\nder gegenüiber Ernährung parenteralen l Eine frühe mehrfach betont: enterale hypo- Ernährung, bzw. trophisch auch Neu ist wird klar favorisiert kalorisch, mit niedri- eine schwache Empfehlung ger Evidenz zum Einsatz postpylorischer bei mit Patienten Ernährungssonden Aspi- oder hoher Ernährungsintoleranz rationsgefahr. Neu sind die Stellungnah Zu Omega-3-Fettsäuren, Arginin men Glutamin, empfohlen welche nicht unde der Neu  aktuellen Version werden. ist a', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']",['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],The '1-hour bundle therapy' approach for the management of sepsis emphasizes early initiation of resuscitation and treatment. It recommends administering at least 30ml/kg of crystalloid solution within the first 3 hours of diagnosing septic shock. This approach builds upon earlier recommendations such as early goal-directed therapy (EGDT) and emphasizes the importance of prompt resuscitation and treatment in sepsis management.,noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
How does monitoring lactate levels impact clinical treatment outcomes in patients with septic shock?,How does monitoring lactate levels impact clinical treatment outcomes in patients with septic shock?,"['   | StressulkusStressulkusprophylaxe bei Risikofaktoren für Gl-Blutung                                     | nan                                                                                                                                                                                            | Starke EmpfehlungEvidenz niedrio       |\n|  3 | S    | Anwendung von Protonenpumpenblocker oder H2-Blocker                                                    | nan                                                                                                                                                                                            | Schwache Empfehlunc                    |\n|  4 | nan  | nan                                                                                                    | nan                                                                                                                                                                                            | BPS                                    |\n|  5 | nan  | Keine Stressulkusprophylaxe bei Patienten ohne Risiko für Gl-Blutung                                   | nan                     ', 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-', ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", 'ressor agents); c) no new po- d) low tentially serious conditions; ventilatory and end-expiratory pressure e) requiring levels of requirements: and F102 that could be safely delivered with a face mask or nasal cannula. If the spon- breathing trial is successful taneous consideration should be given for extu- Appendix bation (see D). Spontaneous breathing trial options n include level of pressure continu- support with ous positive airway pressure 5 cm H.O or a T-piece\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Recent studies demonstrate that daily spontaneous breathing trials the c duration of mechanical ventilation ducet (78-80). Although these studies had limited of patients with documented ALI/ numbers ARDS. believe that there is to no reason different out- ALI/ARDS patients would have comes from other critically ill patients. Suc- breath- cessful completion of spontaneous of a high likelihood trials leads to ing discontinuation of successful mechanical ventilation.\n\n### L. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis\n\n1. Protocols should be used when sedation of critically ill mechanically ventilated patients is required. The protocol should include the usec of a sedation goal, ,mea- a standardized subjective sured by seda- tion scale.\n\nR\n\nRationale (Ll and L2). Mechanically ven- tilated patients receiving continuous sedation duration of a significantly have longer may mechanical ventilation as well as ICU and hos- pital length of stay (81). A daily interruption or ""continuous"" sedative infusion lightening of a patient is awake the until the may decrease 1 ICU duration of and ventilation mechanical (82). The sedation stay use  protocols in mechanically ventilated patients has shown a duration of reduced Iventilation, mechanica. length of stay, and tracheostomy rates (83).\n\nblockers should be 3. Neuromuscular avoided if all possible in the septic patient due to the risk of prolonged neu- blockade following discon- romuscular tinuation. If blockers neuromuscular than the first must be e used for longer hours mechanical ventilation, either intermittent bolus as required or contin uous infusion with monitoring of depth of block: with train of four rmonitoring should be used\n\nRationale. Prolonged skeletal muscle n critically ill weakness has been reported in patients following the use of intermediate- and long-acting neuromuscular blockers (84-91). The risk of prolonged be re- paralysis may\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nof the duced if an intermittent assessment depth blockade is of neuromuscular per- formed (92, 93),\n\n### M. Glucose Control\n\n1. Following initial stabilization of patients with severe sepsis, maintain blood glu- <150 mg/dL (8.3 mmol/L). Studies cose the role e of glycemic control supportingt have used continuous infusion of insulin and glucose. With this protocol, glucose should be monitored frequently after ini 30-60 tiation of the protocol (every mins) and on a regular basis (every 4 hrs. the blood glucose concentration once has stabilized\n\noiuue Rationale. A large single-center trial of showed signit postoperative e surgical patients icant improvement in I survival when continu- ous infusion insulin  was used to maintair 80 and 110 mg/dL (4.4-6.1 glucose between (94). Exogenous glucose was begun mmol/L) simultaneously with insulin with frequent monitoring of glucose (every 1 hr) and inten- sity of monitoring greatest at the time of ini- tiation of insulin. Hvpoglvcemia 1may occur There is 1 no reason to think that these data are not generalizable to all severely septic pa- tients. Post hoc data analysis of the trial data revealed that although best results were ob- glucose was maintained between tained when: 80 and 110 mg/dL (4.4 and 6.1 mmol/L) <150 mg/dL (8.3 mmol/L achieving a goal of < also improved outcome when compared with This goal will likely higher concentrations.T reduce the risk of hypoglycemia. The contro. of the blood glucose concentration appears to be more important than the amount of insulin infused (95, 96). The frequency of blood glu cose determinations may require the use of central or arterial catheters for blood sam pling\n\n2. In patients with severe sepsis, a strategy of glycemic control should include a nu- trition protocol with the preferential use of the enteral route.', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�']",['映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�'],"Monitoring lactate levels in patients with septic shock impacts clinical treatment outcomes by allowing for effective assessment of prognosis and treatment response. High early arterial blood lactate (LAC) levels suggest poor prognosis, while 34-hour LAC levels and lactate clearance rate (LCR) can effectively evaluate clinical treatment effectiveness and prognosis. Clinical studies assessing lactate-guided resuscitation have shown a significant decrease in mortality compared to groups without lactate monitoring. Meta-analyses also indicate that early lactate clearance strategies reduce mortality compared to conventional care or ScvO2 monitoring. Additionally, in randomized controlled trials evaluating the treatment of septic shock with adjunctive therapy, patients with LAC levels >4.5mmol/L who received adjunctive therapy showed significantly improved 7-day survival rates compared to the control group.",noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"What are the indications and considerations for using hydrocortisone therapy in children with catecholamine resistance and suspected or proven adrenal insufficiency, particularly in cases of severe septic shock and purpura?","What are the indications and considerations for using hydrocortisone therapy in children with catecholamine resistance and suspected or proven adrenal insufficiency, particularly in cases of severe septic shock and purpura?","['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', '-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', "":1851-1858 Esteban A. Alia I. Tobin MJ, et al: Effect of spontaneous breathing trial duration attemnts to discontinue me chanical ventilation Snanish Lung Failur Collaborative Group, Am J Respir Crit Care Med 1999: 159:512-518 Ely EW. Baker AM. Dunagan DP., et al: Ef fect on the duration of mechanical ventila tion of identifving patients capable o breathing spontaneously, N Enal J Med 1996:335:1864-1869 Esteban A. Alia I. Gordo E. et al: Extubatior outcome after spontaneous breathing trial: with T-tube or pressure support ventilation The Snanish Lung Failure Collaborativ Group. Am J Respir Crit Care Med 1997 156:459-465 Kollef MH, Levy NT. Ahrens TS, et al: The use of continuous IV sedation is associated with prolongation of mechanical ventila tion Chest 1998: 114:541-548 Kress JP. Pohlman AS. O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechani cal ventilation. N Enal J Med 2000: 342 1471-1477 Brook AD. Ahrens TS, Schaiff R, et al: Effec of a nursing-implemented sedation protoco on the duration of mechanical ventilation Crit Care Med 1999: 27:2609-2615 Giostra E. Magistris MR. Pizzolato G. et al Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group o: seven patients and two sporadic cases, with electrophysiologic and histologic examina tion. Chest 1994: 106:210-220 Rossiter A, Souney PF, McGowan S, et al Pancuronium-induced prolonged neuro muscular blockade. Crit Care Med 1991 19:1583-1587 Partridge BL, Abrams JH, Bazemore C, et al Prolonged neuromuscular blockade afte long-term intusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-1179 Vanderheyden BA, Reynolds HN, Gerole KB, et al: Prolonged paralysis after long term vecuronium infusion. Crit Care Med 1992; 20:304-30 Meyer KC, Prielipp RC, Grossman JE, et al Prolonged weakness after infusion of atra curium in two intensive care unit patients Anesth Analg 1994: 78:772-774 Manthous CA. Chatila W: Prolonged weak ness after withdrawal of atracurium. Am. Respir Crit Care Med 1994; 150:1441-1443 Prielipp RC, Coursin DB, Scuderi PE, et al Comparison o of the e intusior requirement\n\ncenter Trial Group on Tidal Volume reduc tion in ARDS. Am J Respir Crit Care Med 1998:158:1831-1838 Brower RG. Shanholtz CB. Fessler HE, et al Prospective, randomized, controlled clinica trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients, Crit Care Med 1999: 27:1492-1498 Brower RG Fessler HE: Mechanical venti lation in acute lung iniury and acute respi ratory distress Clin Chest Med svndrome 2000:21:491-510 Eichacker PO. Gerstenberger EP. Bank: SM. et al: Meta-analysis of acute lung iniury and acute respiratory distress svndrome tri als testing low tidal volumes. Am J Respit Crit Care Med 2002: 166:1510-1514 with lower tidal volumes Ventilation as compared with traditional tidal volumes fo: acute lung injury and the acute respirator: distress svndrome The Acute Respiratory Distress Syndrome Network. N Enal J Mer 2000: 342:1301-1308 Hickling KG. Walsh J. Henderson S, et al Low mortality rate in adult respiratory dis tress svndrome : using low-volume, pres sure-limited ventilation with nermissive by percapnia: A prospective study. Crit Car Med 1994:22:1568-1578 Bidani A. Tzouanakis AE, Cardenas VJ, et al Permissive hypercapnia in acute respiratory failure. JAMA 272:957-962 J. Ravenscraft - SA: Mean Marini 1 airway pressure: Physiologic determinants clinical importance-Part I: Physiologic de measurements. Crit terminants and Med 1992: 20:1461-1472 Gattinoni L, Marcolin R."", ' wissenschaftlich zu schaffen, das einzigartig ist. Das Buch Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel L-E. Grelon E. Megarbane Thoraxdrainggen iedoch, herausgegeber men sind sicherlich noch nicht um B Anquel N et al (2014) Hiab versus low blood- von Thomas Kiefer erfiillt ganz klar diese aufgearbeitet, aber Thomas Kiefer pressuretargetin patientswith senticshock NEng Definition, Und dies gleich aus mehrerer existierenden wissenschaftlichen E JMed 370(17):1583-1593 10 Holst IB Haase N Wettersley I Wernerman Gründen. nisse gründlich aufgearbeitet. Er ha Aneman A. Guttormsen AB etal (2013) Transfusior Zu allererst ist dies Erkenntnisse an ieder Stelle in eine reauirements in septic shock (TRIsS) trial. ein enorm praxisori- baren, einfachen Art und Weise ein comparing the effects and safety of liberal versus restrictivered blood cell transfusion in senticshoc entiertes Buch Die immer offen und ehrlich betonend patients in the ICU: protocol for a randomises Drainage des Pleu- wissen und was wir nicht wissen. D controlledtrial. Trials 14:150 Thorax raspaltes und das dazu. dass er einige der häufig zitie Damiani E. Donati A. Serafini G. Rinaldi L, Adraric drainagen E Pelaia P et al (2015) Effect of performance Management vor men entlarvt -er tut dies in einere improvement programson compliance with sepsi Thoraxdrainager an Fakten orientieren und sachlich bundles and mortality: a svstematic review and sind fundamentaler und Weise. Dieser aufrichtige und s meta-analysis of observational studies. PLOS ONP 10(5):e012582) Bestandteil der tho- Stil der Diskussion und das sich dar Scheer CS, Fuchs C, Kuhn SO, Vollmer M, Rehberc raxchirurgischen Arbeit. Die Tatsache., dass gebende Management, basierend a S. Friesecke S et al (2017) Ouality improvemen vorliegenden wissenschaftlichen Eir diese Themen in dem Buch mit grofBer Ernst initiative for severe sepsis and septicshockreduce: 90-dav mortality: A 7.5-year observational study haftigkeit besprochen werden, zeugen vor sen, zeichnen dieses Buch im Besc Crit Care Med 45(2):241-25: seiner Intention: es will praxisorientiert sein aus Bloos E. Thomas-Ruddel D, Ruddel H, Enge Das Buch will in einer einfachen, praktischer Schlussendlich ist dieses Buch gese C. Schwarzkopf D. Marshall JC et al (2014 Impact of compliance with infection management Weise hilfreich sein, Einzelne einfache De um im klinischen Alltag zu untersti quidelines on outcome in patients with severe tails, die bei der täglichen Arbeit helfen, die zu helfen, Es enthält Aspekte der ä sepsis: A prospective observational multi-centel für sich genommen jedoch nicht die grole wie der pflegerischen und der phy study, Crit Care 18(2):R42 Azuhata I. Kinoshita K. Kawano D. Komatsu Aufmerksamkeit genieBen, können in ihre rapeutischen Arbeit, was sich auch SakuraiA. Chiba Yetal (2014) Time from admissior Addition einen signifikanten Einfluss auf das Auswahl der Co-Autoren widerspie to initiation of surgery for source control i Gelingen haben. Dieses Buch ist einzigartic Gesamteinfluss des', "" J 2002: 21 330-336 123. Riordan FA, Thomson AP, Ratcliffe JM., et al Admission cortisol ang adrenocorticotro phic hormone levels in children with me ningococcal disease: Evidence of adrenal in suffciency: Care Med 1999: 27 2257-2261 124. Min M. U T. Ave M. et al: Hydrocortisone in the of dengue shock managemen syn drome. Southeast Asian J Trop Med Public Health 1975: 6:573-579 125. Sumarmo. Talogo W. Asrin A. et al: Failure of hydrocortisone to affect outcome in den\n\n;1982: 69 gue shock syndrome, Pediatrics 45-49 Hazelzet JA. de Kleiin ED. de Groot R: En dothelial protein C activation in meningo- coccal sepsis. N Enal J Med 2001: 345 1776-1777 127, de Kleiin ED. de Groot R. Hack CE, et al Activation of protein C following infusion o protein C concentrate in children with se vere meningococcal sensis and purpura ful. minans: A randomized., double-blinded, pla cebo-controlled. dose-finding study. Cri. Core Med 2003: 31:1839-184' Bilgin K. Yaramis A. Haspolat K. et al: A randomized trial of granulocvte-macroph colonv-stimulating factor in neonates age with neutropenia. Pediatric: sensis and 2001: 107:36-41 La Gamma EF. De Castro MH: What the rationale for -the granulocvte and granulocvte-macronhage colony stimulating factors in the neonatal intensiv  Suppl 2002: 91 care unit? Acta Paediatr 109-116 130. Chaibou M. Tucci M. Dugas MA, et al: Clin ically 2 significant upper gastrointestina bleeding acquired in a pediatric intensive care unit: A prospective study. Pediatrics 1998:102-933-938 131. Gauvin F. Dugas M. Chaibou M. et al: The impact of clinically significant upper gas- trointestinal bleeding in a pediatric inten sive care unit. Pediatr Crit Care Med 2001 2:294-298 132. Aleiandria MM. Lansang MA. Dans LF, et al immunoglobulin for treating Intravenous sepsis and septic shock. Cochrane Database Syst Reu 2002; (1):CD001090 133. Mever DM. Jessen ME: Results of extracor poreal membrane e oxygenation in childrer with sepsis. The Extracorporeal LifeSuppor Organization. Ann Thorac Surg 1997: 63 756-761 134. Goldman AP. Kerr SJ. Butt W. et al: Extra corporeal support for intractable cardiore spiratory failure due to meningococcal dis ease. Lancet 1997: 349:466-469 135. Brochard L, Rauss A., Benito S, et al: Com parison of three methods of gradual with drawal from 2 support during ventilatory weaning from mechanical ventilation Am J Respir Crit 2 Med 1994: 150 Care 896-903\n\n\n|    | 0                        | 1                                                                                                                                                           |\n|---:|:-------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Source Control Technique | Examples                                                                                  "", ""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation.""]","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","Hydrocortisone therapy should be reserved for use in children with catecholamine resistance and suspected or proven adrenal insufficiency, particularly in cases of severe septic shock and purpura. Patients at risk include children with severe septic shock and purpura, children who have previously received steroid therapies for chronic illness, and children with pituitary or adrenal abnormalities. Adrenal insufficiency in the case of catecholamine-resistant septic shock is assumed at a random total cortisol concentration <1 mcg/dL (496 nmol/L). A positive 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 mcg/dL (248 nmol/L) also supports the diagnosis. Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical diagnosis of adrenal insufficiency) to 50 mg/kg for empirical therapy of shock followed by the same dose as a 24-hour infusion.",noise_robustness,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
How is antimicrobial therapy recommended to be initiated for patients suspected of sepsis or septic shock?,How is antimicrobial therapy recommended to be initiated for patients suspected of sepsis or septic shock?,['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],"Antimicrobial therapy should be initiated promptly for patients suspected of sepsis or septic shock without significant delay. It is recommended to routinely perform microbial cultures (at least including two sets of blood cultures) before starting antibiotic therapy. Sampling for culture before initiating antimicrobial therapy is associated with improved prognosis. If sampling can be done promptly, blood samples should be collected first for culture; if specimens cannot be obtained immediately, antimicrobial therapy should be initiated as soon as possible.",noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"How do protocol monitoring intervals impact glucose control in sepsis? Also, what's the efficacy of adjunctive therapies for regulating glucose in sepsis? Does blood sampling method choice affect glucose regulation? And what precautions are advised for Point-of-Care glucose tests in sepsis?",How does frequent monitoring contribute to glucose control in the provided protocol?,"['                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 17 | N      | RelaxierungGlucosekontrolle | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 18 | N      | RelaxierungGlucosekontrolle | Analgosedierung, Minimal mögliche Analgosedierund                                                                                                                                                                                                                                            | BPS                                                 |\n| 19 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                          ', '                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |', '                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 17 | N      | RelaxierungGlucosekontrolle | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 18 | N      | RelaxierungGlucosekontrolle | Analgosedierung, Minimal mögliche Analgosedierund                                                                                                                                                                                                                                            | BPS                                                 |\n| 19 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                          ', '        |\n| 21 | nan   | nan                                                           | Keine Gabe von FFP ohne klinisch manifeste Blutung, ohne bevorstehende Operatiorklinischer Blutung, >50.000/ul bei Blutung oder Eingriffer                                   | Schwache EmpfehlungEvidenz sehr niedrid Schwache EmpfehlungEvidenz sehr niedrig |\n| 22 | nan   | ImmunglobulineHämofiltration/g                                | Keine Gabe von lmmunglobuliner                                                                                                                                               | nan                                                                             |\n| 23 | K     | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Evidenz sehr niedric                                                            |\n| 24 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | nan                   ', '                                                          |\n| 25 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Starke EmpfehluncEvidenz moderat                                                |\n| 26 | nan   | Antikoaqulanzien                                              | Kein Einsatz von Antithrombin zur Therapie von Sepsis/septischem SchockKeine spezifische Empfehlung zu Thrombomodulin oder Heparin zur Therapie von Sepsis,septischem Schock | -                                                                               |\n\nNierenersatzverfahren als grundsätzlich gleichwertig betrachtet. Bei hämodyna- misch instabilen Patienten werden kon- diese tinuierliche Verfahren favorisiert; hat jedoch eine schwache Empfehlung c nied- Empfehlungsstärke und eine sehr Neu ist, rige Qualität der Evidenz. dass bei steigen- Nierenersatzverfahren den Kreatininwerten oder Oligurie bzw. klaren Indikation ab Fehlen bei  1 einer die geraten wird; Rationale ist e Nutzen- Risiko-Abwägung von Nierenersatzver-\n\nfahren und möglichen Komplikationen, allem in Bezug auf intravasale Ka- vor theter.\n\n### Adjunktive Therapien der Sepsis\n\nDie Empfehlungen hinsichtlich der Kon- trolle einer Hyperglykämie sind weitge- hend unverändert geblieben; bei der Ver- wendung von Point-of-Care- Testverfah- ren wird zur Vorsicht geraten, Glukose- werte sollten initialalle 1-2 h und im wei-\n\nteren Verlauf bei zunehmender Stabilität alle 4h gemessen werden. Anzustreben sind Werte unter 180 mg/dlund eine The- rapie sollte erst nach zwei aufeinander- folgenden Werten >180 mg/dll begonnen werden. Diese Empfehlungen haben je- weils eine hohe Empfehlungsstärke bzw. sind Best Practice']","['                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 17 | N      | RelaxierungGlucosekontrolle | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 18 | N      | RelaxierungGlucosekontrolle | Analgosedierung, Minimal mögliche Analgosedierund                                                                                                                                                                                                                                            | BPS                                                 |\n| 19 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                          ', '                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |']","Frequent monitoring contributes to glucose control in the provided protocol by allowing for close observation of glucose and insulin infusion rates. This frequent monitoring ensures that glucose and insulin levels remain stable, with measurements typically taken every 1 to 2 hours until the infusion rates stabilize. Additionally, periodic point-of-care (POC) measurements using a reference method help to verify the accuracy of glucose and insulin levels, thus optimizing glucose control in patients following the protocol.",multi_context,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
"How can glucose control be optimized for severe sepsis patients, considering blood glucose, nutritional route, and sedation, analgesia, and neuromuscular management?","How should glucose control be managed in patients with severe sepsis, particularly regarding blood glucose levels and the preferred route of nutrition?","['ressor agents); c) no new po- d) low tentially serious conditions; ventilatory and end-expiratory pressure e) requiring levels of requirements: and F102 that could be safely delivered with a face mask or nasal cannula. If the spon- breathing trial is successful taneous consideration should be given for extu- Appendix bation (see D). Spontaneous breathing trial options n include level of pressure continu- support with ous positive airway pressure 5 cm H.O or a T-piece\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Recent studies demonstrate that daily spontaneous breathing trials the c duration of mechanical ventilation ducet (78-80). Although these studies had limited of patients with documented ALI/ numbers ARDS. believe that there is to no reason different out- ALI/ARDS patients would have comes from other critically ill patients. Suc- breath- cessful completion of spontaneous of a high likelihood trials leads to ing discontinuation of successful mechanical ventilation.\n\n### L. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis\n\n1. Protocols should be used when sedation of critically ill mechanically ventilated patients is required. The protocol should include the usec of a sedation goal, ,mea- a standardized subjective sured by seda- tion scale.\n\nR\n\nRationale (Ll and L2). Mechanically ven- tilated patients receiving continuous sedation duration of a significantly have longer may mechanical ventilation as well as ICU and hos- pital length of stay (81). A daily interruption or ""continuous"" sedative infusion lightening of a patient is awake the until the may decrease 1 ICU duration of and ventilation mechanical (82). The sedation stay use  protocols in mechanically ventilated patients has shown a duration of reduced Iventilation, mechanica. length of stay, and tracheostomy rates (83).\n\nblockers should be 3. Neuromuscular avoided if all possible in the septic patient due to the risk of prolonged neu- blockade following discon- romuscular tinuation. If blockers neuromuscular than the first must be e used for longer hours mechanical ventilation, either intermittent bolus as required or contin uous infusion with monitoring of depth of block: with train of four rmonitoring should be used\n\nRationale. Prolonged skeletal muscle n critically ill weakness has been reported in patients following the use of intermediate- and long-acting neuromuscular blockers (84-91). The risk of prolonged be re- paralysis may\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nof the duced if an intermittent assessment depth blockade is of neuromuscular per- formed (92, 93),\n\n### M. Glucose Control\n\n1. Following initial stabilization of patients with severe sepsis, maintain blood glu- <150 mg/dL (8.3 mmol/L). Studies cose the role e of glycemic control supportingt have used continuous infusion of insulin and glucose. With this protocol, glucose should be monitored frequently after ini 30-60 tiation of the protocol (every mins) and on a regular basis (every 4 hrs. the blood glucose concentration once has stabilized\n\noiuue Rationale. A large single-center trial of showed signit postoperative e surgical patients icant improvement in I survival when continu- ous infusion insulin  was used to maintair 80 and 110 mg/dL (4.4-6.1 glucose between (94). Exogenous glucose was begun mmol/L) simultaneously with insulin with frequent monitoring of glucose (every 1 hr) and inten- sity of monitoring greatest at the time of ini- tiation of insulin. Hvpoglvcemia 1may occur There is 1 no reason to think that these data are not generalizable to all severely septic pa- tients. Post hoc data analysis of the trial data revealed that although best results were ob- glucose was maintained between tained when: 80 and 110 mg/dL (4.4 and 6.1 mmol/L) <150 mg/dL (8.3 mmol/L achieving a goal of < also improved outcome when compared with This goal will likely higher concentrations.T reduce the risk of hypoglycemia. The contro. of the blood glucose concentration appears to be more important than the amount of insulin infused (95, 96). The frequency of blood glu cose determinations may require the use of central or arterial catheters for blood sam pling\n\n2. In patients with severe sepsis, a strategy of glycemic control should include a nu- trition protocol with the preferential use of the enteral route.', "":1851-1858 Esteban A. Alia I. Tobin MJ, et al: Effect of spontaneous breathing trial duration attemnts to discontinue me chanical ventilation Snanish Lung Failur Collaborative Group, Am J Respir Crit Care Med 1999: 159:512-518 Ely EW. Baker AM. Dunagan DP., et al: Ef fect on the duration of mechanical ventila tion of identifving patients capable o breathing spontaneously, N Enal J Med 1996:335:1864-1869 Esteban A. Alia I. Gordo E. et al: Extubatior outcome after spontaneous breathing trial: with T-tube or pressure support ventilation The Snanish Lung Failure Collaborativ Group. Am J Respir Crit Care Med 1997 156:459-465 Kollef MH, Levy NT. Ahrens TS, et al: The use of continuous IV sedation is associated with prolongation of mechanical ventila tion Chest 1998: 114:541-548 Kress JP. Pohlman AS. O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechani cal ventilation. N Enal J Med 2000: 342 1471-1477 Brook AD. Ahrens TS, Schaiff R, et al: Effec of a nursing-implemented sedation protoco on the duration of mechanical ventilation Crit Care Med 1999: 27:2609-2615 Giostra E. Magistris MR. Pizzolato G. et al Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group o: seven patients and two sporadic cases, with electrophysiologic and histologic examina tion. Chest 1994: 106:210-220 Rossiter A, Souney PF, McGowan S, et al Pancuronium-induced prolonged neuro muscular blockade. Crit Care Med 1991 19:1583-1587 Partridge BL, Abrams JH, Bazemore C, et al Prolonged neuromuscular blockade afte long-term intusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-1179 Vanderheyden BA, Reynolds HN, Gerole KB, et al: Prolonged paralysis after long term vecuronium infusion. Crit Care Med 1992; 20:304-30 Meyer KC, Prielipp RC, Grossman JE, et al Prolonged weakness after infusion of atra curium in two intensive care unit patients Anesth Analg 1994: 78:772-774 Manthous CA. Chatila W: Prolonged weak ness after withdrawal of atracurium. Am. Respir Crit Care Med 1994; 150:1441-1443 Prielipp RC, Coursin DB, Scuderi PE, et al Comparison o of the e intusior requirement\n\ncenter Trial Group on Tidal Volume reduc tion in ARDS. Am J Respir Crit Care Med 1998:158:1831-1838 Brower RG. Shanholtz CB. Fessler HE, et al Prospective, randomized, controlled clinica trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients, Crit Care Med 1999: 27:1492-1498 Brower RG Fessler HE: Mechanical venti lation in acute lung iniury and acute respi ratory distress Clin Chest Med svndrome 2000:21:491-510 Eichacker PO. Gerstenberger EP. Bank: SM. et al: Meta-analysis of acute lung iniury and acute respiratory distress svndrome tri als testing low tidal volumes. Am J Respit Crit Care Med 2002: 166:1510-1514 with lower tidal volumes Ventilation as compared with traditional tidal volumes fo: acute lung injury and the acute respirator: distress svndrome The Acute Respiratory Distress Syndrome Network. N Enal J Mer 2000: 342:1301-1308 Hickling KG. Walsh J. Henderson S, et al Low mortality rate in adult respiratory dis tress svndrome : using low-volume, pres sure-limited ventilation with nermissive by percapnia: A prospective study. Crit Car Med 1994:22:1568-1578 Bidani A. Tzouanakis AE, Cardenas VJ, et al Permissive hypercapnia in acute respiratory failure. JAMA 272:957-962 J. Ravenscraft - SA: Mean Marini 1 airway pressure: Physiologic determinants clinical importance-Part I: Physiologic de measurements. Crit terminants and Med 1992: 20:1461-1472 Gattinoni L, Marcolin R."", ""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","['ressor agents); c) no new po- d) low tentially serious conditions; ventilatory and end-expiratory pressure e) requiring levels of requirements: and F102 that could be safely delivered with a face mask or nasal cannula. If the spon- breathing trial is successful taneous consideration should be given for extu- Appendix bation (see D). Spontaneous breathing trial options n include level of pressure continu- support with ous positive airway pressure 5 cm H.O or a T-piece\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Recent studies demonstrate that daily spontaneous breathing trials the c duration of mechanical ventilation ducet (78-80). Although these studies had limited of patients with documented ALI/ numbers ARDS. believe that there is to no reason different out- ALI/ARDS patients would have comes from other critically ill patients. Suc- breath- cessful completion of spontaneous of a high likelihood trials leads to ing discontinuation of successful mechanical ventilation.\n\n### L. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis\n\n1. Protocols should be used when sedation of critically ill mechanically ventilated patients is required. The protocol should include the usec of a sedation goal, ,mea- a standardized subjective sured by seda- tion scale.\n\nR\n\nRationale (Ll and L2). Mechanically ven- tilated patients receiving continuous sedation duration of a significantly have longer may mechanical ventilation as well as ICU and hos- pital length of stay (81). A daily interruption or ""continuous"" sedative infusion lightening of a patient is awake the until the may decrease 1 ICU duration of and ventilation mechanical (82). The sedation stay use  protocols in mechanically ventilated patients has shown a duration of reduced Iventilation, mechanica. length of stay, and tracheostomy rates (83).\n\nblockers should be 3. Neuromuscular avoided if all possible in the septic patient due to the risk of prolonged neu- blockade following discon- romuscular tinuation. If blockers neuromuscular than the first must be e used for longer hours mechanical ventilation, either intermittent bolus as required or contin uous infusion with monitoring of depth of block: with train of four rmonitoring should be used\n\nRationale. Prolonged skeletal muscle n critically ill weakness has been reported in patients following the use of intermediate- and long-acting neuromuscular blockers (84-91). The risk of prolonged be re- paralysis may\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nof the duced if an intermittent assessment depth blockade is of neuromuscular per- formed (92, 93),\n\n### M. Glucose Control\n\n1. Following initial stabilization of patients with severe sepsis, maintain blood glu- <150 mg/dL (8.3 mmol/L). Studies cose the role e of glycemic control supportingt have used continuous infusion of insulin and glucose. With this protocol, glucose should be monitored frequently after ini 30-60 tiation of the protocol (every mins) and on a regular basis (every 4 hrs. the blood glucose concentration once has stabilized\n\noiuue Rationale. A large single-center trial of showed signit postoperative e surgical patients icant improvement in I survival when continu- ous infusion insulin  was used to maintair 80 and 110 mg/dL (4.4-6.1 glucose between (94). Exogenous glucose was begun mmol/L) simultaneously with insulin with frequent monitoring of glucose (every 1 hr) and inten- sity of monitoring greatest at the time of ini- tiation of insulin. Hvpoglvcemia 1may occur There is 1 no reason to think that these data are not generalizable to all severely septic pa- tients. Post hoc data analysis of the trial data revealed that although best results were ob- glucose was maintained between tained when: 80 and 110 mg/dL (4.4 and 6.1 mmol/L) <150 mg/dL (8.3 mmol/L achieving a goal of < also improved outcome when compared with This goal will likely higher concentrations.T reduce the risk of hypoglycemia. The contro. of the blood glucose concentration appears to be more important than the amount of insulin infused (95, 96). The frequency of blood glu cose determinations may require the use of central or arterial catheters for blood sam pling\n\n2. In patients with severe sepsis, a strategy of glycemic control should include a nu- trition protocol with the preferential use of the enteral route.', "":1851-1858 Esteban A. Alia I. Tobin MJ, et al: Effect of spontaneous breathing trial duration attemnts to discontinue me chanical ventilation Snanish Lung Failur Collaborative Group, Am J Respir Crit Care Med 1999: 159:512-518 Ely EW. Baker AM. Dunagan DP., et al: Ef fect on the duration of mechanical ventila tion of identifving patients capable o breathing spontaneously, N Enal J Med 1996:335:1864-1869 Esteban A. Alia I. Gordo E. et al: Extubatior outcome after spontaneous breathing trial: with T-tube or pressure support ventilation The Snanish Lung Failure Collaborativ Group. Am J Respir Crit Care Med 1997 156:459-465 Kollef MH, Levy NT. Ahrens TS, et al: The use of continuous IV sedation is associated with prolongation of mechanical ventila tion Chest 1998: 114:541-548 Kress JP. Pohlman AS. O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechani cal ventilation. N Enal J Med 2000: 342 1471-1477 Brook AD. Ahrens TS, Schaiff R, et al: Effec of a nursing-implemented sedation protoco on the duration of mechanical ventilation Crit Care Med 1999: 27:2609-2615 Giostra E. Magistris MR. Pizzolato G. et al Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group o: seven patients and two sporadic cases, with electrophysiologic and histologic examina tion. Chest 1994: 106:210-220 Rossiter A, Souney PF, McGowan S, et al Pancuronium-induced prolonged neuro muscular blockade. Crit Care Med 1991 19:1583-1587 Partridge BL, Abrams JH, Bazemore C, et al Prolonged neuromuscular blockade afte long-term intusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-1179 Vanderheyden BA, Reynolds HN, Gerole KB, et al: Prolonged paralysis after long term vecuronium infusion. Crit Care Med 1992; 20:304-30 Meyer KC, Prielipp RC, Grossman JE, et al Prolonged weakness after infusion of atra curium in two intensive care unit patients Anesth Analg 1994: 78:772-774 Manthous CA. Chatila W: Prolonged weak ness after withdrawal of atracurium. Am. Respir Crit Care Med 1994; 150:1441-1443 Prielipp RC, Coursin DB, Scuderi PE, et al Comparison o of the e intusior requirement\n\ncenter Trial Group on Tidal Volume reduc tion in ARDS. Am J Respir Crit Care Med 1998:158:1831-1838 Brower RG. Shanholtz CB. Fessler HE, et al Prospective, randomized, controlled clinica trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients, Crit Care Med 1999: 27:1492-1498 Brower RG Fessler HE: Mechanical venti lation in acute lung iniury and acute respi ratory distress Clin Chest Med svndrome 2000:21:491-510 Eichacker PO. Gerstenberger EP. Bank: SM. et al: Meta-analysis of acute lung iniury and acute respiratory distress svndrome tri als testing low tidal volumes. Am J Respit Crit Care Med 2002: 166:1510-1514 with lower tidal volumes Ventilation as compared with traditional tidal volumes fo: acute lung injury and the acute respirator: distress svndrome The Acute Respiratory Distress Syndrome Network. N Enal J Mer 2000: 342:1301-1308 Hickling KG. Walsh J. Henderson S, et al Low mortality rate in adult respiratory dis tress svndrome : using low-volume, pres sure-limited ventilation with nermissive by percapnia: A prospective study. Crit Car Med 1994:22:1568-1578 Bidani A. Tzouanakis AE, Cardenas VJ, et al Permissive hypercapnia in acute respiratory failure. JAMA 272:957-962 J. Ravenscraft - SA: Mean Marini 1 airway pressure: Physiologic determinants clinical importance-Part I: Physiologic de measurements. Crit terminants and Med 1992: 20:1461-1472 Gattinoni L, Marcolin R.""]","Following initial stabilization of patients with severe sepsis, blood glucose levels should be maintained below 150 mg/dL (8.3 mmol/L). Continuous infusion of insulin and glucose is recommended, with frequent glucose monitoring after initiation of the protocol. Additionally, a nutrition protocol should be implemented, preferably using the enteral route.",multi_context,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
"How is GM-CSF used in treating neutropenic sepsis or primary immune deficiency, considering factors like fluid resuscitation, vasopressors, stress ulcer prophylaxis, and sepsis diagnostics?",How is Granulocyte Macrophage Colony Stimulating Factor utilized in the treatment of patients with neutropenic sepsis or primary immune deficiency?,"['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', "" Large fluid deficits typically ex- ist. and initial volume resuscitation, usuall requires 40-60 mL/kg but can be much higher (112-114) 3. Vasopressors/Inotropes (Should Onluy Be Used After Anpropriate Volume Resuscita tion). Children with severe sepsis can present with low cardiac output and high svstemid vascular resistance, high cardiac output and low svstemic vascular resistance., or low car diac output and low svstemic vascular resis tance shock. Denending s on which situatior exists, inotropic support should be started in the case of fluid refractory shock or a combi nation of an inotrope together with a vaso- pressor or a vasodilator, Dopamine is the firs choice of support for the pediatric patient with hypotension refractory to fluid resuscitation The choice of vasoactive agent is determined by the clinica examination Dopamine refractory shock may reverse with epinephrine infusion (l14). Pediatri norepinephrine patients with low cardiac output states may benefit from use of dobutamine. The e use o vasodilators can reverse shock in pediatric pa tients who remain hemodynamically unstable with a high systemic vascular resistance state despite fluid Iresuscitation and implementa tion of inotropic support (114, 115). Nitroso- vasodilators with a very short half-lifte (nitro prusside or nitroglvcerin) are used as first-lin therapy for children with epinephrine-resis tant low cardiac output and elevated systemid vascular-resistance shock. Inhaled nitric oxid reduced extracorporeal membrane oxvgen ation (ECMO) use when given to term neo nates with persistent pulmonary artery hyper\n\n### Q. Stress Ulcer Prophylaxis\n\nRecommendation: Grade A\n\nRationale. Although no study has been performed specifically in patients with severe of trials confirming the benefit sepsis, large stress ulcer prophylaxis in general ICU popu- lations have included significant numbers septic patients (105-108). This benefit should be applicable to patients with severe sepsis and shock. In addition, the conditions septic shown to benefit from stress ulcer prophvlaxis (coagulopathy, mechanical ventilation, hypo: o patients frequently are tension) present with severe sepsis and septic shock.\n\n### R. Consideration for Limitation of Support\n\n+ 1. Advance care planning, including 5 the communication of likely s and outcomes of treatment. should be realistic goals discussed with patients and families. De- for less or cisions support aggressive withdrawal of support may h be in the pa- tient's best interest.\n\nIt is too frequent that inade- Rationale, physician/family communication char- quate acterizes end-of-life care in the ICU. The leve) of life ICU patients 1 support g given may not and fre- be consistent with their wishes, Early quent caregiver discussions with patients whd face death in the ICU and their loved ones may facilitate with and application appropriate drawal of life-sustaining therapies.\n\n### S. Pediatric Considerations\n\n1. Mechanical Ventilation. Due low to functional capacity, young infants residual and neonates with severe sepsis may require early intubation (109). The principles of lung- protective strategies are applied to children as to adults. In premature infants, addi- they are tional attention is paid to avoiding hyperox- emia to prevent retinopathy. 2. Fluid Resuscitation. Intravenous access for f fluid resuscitation and inotrope/vasopres- difficult to attain in chil- sor infusion is more dren than in adults. The Heart As- American sociation has developed pediatric advanced life establish guidelines for support emergency\n\nof the and tensior newborr sepsis in randomized controlled trial (116), When pedi atric patients remain in a normotensive lovy cardiac output and high vascular resistance state. despite epinephrine and nitrosovasodi lator therapy, then the use of a phosphodies terase inhibitor should be strongly considered (117-119). Pentoxifylline (not available in the United States) improved outcome in prema-  with given for f ture neonates when sensis brs/day for 5 davs in a randomized controlled trial (120) 4 Theraneutic End Points. Therapeutic end points are canillary refill of <2 secs nor mal pulses with no differential between ne ripheral and central pulses, warm extremities urine output >1 mL.ko-1.hr"", 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion', "" cardiac output\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Two large e prospective clinical trials that included critically ill ICU patients who had severe sepsis failed to demonstrate benefit from increasing oxygen delivery to su- (37. pranormal levels by use of dobutamine 38). The: goal of resuscitation should instead be to achieve adequate levels of oxygen deliv. ery or avoid flow-dependent tissue e hypoxia.\n\n### Steroids H.\n\n### Grade\n\nRationale. One multiple-center, random- ized, controlled trial (RCT) with patients in se- shock showed a a significant shock septic vere reversal and reduction of mortality rate in 1 pa- tients with relative adrenal insufficiency (defined IACTH as post-adrenocorticotropic hormone cortisol increase =9 μg/dL) (39). Two additional RCTs showed significant smaller effects shock reversal (40, 41). In the first study, pa- had tients shock (systolic septic severe blood pressure <90 )mm despite vasopres- the latter sors) than in two studies (systolic blood >90 mm Hg with vasopressors).\n\na. Some experts would use a 250-μg ACTH stimulation test to identify responders (>9 μg/dL increase in cortisol 30-60 mins post ACTH administration) and discontinue therapy in these patients. Clinicians should for ACTH not wait stimulation results administer corticosteroids.\n\nRationale. One study demonstrated that an incremental increase of >9 μg/dL after 250-μg ACTH stimulation test (responders) identifies survivors of septic shock (42). A subsequent trial demonstrated that stress dose steroids improved e patients who failed to produce survival in those this increase in cortisol with ACTH (nonre sponders). Treatment with corticosteroids was ineffective in responders (39). Recommenda- tions for t the identification of relative adrenal insufficiency vary based on different cutoff levels of random cortisol, peak cortisol after stimula- tion, incremental cortisol increase atter stimu lation, a and combinations of these criteria (43 45). In patients with septic shock, clinicians should e of dexa- consider administering a dose methasone until such time e that an ACTH stim ulation test can be administered because dexa- does not methasone, unlike e hvdrocortisone, interfere with the cortisol assay.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nGrade\n\nRationale. There has been no comparative between a fixed duration and clinically study guided regimen. Two RCTs used a fixed dura tion protocol for treatment (39, 41), and inone RCT, therapy was decreased I after shock reso- lution and discontinued after 6 days (40).\n\nc. Some experts would consider tapering the dose of corticosteroids at the end of therapy.\n\nRationale. One study showed hemody- namic and immunologic rebound effects after abrupt cessation of corticosteroids (46).\n\nd. Some experts would add fludrocortisone (50 μg orally four times per day) to this regimen.\n\nE Grade\n\nof 50 Rationale. One study added ug fludrocortisone orally (39). Since hydrocorti- has intrinsic mineralocorticoid activity, sone to whether fludrocor- there is controversy as tisone should be added\n\nRationale. Two randomized prospective clinical trials and two meta-analyses s concluded that for therapy of severe sepsis or septic shock high-dose corticosteroid therapy is ineffective or harmful (47-50). There may be reasons to main- doses of corticosteroid for medical tain higher conditions other than septic shock\n\n3. In the absence of shock, corticosteroids should not be administered for the treat- ment sepsis. There is, however, no contraindication to continuing g mainte nance steroid therapy or t to using stress dose steroids if the patient's history corticosteroid administration or the pa tient's endocrinel history warrants.\n\nRationale. There are no studies document the s of steroids improve ing that stress doses of shock sepsis in the absence outcome unless the patient requires stress dose replace- ment due to a prior history of steroid therapy or adrenal dysfunction.\n\n### I. Recombinant Human Activated Protein C (rhAPC)\n\n1. rhAPC is recommended in patients at high risk of death (Acute Physiology and Chronic Health Evaluation II ≥25, sepsis-induced organ failure, septic shock, multiple""]","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', "" Large fluid deficits typically ex- ist. and initial volume resuscitation, usuall requires 40-60 mL/kg but can be much higher (112-114) 3. Vasopressors/Inotropes (Should Onluy Be Used After Anpropriate Volume Resuscita tion). Children with severe sepsis can present with low cardiac output and high svstemid vascular resistance, high cardiac output and low svstemic vascular resistance., or low car diac output and low svstemic vascular resis tance shock. Denending s on which situatior exists, inotropic support should be started in the case of fluid refractory shock or a combi nation of an inotrope together with a vaso- pressor or a vasodilator, Dopamine is the firs choice of support for the pediatric patient with hypotension refractory to fluid resuscitation The choice of vasoactive agent is determined by the clinica examination Dopamine refractory shock may reverse with epinephrine infusion (l14). Pediatri norepinephrine patients with low cardiac output states may benefit from use of dobutamine. The e use o vasodilators can reverse shock in pediatric pa tients who remain hemodynamically unstable with a high systemic vascular resistance state despite fluid Iresuscitation and implementa tion of inotropic support (114, 115). Nitroso- vasodilators with a very short half-lifte (nitro prusside or nitroglvcerin) are used as first-lin therapy for children with epinephrine-resis tant low cardiac output and elevated systemid vascular-resistance shock. Inhaled nitric oxid reduced extracorporeal membrane oxvgen ation (ECMO) use when given to term neo nates with persistent pulmonary artery hyper\n\n### Q. Stress Ulcer Prophylaxis\n\nRecommendation: Grade A\n\nRationale. Although no study has been performed specifically in patients with severe of trials confirming the benefit sepsis, large stress ulcer prophylaxis in general ICU popu- lations have included significant numbers septic patients (105-108). This benefit should be applicable to patients with severe sepsis and shock. In addition, the conditions septic shown to benefit from stress ulcer prophvlaxis (coagulopathy, mechanical ventilation, hypo: o patients frequently are tension) present with severe sepsis and septic shock.\n\n### R. Consideration for Limitation of Support\n\n+ 1. Advance care planning, including 5 the communication of likely s and outcomes of treatment. should be realistic goals discussed with patients and families. De- for less or cisions support aggressive withdrawal of support may h be in the pa- tient's best interest.\n\nIt is too frequent that inade- Rationale, physician/family communication char- quate acterizes end-of-life care in the ICU. The leve) of life ICU patients 1 support g given may not and fre- be consistent with their wishes, Early quent caregiver discussions with patients whd face death in the ICU and their loved ones may facilitate with and application appropriate drawal of life-sustaining therapies.\n\n### S. Pediatric Considerations\n\n1. Mechanical Ventilation. Due low to functional capacity, young infants residual and neonates with severe sepsis may require early intubation (109). The principles of lung- protective strategies are applied to children as to adults. In premature infants, addi- they are tional attention is paid to avoiding hyperox- emia to prevent retinopathy. 2. Fluid Resuscitation. Intravenous access for f fluid resuscitation and inotrope/vasopres- difficult to attain in chil- sor infusion is more dren than in adults. The Heart As- American sociation has developed pediatric advanced life establish guidelines for support emergency\n\nof the and tensior newborr sepsis in randomized controlled trial (116), When pedi atric patients remain in a normotensive lovy cardiac output and high vascular resistance state. despite epinephrine and nitrosovasodi lator therapy, then the use of a phosphodies terase inhibitor should be strongly considered (117-119). Pentoxifylline (not available in the United States) improved outcome in prema-  with given for f ture neonates when sensis brs/day for 5 davs in a randomized controlled trial (120) 4 Theraneutic End Points. Therapeutic end points are canillary refill of <2 secs nor mal pulses with no differential between ne ripheral and central pulses, warm extremities urine output >1 mL.ko-1.hr""]",Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is administered to patients with neutropenic sepsis or primary immune deficiency. A randomized controlled trial demonstrated improved outcomes in neonates with sepsis and an absolute neutrophil count <1500/µL when treated with a 7-day course of GM-CSF.,multi_context,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
"How does a restrictive fluid therapy strategy impact ARDS patient outcomes, including ventilation duration, ICU stay, renal failure, mortality rates, and its potential benefits in septic patients? Contrast with fluid balance strategies, based on studies evaluating mortality, oxygenation, lung injury scores, and mechanical ventilation in critically ill patients, including a study of 1000 patients with acute lung injury, compared to open fluid therapy.",How does the use of restrictive fluid therapy strategy impact the outcomes of patients with ARDS (Acute Respiratory Distress Syndrome)?,"['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动', '剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ']",['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动'],"Restrictive fluid therapy strategy for ARDS patients can reduce mechanical ventilation time and ICU stay without significantly affecting the incidence of renal failure or mortality. It also benefits in lowering the occurrence of ARDS in septic patients, with a decrease in extravascular lung water index within 12 hours of septic shock onset correlating with improved survival. Limited studies suggest that compared to fluid balance strategy, restrictive fluid therapy leads to lower mortality, shorter mechanical ventilation, and shorter hospital stays in critically ill patients. However, in a study of 1000 patients with acute lung injury, restrictive fluid therapy did not significantly improve 60-day mortality compared to open fluid therapy, although it did improve oxygenation, decrease lung injury scores, and shorten mechanical ventilation time.",reasoning,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"What are the recommended anticoagulant choices for managing hyperglycemia and renal replacement therapy in sepsis, with a focus on thrombomodulin or heparin? Considerations include renal replacement therapy equivalence, preference for continuous methods in unstable patients, and factors influencing anticoagulant selection.",What are the recommendations regarding the use of anticoagulants in the treatment of sepsis/septic shock?,"['        |\n| 21 | nan   | nan                                                           | Keine Gabe von FFP ohne klinisch manifeste Blutung, ohne bevorstehende Operatiorklinischer Blutung, >50.000/ul bei Blutung oder Eingriffer                                   | Schwache EmpfehlungEvidenz sehr niedrid Schwache EmpfehlungEvidenz sehr niedrig |\n| 22 | nan   | ImmunglobulineHämofiltration/g                                | Keine Gabe von lmmunglobuliner                                                                                                                                               | nan                                                                             |\n| 23 | K     | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Evidenz sehr niedric                                                            |\n| 24 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | nan                   ', '                                                          |\n| 25 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Starke EmpfehluncEvidenz moderat                                                |\n| 26 | nan   | Antikoaqulanzien                                              | Kein Einsatz von Antithrombin zur Therapie von Sepsis/septischem SchockKeine spezifische Empfehlung zu Thrombomodulin oder Heparin zur Therapie von Sepsis,septischem Schock | -                                                                               |\n\nNierenersatzverfahren als grundsätzlich gleichwertig betrachtet. Bei hämodyna- misch instabilen Patienten werden kon- diese tinuierliche Verfahren favorisiert; hat jedoch eine schwache Empfehlung c nied- Empfehlungsstärke und eine sehr Neu ist, rige Qualität der Evidenz. dass bei steigen- Nierenersatzverfahren den Kreatininwerten oder Oligurie bzw. klaren Indikation ab Fehlen bei  1 einer die geraten wird; Rationale ist e Nutzen- Risiko-Abwägung von Nierenersatzver-\n\nfahren und möglichen Komplikationen, allem in Bezug auf intravasale Ka- vor theter.\n\n### Adjunktive Therapien der Sepsis\n\nDie Empfehlungen hinsichtlich der Kon- trolle einer Hyperglykämie sind weitge- hend unverändert geblieben; bei der Ver- wendung von Point-of-Care- Testverfah- ren wird zur Vorsicht geraten, Glukose- werte sollten initialalle 1-2 h und im wei-\n\nteren Verlauf bei zunehmender Stabilität alle 4h gemessen werden. Anzustreben sind Werte unter 180 mg/dlund eine The- rapie sollte erst nach zwei aufeinander- folgenden Werten >180 mg/dll begonnen werden. Diese Empfehlungen haben je- weils eine hohe Empfehlungsstärke bzw. sind Best Practice']","['        |\n| 21 | nan   | nan                                                           | Keine Gabe von FFP ohne klinisch manifeste Blutung, ohne bevorstehende Operatiorklinischer Blutung, >50.000/ul bei Blutung oder Eingriffer                                   | Schwache EmpfehlungEvidenz sehr niedrid Schwache EmpfehlungEvidenz sehr niedrig |\n| 22 | nan   | ImmunglobulineHämofiltration/g                                | Keine Gabe von lmmunglobuliner                                                                                                                                               | nan                                                                             |\n| 23 | K     | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Evidenz sehr niedric                                                            |\n| 24 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | nan                   ', '                                                          |\n| 25 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Starke EmpfehluncEvidenz moderat                                                |\n| 26 | nan   | Antikoaqulanzien                                              | Kein Einsatz von Antithrombin zur Therapie von Sepsis/septischem SchockKeine spezifische Empfehlung zu Thrombomodulin oder Heparin zur Therapie von Sepsis,septischem Schock | -                                                                               |\n\nNierenersatzverfahren als grundsätzlich gleichwertig betrachtet. Bei hämodyna- misch instabilen Patienten werden kon- diese tinuierliche Verfahren favorisiert; hat jedoch eine schwache Empfehlung c nied- Empfehlungsstärke und eine sehr Neu ist, rige Qualität der Evidenz. dass bei steigen- Nierenersatzverfahren den Kreatininwerten oder Oligurie bzw. klaren Indikation ab Fehlen bei  1 einer die geraten wird; Rationale ist e Nutzen- Risiko-Abwägung von Nierenersatzver-\n\nfahren und möglichen Komplikationen, allem in Bezug auf intravasale Ka- vor theter.\n\n### Adjunktive Therapien der Sepsis\n\nDie Empfehlungen hinsichtlich der Kon- trolle einer Hyperglykämie sind weitge- hend unverändert geblieben; bei der Ver- wendung von Point-of-Care- Testverfah- ren wird zur Vorsicht geraten, Glukose- werte sollten initialalle 1-2 h und im wei-\n\nteren Verlauf bei zunehmender Stabilität alle 4h gemessen werden. Anzustreben sind Werte unter 180 mg/dlund eine The- rapie sollte erst nach zwei aufeinander- folgenden Werten >180 mg/dll begonnen werden. Diese Empfehlungen haben je- weils eine hohe Empfehlungsstärke bzw. sind Best Practice']","There are no specific recommendations regarding the use of anticoagulants in the treatment of sepsis/septic shock. However, there is no recommendation for the use of antithrombin, thrombomodulin, or heparin in the therapy for sepsis/septic shock. The evidence regarding this matter is very low.",reasoning,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
"What is the recommended sampling method for urine culture in patients suspected of sepsis or septic shock according to the ""Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock (2022)""?","What is the recommended sampling method for urine culture in patients suspected of sepsis or septic shock according to the ""Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock (2022)""?",['对于怀疑脓毒症或者脓毒性休克患者，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。在抗菌药物治疗开始之前先采样培养与改善预后有关。如果能及时采样， 则先采集血样进行培养；如果不能即将获得标本，尽快启动抗菌药物治疗。患者的标本来源包括血液、脑脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超过48h且感染部位不明的患者，建议至少进行需氧瓶和厌氧瓶两组血培养。对于怀疑导管感染的患者，建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。'],"['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']",nan,counter_factual,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"What protocol is recommended for glucose control, including the administration of insulin therapy, when glucose levels exceed 10 mmol/l (180 mg/dl)?","What protocol is recommended for glucose control, including the administration of insulin therapy, when glucose levels exceed 10 mmol/l (180 mg/dl)?","['context:                                                                                                                                                                             | Starke EmpfehlungEvidenz hoch                       |\n| 17 | N      | RelaxierungGlucosekontrolle | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 18 | N      | RelaxierungGlucosekontrolle | Analgosedierung, Minimal mögliche Analgosedierund                                                                                                                                                                                                                                            | BPS                                                 |\n| 19 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                          \noutput: Insulintherapie wird nicht empfohlen, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeben.']","['                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 17 | N      | RelaxierungGlucosekontrolle | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 18 | N      | RelaxierungGlucosekontrolle | Analgosedierung, Minimal mögliche Analgosedierund                                                                                                                                                                                                                                            | BPS                                                 |\n| 19 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                          ']","Insulin therapy is recommended when glucose levels exceed 10 mmol/l (180 mg/dl), as per the protocol for glucose control. This protocol suggests initiating insulin therapy if two consecutive glucose measurements indicate a level above this threshold.",counter_factual,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
What are the current recommendations for thrombosis prophylaxis based on the guidelines provided?,What are the current recommendations for thrombosis prophylaxis based on the guidelines provided?,"['Die Empfehlungen zur Thromboseprophylaxe in der aktuellen Leitlinienversion sind strukturiert und prägnant dargelegt. Im Kern wird die Anwendung einer medikamentösen Thromboseprophylaxe empfohlen, wenn keine Kontraindikationen vorliegen (starke Empfehlung, moderate Qualität der Evidenz), wobei niedermolekulare Heparinpräparate gegenüber unfraktioniertem Heparin bevorzugt werden (starke Empfehlung, moderate Qualität der Evidenz).']","[' | nan                                    |\n| 26 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n| 27 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n\nBPS Best Practice Statement, Ha Hämoglobin, FFP Fresh Frozen Plasma, PEEP positive endexpiratory pressure"", paO2 arterieller Sauerstoffpartialdruck FIO  inspiratorische Sauerstofffraktion, HFOV.high frequency oscillatory yentilation"" Gl gastrointestina\n\nWeiterhin wird unverändert von der Anwendung von Hydrokortison bei sep- tischem Schock abgeraten, wenn man durch Volumen- und Vasopressorthera- pie eine hämodynamische Stabilität zielen kann; falls dies nicht gelingt, , wird die Gabe von Hydrokortison in einer Ta- gesdosis von 200 mg empfohlen. Die Gabe von Selen wird gemäf den deutschen SISPCT-Studie als Daten dere ,strong recommendation"" nicht empfoh- len [19].\n\n### Ernährung\n\nIn der aktuellen Version der Leitlinien ist der Stellenwert der enteralen Ernährung\n\nder gegenüiber Ernährung parenteralen l Eine frühe mehrfach betont: enterale hypo- Ernährung, bzw. trophisch auch Neu ist wird klar favorisiert kalorisch, mit niedri- eine schwache Empfehlung ger Evidenz zum Einsatz postpylorischer bei mit Patienten Ernährungssonden Aspi- oder hoher Ernährungsintoleranz rationsgefahr. Neu sind die Stellungnah Zu Omega-3-Fettsäuren, Arginin men Glutamin, empfohlen welche nicht unde der Neu  aktuellen Version werden. ist a', 'uch die e Empfehlung gegen rou- des tinemäfsiges Monitoring gastralen Residualvolumens. Bei Ernährungsin- und hohem toleranz Aspirationsrisiko\n\nwird das Monitoring des gastralen Resi- dualvolumens jedoch empfohlen.\n\n### Antikoaqulation, Thrombose- und Stressulkusprophylaxe\n\nDie Empfehlungen zur :Thrombosepro- der aktuellen Leitli- phylaxe sind in c nienversion strukturierter : und prag- dies Im Kern 1 betrifft dargelegt. nanter die Anwendung einer medikamentöser Thromboseprophylaxe beim Fehlen von Kontraindikationen (hohe Empfehlungs: der stärke, moderate Qualität r Evidenz mit Bevorzugungvon niedermolekularen unfrak- gegeniiber Heparinpraparaten tioniertem Heparin (hohe Empfehlungs-\n\n2 Vereinfachte Darstellung von Empfehlungsstärke und Qualität der Evidenz nach GRADE-System (Grading of Recommendations Assessment\n\n\n|    | 0                                      | 1                                                                                                                                              |\n|---:|:---------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Development,and Evaluation,[1,3]       | Development,and Evaluation,[1,3]                                                                                                               |\n|  1 | Empfehlungsstärke                      | Empfehlungsstärke                                                                                                                              |\n|  2 | Starke Empfehlungstrong recommendation | Mainahmen, welche in den meisten Fällen angewandt werden sollten                                                                               |\n|  3 | Schwache Empfehluncweak recommendation | MaBnahmen, welche nach individueller Abwäqung für den jeweiligen Patienten sinnvoll sein können          ']","The current recommendations for thrombosis prophylaxis include the application of pharmacological thrombosis prophylaxis in the absence of contraindications, with a preference for low molecular weight heparin over unfractionated heparin. These recommendations are structured and pragmatic, emphasizing the use of pharmacological thrombosis prophylaxis in most cases.",counter_factual,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
How does the distribution of ECMO centers reflect disparities in medical resources across different regions in China?,How does the distribution of ECMO centers reflect disparities in medical resources across different regions in China?,"['这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小\n的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底\n新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症']","['这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小', '的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�']","The distribution of ECMO centers reflects significant regional disparities in China. In 2018, among the 31 provinces excluding Hong Kong, Macao, and Taiwan, all provinces except Hainan, Qinghai, and Tibet had ECMO treatment centers. However, there were considerable differences in the number of cases treated among provinces, with some provinces performing over 300 cases while others fewer than 5. Disparities were evident based on economic factors as well, with economically developed coastal areas performing over 1400 cases annually compared to around 400 cases in inland regions. Additionally, statistics from CSECLS show that by the end of 2020, there were 500 centers performing extracorporeal life support techniques in China, roughly equivalent to the total number of international ELSO registered units. However, the number of completed ECMO cases was only about one-third of this total, with nearly half of ECMO centers performing fewer than 5 cases. The analysis further revealed that larger ECMO centers had better patient outcomes compared to smaller ones, with a significant difference observed in survival rates between different types of ECMO centers. This disparity suggests a challenge for regional ECMO center formation in China and contributes to differences in patient outcomes compared to foreign countries. Establishing regional ECMO centers could ensure the rational utilization of ECMO technology, prevent the waste of medical resources, and provide a comprehensive regional system for the rescue of critically ill patients.",counter_factual,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
What is the role of rhAPC (recombinant human activated protein C) in the treatment of severe sepsis and septic shock?,What is the role of rhAPC (recombinant human activated protein C) in the treatment of severe sepsis and septic shock?,"['counterfactual_context: The role of rhAPC (recombinant human activated protein C) in the treatment of severe sepsis and septic shock was not established due to limited understanding of its effects on the inflammatory response and coagulation in sepsis. Clinical trials investigating its efficacy in improving organ dysfunction in patients with sepsis did not yield conclusive results. As a result, rhAPC was not recommended for routine use in the treatment of severe sepsis and septic shock.']","[' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in']",The role of rhAPC (recombinant human activated protein C) in the treatment of severe sepsis and septic shock is to improve induced organ dysfunction. It acts as an endogenous anticoagulant with anti-inflammatory properties and has been shown in multiple controlled trials to benefit patients with sepsis-induced organ dysfunction.,counter_factual,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
How effective are β-2 receptor agonists in reducing hospitalization time and mechanical ventilation days in patients with ARDS?,How effective are β-2 receptor agonists in reducing hospitalization time and mechanical ventilation days in patients with ARDS?,['How effective are β-2 receptor agonists in reducing hospitalization time and mechanical ventilation days in patients with ARDS?\n，\n推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动\n剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�\n�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持'],['剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�'],nan,counter_factual,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What is the recommended initial fluid resuscitation volume for patients with septic shock caused by sepsis according to the guidelines?,What is the recommended initial fluid resuscitation volume for patients with septic shock caused by sepsis according to the guidelines?,['脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�\n��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],"['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']",nan,counter_factual,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
What are the recommended procedures for blood culture collection in patients suspected of septic shock?,What are the recommended procedures for blood culture collection in patients suspected of septic shock?,['推荐意见 2：建议在拟诊为脓毒性休克的患者，起始 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏。'],"['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�']","The recommended procedures for blood culture collection in patients suspected of septic shock include collecting at least two sets of blood cultures, with one set obtained through percutaneous puncture and the other set obtained from each vascular access device. For patients with indwelling central venous catheters for more than 48 hours and unclear infection sites, it is suggested to collect at least two sets of blood cultures, one from an aerobic bottle and one from an anaerobic bottle.",counter_factual,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"How do concentrations of Protein C and Activated Protein C differ in children compared to adults, and what evidence exists regarding their administration in pediatric sepsis management?","How do concentrations of Protein C and Activated Protein C differ in children compared to adults, and what evidence exists regarding their administration in pediatric sepsis management?",['Protein C and Activated Protein C concentrations in children reach adult levels earlier than in adults. There has been one dose-finding placebo-controlled study performed using protein C concentrate. This study was not powered to show an effect on mortality rate but did show a positive effect on sepsis-induced coagulation disturbances. No randomized studies using rhAPC have been performed.'],"['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","Concentrations of Protein C and Activated Protein C are greater in young children compared to adults. Evidence regarding their administration in pediatric sepsis management includes a dose-finding placebo-controlled study using protein C concentrate, which showed a positive effect on sepsis-induced coagulation disturbances. However, no randomized studies using rhAPC have been performed.",counter_factual,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
How effective are anticoagulants in treating sepsis and septic shock according to recent research findings?,How effective are anticoagulants in treating sepsis and septic shock according to recent research findings?,['近期关于抗凝血酶用于脓毒症及脓毒性休克的研究取得了较好发展，多项研究结果均显示，抗凝血酶在降低患者病死率方面表现出显著的效果，且未与患者出血风险的增加相关，因此强烈推荐使用该药物。'],['��疗脓毒症和脓毒性休克 (强推荐， 中等证据质量)。\n目前多项关于抗凝血酶治疗脓毒症和脓毒性休克的研究结果均显示，抗凝血酶未能显著 降低患者病死率，且与患者出血风险的增加有关〕，因此不推荐使用该药物。\n近期关于肝素用于脓毒症及脓毒性休克的研究取得了较好发展，两项系统评价显示， 肝 素对无大出血风险的脓毒症患者的生存率具有潜在的收益。Yang 等开展了一项纳入 224 例 患者的 RCT，结果表明，早期赋予肝素治疗可显著抑制血小板减少，进而改善患者组织灌 注，降低活动性出血的风险。国内 RCT 研究显示，血必净注射液治疗可改善脓毒症患者的 凝血指标，改善血流动力学障碍，降低脓毒症患者 DIC 发生率和脓毒症并发弥散性血管内 凝血(DIC)患者的 28d病死率。在脓毒症合并凝血功能障碍或者发生 DIC 时，可使用血必 净注射液治疗。\n7.6    肾脏替代治疗\n推荐意见 25：对于脓毒症合并急性肾损伤 (AKI)的患者，如需行 RRT，CRRT 和间歇 性 RRT 均可(弱推荐，中等证据质量)。\n对于血流动力学不稳定的脓毒症患者，建议使用 CRRT  (弱推荐， 极低证据质量)。尽 管许多非随�'],"Anticoagulants have not shown a significant reduction in patient mortality and are associated with an increased risk of bleeding, therefore not recommended for the treatment of sepsis and septic shock according to recent research findings.",counter_factual,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"How shuld fluid resusciation be intiated in patinets with septic shock, and what are the recomended initial resusciation tragets?","How should fluid resuscitation be initiated in patients with septic shock, and what are the recommended initial resuscitation targets?","['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反']","['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反']","Fluid resuscitation in patients with septic shock should be initiated early, preferably within 3 hours of diagnosis. It is recommended to administer at least 30ml/kg of crystalloid solution for initial resuscitation. After completing the initial resuscitation, the hemodynamic status should be evaluated to guide further fluid use. The recommended initial resuscitation target for mean arterial pressure (MAPP) is ≥65mmHg. It is crucial to start fluid resuscitation early in septic shock. The '1-hour bundle therapy' strategy proposed by the 'Save Sepsis Campaign' emphasizes the importance of early resuscitation and treatment. Studies such as the PROCESS and ARISE trials support the administration of approximately 30ml/kg of crystalloid solution within the first 3 hours for early resuscitation. It is important to cautiously administer fluids during ongoing intensive care, considering the harmful effects of sustained fluid balance positivity. Therefore, fluid administration should be carefully managed based on fluid responsiveness assessment, and dynamic indicators such as passive leg raising test, volume challenge test, changes in stroke volume after fluid infusion, changes in systolic pressure, changes in pulse pressure, and changes in chest pressure after mechanical ventilation can help predict fluid responsiveness and improve diagnostic accuracy. It is recommended to use a MAP of 65mmHg as the initial resuscitation target for patients requiring vasopressor therapy. For patients with elevated blood lactate levels, it is suggested to guide resuscitation based on lactate levels and restore lactate to normal levels.",error_correction,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
What are the recommendd protocals for Insulinntherapy based on glucose control measurements?,What are the recommended protocols for Insulintherapie based on glucose control measurements?,"['                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |']","['                                                                                                                                  | Starke EmpfehlungEvidenz hoch                       |\n| 20 | N      | RelaxierungGlucosekontrolle | Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert>10 mmol/l(>180 mg/dl) ergeber                                                                                                                                                                            | Starke EmpfehlungEvidenz hoch                       |\n| 21 | N      | nan                         | Engmaschige Kontrolle 1-bis 2-stündlich bis Infusionsraten von Glucose und Insulin stabil, spä-POC-Messungen mit Referenzmethode überprüfer                                                                                                                                                  | BPSBPS                                              |\n| 22 | nan    | verfahrer                   | Blutentnahme bevorzugt aus arteriellem KathetelEinsatz von intermittierender Dialyse oder kontinuierlicher Hämofiltration bei Nierenversagen                                                                                                                                                 | Evidenz niedrig                                     |\n| 23 |']","Protokoll zur Glucosekontrolle: Insulintherapie, wenn 2 Messungen einen Glucosewert > 10 mmol/l (> 180 mg/dl) ergeben",error_correction,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
How does the use of combinaion therapy affect the progonsis of patients with severe sepsis or septic shock?,How does the use of combination therapy affect the prognosis of patients with severe sepsis or septic shock?,"['体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�', '�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�']",['体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�'],"Combination therapy can improve the survival rate of patients with severe sepsis, particularly those with septic shock. However, for septic patients without shock, studies suggest that combination therapy may not significantly improve patient prognosis and could even increase the risk of mortality. For patients with neutropenia, research consistently shows that combination antibiotic therapy does not provide significant clinical benefits for low-risk patients without shock. There is currently insufficient evidence for high-risk patients with hemodynamic instability or organ failure.",error_correction,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are the challengs and risks assosiated with selecting anticoagulaton stratgies for ECMO patients?,What are the challenges and risks associated with selecting anticoagulation strategies for ECMO patients?,"['的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�', '��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�']","['新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�', '��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�']","Anticoagulation strategies for ECMO patients pose significant challenges and risks. ECMO patients are prone to a hypercoagulable state, increasing the risk of thrombus formation within the ECMO circuit. Continuous systemic anticoagulation therapy is typically administered to prevent clot formation in the ECMO circuit, but recent studies have shown a high incidence of bleeding events during ECMO support, ranging from 17% to 51%. This poses a dilemma in choosing the appropriate anticoagulation strategy, especially for patients with trauma or high bleeding risk, as there is often a contraindication for anticoagulation. Therefore, the selection of anticoagulation strategies for ECMO patients is associated with significant risks and challenges.",error_correction,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
"How should clinisians manag hyperkapnia in patints with ALI/ARDS, and what are the consideations regardng its effects on respiratry parametrs and patint outcmes?","How should clinicians manage hypercapnia in patients with ALI/ARDS, and what are the considerations regarding its effects on respiratory parameters and patient outcomes?","[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","Clinicians managing hypercapnia in patients with ALI/ARDS should allow permissive hypercapnia, permitting Paco2 to increase above normal levels if necessary, to minimize plateau pressures and tidal volumes. This approach, in conjunction with limiting tidal volume and minute ventilation, has been shown to be safe and has demonstrated improved outcomes in patients. However, permissive hypercapnia should not be the primary treatment goal and is limited in patients with preexisting metabolic acidosis or increased intracranial pressure. Sodium bicarbonate infusion may be considered in select patients to facilitate permissive hypercapnia. Monitoring of respiratory parameters such as plateau pressures and tidal volumes is essential to ensure patient safety and optimize outcomes.",error_correction,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
How does the use of restrictiv fluid therapie impact mechical ventilation time and ICU stay in ARDS patients?,How does the use of restrictive fluid therapy impact mechanical ventilation time and ICU stay in ARDS patients?,"['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动', '剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ']",['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动'],"Restrictive fluid therapy in ARDS patients can reduce mechanical ventilation time and ICU stay without significantly impacting the incidence of renal failure or mortality. Studies have shown that this strategy benefits in lowering the incidence of ARDS in septic patients, with a decrease in extravascular lung water index within 12 hours of septic shock onset correlating with improved survival rates. Small sample studies indicate lower mortality, shorter mechanical ventilation time, and shorter hospital stays in critically ill patients treated with restrictive fluid therapy compared to fluid balance strategies. A study involving 1000 patients with acute lung injury found no significant improvement in 60-day mortality in the restrictive fluid therapy group compared to the open fluid therapy group, but there were improvements in oxygenation, decreased lung injury scores, and reduced mechanical ventilation time.",error_correction,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
What are the clinical implicashuns of sepsis and septic shock in terms of organ dysfunctshun?,What are the clinical implications of sepsis and septic shock in terms of organ dysfunction?,"['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']","['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']","Sepsis and septic shock can lead to life-threatening organ dysfunction due to a dysregulated host response to infection. Septic shock, a severe form of sepsis, is characterized by serious circulatory, cellular, and metabolic disturbances, posing a higher risk of mortality compared to sepsis alone.",error_correction,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
Wat are the recommendd procedures for blood culure sampling in patients suspectd of septic shock?,What are the recommended procedures for blood culture sampling in patients suspected of septic shock?,"['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�']",['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],"The recommended procedures for blood culture sampling in patients suspected of septic shock include taking at least two sets of blood cultures, one from a percutaneous skin puncture and one from each vascular access device.",error_correction,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"What considerations should be made regarding the use of hydrocortisone tharapy in children with catecholamine resistence and suspected or proven adrenal insufficiency, particulary in cases of sever septic shock and purpura?","What considerations should be made regarding the use of hydrocortisone therapy in children with catecholamine resistance and suspected or proven adrenal insufficiency, particularly in cases of severe septic shock and purpura?","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","Hydrocortisone therapy should be reserved for use in children with catecholamine resistance and suspected or proven adrenal insufficiency, particularly in cases of severe septic shock and purpura. Patients at risk include children who have previously received steroid therapies for chronic illness and children with pituitary or adrenal abnormalities. Adrenal insufficiency in the case of catecholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). Additionally, a positive 30- or 60-min ACTH stimulation test with an increase in cortisol of ≤9 ug/dL (248 nmol/L) also supports the diagnosis. Dose recommendations for hydrocortisone vary, ranging from 1-2 mg/kg for stress coverage (based on clinical diagnosis of adrenal insufficiency) to 50 mg/kg for empirical therapy of shock followed by the same dose as a 24-hour infusion.",error_correction,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
Wat is the significanc of low evidance in the context of non-surgicall patients' gastric residuel volume monitiring and nutritional intoleranse assesment?,What is the significance of low evidence in the context of non-surgical patients' gastric residual volume monitoring and nutritional intolerance assessment?,"['                         | Kein routinemä(siges Monitoring von gastralem Residualvolumen beinichtchirurgischen Patien-ten; Monitoring von gastralem Residualvolumen bei Ernährungsintoleranz und hohem Aspirati-onsrisikc | Schwache EmpfehluncEvidenz niedrig     |\n| 13 | nan  | nan                                                                                                    | Prokinetika bei Ernährungsintoleranz                                                                                                                                                           | Schwache EmpfehluncEvidenz niedrig     |\n| 14 | nan  | Keine Anwendung von Seler                                                                              | Keine Anwendung von Seler                                                                                                                                                                      | nan                                    |\n| 15 | nan  | Keine Anwendung von Arginir                                                                            | Keine Anwendung von Arginir                                                                                                                                                                    | nan                        ', '            |\n| 16 | nan  | Keine Anwendung von Arginir                                                                            | Keine Anwendung von Arginir                                                                                                                                                                    | Evidenz niedrig                        |\n| 17 | -    | Keine Anwendung von Arginir                                                                            | Keine Anwendung von Arginir                                                                                                                                                                    | nan                                    |\n| 18 | -    | Keine spezifische Empfehlung für/gegen Carnitir                                                        | nan                                                                                                                                                                                            | nan                                    |\n| 19 | -    | Keine spezifische Empfehlung für/gegen Carnitir                                               ']","['                         | Kein routinemä(siges Monitoring von gastralem Residualvolumen beinichtchirurgischen Patien-ten; Monitoring von gastralem Residualvolumen bei Ernährungsintoleranz und hohem Aspirati-onsrisikc | Schwache EmpfehluncEvidenz niedrig     |\n| 13 | nan  | nan                                                                                                    | Prokinetika bei Ernährungsintoleranz                                                                                                                                                           | Schwache EmpfehluncEvidenz niedrig     |\n| 14 | nan  | Keine Anwendung von Seler                                                                              | Keine Anwendung von Seler                                                                                                                                                                      | nan                                    |\n| 15 | nan  | Keine Anwendung von Arginir                                                                            | Keine Anwendung von Arginir                                                                                                                                                                    | nan                        ', '            |\n| 16 | nan  | Keine Anwendung von Arginir                                                                            | Keine Anwendung von Arginir                                                                                                                                                                    | Evidenz niedrig                        |\n| 17 | -    | Keine Anwendung von Arginir                                                                            | Keine Anwendung von Arginir                                                                                                                                                                    | nan                                    |\n| 18 | -    | Keine spezifische Empfehlung für/gegen Carnitir                                                        | nan                                                                                                                                                                                            | nan                                    |\n| 19 | -    | Keine spezifische Empfehlung für/gegen Carnitir                                               ']",The significance of low evidence in the context of non-surgical patients' gastric residual volume monitoring and nutritional intolerance assessment implies that there is not enough substantial evidence to support or recommend specific interventions or practices. This suggests a lack of certainty regarding the effectiveness or necessity of these interventions in these particular situations.,error_correction,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
